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ABSTRACT 
The aim of this thesis is to investigate and quantify the prevalence, knowledge 
and regulations regarding counter medicines. Using various methods and analytical 
tools to aid in this investigation.  
The problem of counterfeits is an ever-growing issue, especially with regards to 
the increase of production and sales of counterfeits. These medicines show to have an 
increasing health risk to the public. Everyone is at risk. On record 50% of products sold 
are counterfeits and 30% of those are counterfeit medicines.  
The information that is widely known about counterfeit medicines is that they 
pose public health risks and how the chemical composition is a key to determining 
them. What is not widely known is the connection throughout the supply chain, from 
manufacturer to the individuals that are at risk. 
The data used for this research includes; product data consisting of tablet, 
powders and mixture forms, individual opinions collected via questionnaire, 
background research about counterfeit medicines, specifically the directives used in 
place as a preventive measure and lastly the data collection for characteristics of online 
pharmacies. 
The instrumentation used for the FT-NIR determination of counterfeit 
pharmaceuticals was made on the PerkinElmer Spectrum Two N Fourier-Transform 
Near Infrared Spectrometer. The data sets were processed via the use of standard 
normal variant second derivative spectra (SNV-D2).  
The identification of the counterfeit medicines was a success along with 
identifying partial trends to how the public perceives self-prescription and their 
opinions of counterfeit medicines.  Strengths and limitations regarding the new 
directives were also identified leading to possible adaptations to fortify the prevention 
of counterfeits being supplied in the future.  
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It is hoped that this research will inform practitioners about the management 
practices for preventing counterfeit medicines from entering the supply chain and 
endangering the public’s health. 
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Chapter One: Introduction 
1.1 Introduction  
Counterfeit products occur in all aspects of life, be it what we eat, what we wear 
and even in how we simply tell the time.  As progress is made in each field of 
knowledge, there is an environment being produced where either individuals or 
organisations can attempt to gain an unfair profit from the market.  This is where 
counterfeits are produced via false advertisements, duplicates and modified products 
(Eser et al. 2015). 
Unfortunately, medicinal products, even those that are lifesavers, cannot escape 
the problem of having counterfeit versions. 
The use of medicinal products has been documented for over 60,000 years. 
Physical evidence of the use of herbal remedies was found in a burial site in Shanidar 
Cave in Iraq, showing a Neanderthal man buried with a variety of plants and herbs 
surrounding him.  
Nine plants and herbs were found to be surrounding him, seven of which are 
used for medicinal purposes to this day. Among those found were ephedrine, daises, 
blue bonnets, grape hyacinths, hollyhocks, St Barnaby’s and other thistles. Neanderthals 
lived from about 200,000 years ago to roughly 30,000 years ago (Lietava 1992). 
 With this find, it shows that medicine has been synthesised to aid in the 
alleviation of ailments first with the use of simple plants such as ephedrine, later moving 
on to more advance substances such as cannabis and more (Duffin 2016).  
Over the years this then progressed onto more synthetic medicines that would 
help reduce pain, infection or diseases that once eradicated the populations of the 
world, such as smallpox, which was finally eradicated with a vaccine (Riedel 2005). 
With the development and advancement in medicines, the distribution of such 
products also adapts, thus creating openings in the chain for counterfeits to be placed.  
Page | 21  
This section will discuss the following issues of counterfeit medicines; the history, 
what they are, the distribution and how widely spread they are, why are they perceived 
to be a problem, the regulation and industry practices regarding them.  
 
1.2 History of Counterfeits Medicines 
Medicines are an essential part of society, the public perception of them is an 
avenue that is hardly explored in great depth. As the need for medicines rises, the need 
for profit and gain on such expenditures also increases.  
This enables a way for more advanced counterfeit medicines to be produced, 
which could in turn cause more harm than good to the wellbeing of the public 
(Houston 2012).   
In the last few decades there has been huge strides in the; advancement in the 
scope of science, history being made and multiple creations in technology. One of the 
main improvements to our knowledge base as a society was the creation of the 
Internet. With the Internet came vast openings in the marketplace for a variety of trades 
and the method of sales (Brady 2020). 
Before the Internet was created medicines were bought from brick-and-mortar 
pharmacies where a doctor would advise with the patient and prescribe the correct 
medicine. With the use of the Internet, medicines can be bought online and delivered 
to your door.  
This has had profound changes in society. For instance, in 1983 before the 
Internet went online, 18% of medicines were domestically produced and distributed, 
rising to 75.5% in the year 2000 (née Lybecker 2020). 
For society the populace is overworked, stress builds up and mental illness is 
everywhere. The struggle that goes on opens and creates doors for counterfeits to be 
passed through. Counterfeits at the base of the problem are created for a gain in profit.  
With the stress of illness building up around the United Kingdom (UK) there has 
become a shortage of medicines to cope with the excess. This of course opens avenues 
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for profiteers to take advantage of, and with a new avenue of distribution such as the 
Internet becomes available (Buckley & Gostin 2014). 
Unfortunately, the end user base (the consumer) is not considered when data is 
collected, when identifying perspective on counterfeits, or purchases of medicines.  
Often, the manufacturer, chain of supply and other points of entry in the 
purchase scheme are mainly focused upon during analysis by health care professionals 
(Settanni et al. 2017). This causes issues as we do not know the scale of consumer 
knowledge with regards to process of purchasing medicines.  
In some countries brand named medicine are treated as authenticate and non-
brand names are treated as counterfeit, whereas that may not be the case at all. This is 
often overlooked when samples are tested, and in the end, there is a lack of protection 
for the end users who really need the health care (Settanni et al. 2017). 
With regards to counterfeit medicines, there is no discrimination between 
developing and developed countries, both being at risk. Developing countries are more 
at risk with having counterfeit medicines such as antibiotics, anti-tuberculosis, anti-
malarial and anti-AIDS drugs.  
Developed countries are more likely to suffer with having counterfeit lifestyle 
medications such as anti-cancer, anti-hypertensive, hormonal and anti-cholesterol 
drugs, (World Health Organisation, 2010). 
 
1.3 Counterfeit Medicines 
Due to the changes that society has undergone, and the fact that our knowledge 
has expanded, the overall definition of a counterfeit medicine has changed. Since 2010 
when the World Health Organisation (WHO) stated that “Counterfeit medicines are 
deliberately and fraudulently mislabelled with respect to identity or source” (World 
Health Organisation 2010) the definition has now been adapted to include “spurious / 
falsely labelled / falsified / counterfeit (SFFC) medicines” (WHO 2018).  
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The European Union Council (EUC) on the other hand classifies a falsified 
medicinal product as something else entirely. As definitions change, the appropriate 
policing alters to accommodate the relevant laws which in turn drives further definition 
changes.  
With regards to SFFCs, the WHO is concerned with life-threatening aspects to 
public health. Other substandard medicines do not always qualify under the definitions 
of a counterfeit (Newton 2011). 
As there are many terms that can be used for the description of a counterfeit, it is 
prudent that there is distinguishability between a substandard drug and a counterfeit, 
and what is known as a fake or falsified version.  
Counterfeits are not genuine in any form and are made simply to gain profit. This 
is also the same with a falsified medicine, with the aid of false advertising and other 
false production methods.  
Substandard drugs however are genuine for the most part. What makes them 
different is that they fail to fulfil or achieve the quality specifications that are set for 
drugs to pass, depending on the governing bodies’ regulations and standards 
(Wertheimer 2003, Wertheimer 2005).  
This is most commonly the result of a defect in the manufacturing process.  The 
terminology and distinction between substandard and counterfeit medicines becomes 
more complex when despite having understanding knowledge of the defect it is still 
supplied.  
If a substandard drug is known to have been produced, yet is knowingly 
fraudulently labelled and sold, the drug then becomes a counterfeit. The simple act of 
Mens Rea can subtlety change the defining characteristic of a batch of medicine or 
drug, and the crime committed.  
It is important to understand and be able to identify the differences between 
them. Even though they can both be harmful, a substandard drug is mainly 
manufactured from a known source and thus the authorities can work with the 
manufacturers to limit the risk to public health and stop production.  
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An example of this would be in 2011, when a drug that prevented blood clots was 
removed from the market. This was because the manufacturer responsible for the 
medicine in question, noticed an error with the chemical makeup of the medicine and 
voluntarily removed it. 
 The error that was identified was that the level of the Active Pharmaceutical 
Ingredient (API) in the formula was incorrect for that medicine (Fan et al. 2018).  
Counterfeit medicines are identifiable from their authentic counterparts on a 
chemical level, thus when examined more closely by sensitive instruments they can be 
identified (Newton 2011).  
The most crucial part of any drug formulation is the level of API present. The 
various concentration and deviations from the published amount determine what type 
of medicines they are; substandard, counterfeit or authentic.  
 
1.3.1 Substandard Characteristics: 
 Impurities/ Unknown Ingredients (Alumuzaini 2013): 
o Substandard weight or a tablet or capsule. 
o Altered odour due to diluted API or harmful additives Inactive or 
harmful ingredients, impurities, or contamination such as meld. 
 Reduced bioavailability and stability (Hogerzeil 1991; Pandit 1997; 
Nazerali 1998; Risha 2002; Rimoy 2002; Kayumba 2004; Lon 2006; 
Alumuzaini 2013): 
o Solubility or release of API is not within the specified time range 
due to reduced stability of the drug, and this leads to reduced 
bioavailability of the antibiotic. 
o Most of the limited number of studies that have assessed the 
stability of antimicrobials had suboptimal design. 
o Antibiotics such as ampicillin, but not others such as penicillin 
and tetracyclines, may degrade with high temperatures and 
humidity. 
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o Reduced bioavailability may lead to suboptimal activity of 
antimicrobials; examples include antibacterial such as 
cotrimoxazole, tetracyclines and metronidazole and antiparasitic 
agents such as chloroquine, mefloquine and pyrimethamine. 
 Reduced concentration of API: (Nazerali 1998; Reidenberg 2001; 
Rimoy 2002; Moken 2003): 
o Quantification of the API content of an antimicrobial agent shows 
that the concentration of the API is lower than the claimed 
content declared on the packaging. 
o Poor manufacturing or transportation, decomposition, and poor 
storage conditions and dilution of drugs with other chemicals 
may lead to low concentration of the API. 
 
1.3.2 Counterfeit Characteristics: 
 Reduced volume of API (Alumuzaini 2013): 
o The antimicrobial may be considered counterfeit when the 
substandard amt of the API is included deliberately in the drug. 
 No API available (Ten Ham 1992; Newton 2001; Rozendaal 2001; 
Kelesidis 2007; Delepierre 2012; Alumuzaini 2013): 
o Quantification of the API content of an antimicrobial agent shows 
that the API as declared on the packaging is absent. 
o Antibiotics may contain no API. 
o The AI is replaced by cheap substances, such as flour in oral 
presentations and water in drinkable or injectable presentations. 
 Increased Volume of API (Alumuzaini 2013;): 
o The concentration of the API may be higher than the amount 
reported in the packaging. 
 Altered chemical content (incorrect ingredient or false substitution) 
(Ten Ham 1992; Rozendaal 2001; Moken 2003; Kelesidis 2007; 
Delepierre 2012; Alumuzaini 2013): 
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o Detection of AI in the drug that is not declared on the packaging 
o These products may contain toxic chemical impurities 
o Examples of wrong ingredients include erythromycin, flour, 
starch, or powder, and tap water. 
 Failure of the mass uniformity test (Alumuzaini 2013): 
o The weight of a tablet or capsule is not within the average range 
specified (if done deliberately and not the result of poor 
manufacturing). 
 Inappropriate packaging (Sesay 1998; WHOa 1999; WHOb 1999; 
Gaudiana 2010; Alumuzaini 2013): 
o Packaging has incorrect labelling information about a drugs 
origin or authenticity, and the colour, size of pills, and bar codes 
are often similar to those for the original drug. 
o False representation of identity is commonly used, by copying 
the packaging of another marketed product; the brand name 
may be modified to try to escape laws on infringing intellectual 
property 
o They are generally undisguisable in their outward packaging 
o In developing countries, many of the purchased drugs without 
packaging were counterfeit. 
o Antimicrobials with false packaging and labelling include 
penicillin’s, co-trimoxazole, tetracyclines, chloramphenicol, 
quinolones, aminoglycosides and antimalarials. 
There are four main categories of medicines: (i) those that contain the incorrect 
API, (ii) those that contain the correct API but an incorrect dosage level, (iii) those with 
no API (e.g placebos), and lastly (iv) those with the correct API and the correct dosage 
(Krekora 2008).  
Another classification of a counterfeit, a more complex version, is when the API is 
the correct chemical but the wrong isomer, either (R) or (S). On a rare occasion this 
version finds it way on the marketplace. 
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One such example of the (R) or (S) medicine isomer is that of ibuprofen, the (R) 
being ineffective compared with the effective (S) version as seen in figure 1.  
Figure 1:FThe comparison between (S) and (R) isomers of ibuprofen to illustrate the mirror images of the compound that 
leads to different properties of the compound overall and how they interact within the body. (Singh et al. 2009) 
Further research is being completed regarding the potential of ineffective isomers 
being distributed along the supply chain. Ineffective isomers cause the same problem 
as counterfeit medicines themselves. 
 The isomers control if the mixture is an active or inactive ingredient, thus it is 
responsible for how a medicine effects the individuals   
But what is the true difference between the R and S isomers?  The letter ‘R’ comes 
from the Latin word ‘Rectus’ meaning right-handed which gives way to the relative 
direction of order in which the isomers rotate in the clockwise direction.  
This is visible – under a microscope - when light is passed through the sample. 
The letter ‘S’ however comes from the word ‘sinister’ meaning left-
handed justly meaning the isomer rotates in an anticlockwise direction. These rotational 
directions of order are seen when light is shined through the mixture.  
 
1.4 Distribution of Counterfeits 
Unfortunately, with a profit to be gained, no country, product or manufacturer is 
exempt from the possibility of counterfeits being placed in the supply chain. Over 10% 
of all counterfeit products are counterfeit medicines.  
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Counterfeit medicines are one of the most severe threats to public health 
(Dégardin 2014) due to 50% of products being bought over the Internet, of which 30% 
are a counterfeit version of the product being advertised (Sacré 2010).  
 Regrettably, a high percentage of counterfeit medicines are accounted for with 
purchases over the Internet. Most of the time the medicines are from an unknown 
source. 
According to the WHO: 
“A product that is deliberately and fraudulently mislabelled with 
respect to identity or source. Counterfeiting occurs with both branded 
and generic products and counterfeit medicines may include products 
with the correct ingredients but fake packaging, with the wrong 
ingredients, without active ingredient or with insufficient active 
ingredients” (WHO 2012). 
In 2018, the WHO Global Surveillance and Monitoring System recorded 17% of 
the total reports were on antibiotics and 20% were on anti-malarial drugs, which makes 
the antimicrobials the largest falsified and substandard drugs category.  
These numbers may not be an accurate representation as some countries do not 
have the ability to test for poor quality drugs, and some countries do not report to the 
system (WHO 2018).  
The most common counterfeits are antimicrobials (38%), hormone treatments 
(22%), antihistamines (17%), vasodilators (7%), and drugs for erectile dysfunction (5%) 
and anticonvulsants (2%) (Krakowska 2016). 










Figure 2: An illustration of the global transportation of counterfeiting medicine from around the world, demonstrating how 
large of a reach this market has. It also shows the paths from the producers/manufacturers to the local sellers and thus the 
consumers. (Dégardin 2014) 
The progression of counterfeit medicines within the industry has created links 
between distributors, local sellers, manufacturers and wholesalers. The links can be seen 
in figure 2 which shows that counterfeits can be found almost anywhere.  
Even countries such as Germany, France, Spain and the United Kingdom (UK) are 
not immune for the problem that is counterfeit medicines, as can be seen in figure 2. 
This illustrates that nowhere is safe from counterfeits, due to the process in the supply 
chain. 
 
1.5 Counterfeit Medicine Consequences 
Counterfeit products can be extremely dangerous and detrimental to a patient’s 
health. The best-case scenario of a counterfeit medication being used is that the 
product can be harmless like a sugar pill, whereas on the other hand they can be lethal.  
This is because, even at the best of times, medicines have a toxic effect on the 
body, whereas in worst case scenarios they cause death. This is a serious problem as in 
some cases these drugs are intended to be lifesavers (Blackstone et al. 2014). 
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In 2005, a 23-year-old male was admitted to a rural hospital in eastern Burma 
with a fever and was diagnosed with uncomplicated hypercarotenemic falciparum 
malaria by microscopy (where he had 4.2% infected red blood cells).   
Consequently, he was given 4 mg/kg of oral artesunate, which was a common 
treatment in that area. However, on the third night he became comatose when he was 
injected with intravenous artesunate in response to kidney and liver failure.  
Subsequently, he died of cerebral malaria. The original hospital sent the 
artesunate medicine that was used as treatment for analysis (Islam et al. 2018). The 
Fast-Red dye test was conducted, and it was found that the medicine administered was 
counterfeit. 
 Regrettably, it was not an isolated incident. In 2018 the WHO reported that 
158,000 people die each year from counterfeit anti-malarial drugs in sub-Sahara Africa 
alone (Christensen 2020). 
As medicines are an essential part of society, the public perception of them is an 
avenue that is rarely explored into great depth. As the need for medicines grows, so the 
need for financial and personal gain on such expenditure also increases.  
This provides an incentive for more advanced counterfeit medicines to be 
produced, which could in turn cause more harm than good to the wellbeing of the 
public (Houston 2012).   
The risk to the public’s health is due to the toxicity of the medicine and 
combinations within the body. An example of a toxic or adverse effect occurring would 
be the consumption of alcohol combining with a prescribed medicine (Weathermon & 
Crabb 1999).  
The risk can be limited be calculating and prescribing the correct quantity of the 
drug, considered its level of toxicity. Everything has a toxicity; sugar, water, tea even 
chocolate. The level depends on the quantity consumed. 
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Toxicity is the capacity that a substance has to be either poisonous or toxic 
(Houston 2012). It can come in multiple forms, and each person will have a reaction 
that is unique to themselves, just at varying degrees of severity. Biochemical 
interactions occur between the toxicants - that are formed when metabolised - and the 
target organisms. 
 The classification of the toxicity reflects the mechanism of action that is used by 
the target organism and the duration of which it takes for the substance to take effect. 
Acute and chronic are the two categories in which toxicity can be separated into. Acute 
is the effect when a substance is taken in a single or multiple dosage within 24 hours. 
Chronic is repeated exposure to the substance over an extended period (Zaitsu et al. 
2016). 
For counterfeit medicines, patients would experience a range of problems, 
dependent on the chemical makeup of the medicine used. As there are multiple classes 
of a counterfeit medicine, the first requirement is to establish if there is any API.  
If not, the medicine fails to aid the patient by relieving the ailment or helping 
them to become healthier. In extreme cases this can cause a chain reaction to occur 
that can be harmful to the patient.  
In the case of antibiotics, if a patient with a urinary tract infection is given a 
counterfeit version, the medicine would do little to treat the infection and consequently 
the patient can later develop blood poisoning that could be fatal in some cases 
(Hariharan 2007).  
In another incidence where there was no API but instead there are harmful 
chemicals in its place, for example, powdered cement floor wax, coloured dye, paint 
and even antifreeze in some cases. An example of the latter unfortunately being an 
incident in which over 500 children worldwide had a fatal reaction as a result of 
ingesting a cough syrup that was in fact tainted with diethylene glycol (ie antifreeze) 
(Houston 2012). 
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In some cases, the medicine may contain the correct API but in an excessive 
amount compared to what it should be. Regrettably this was the case in 2012 when 
over 1,000 people became seriously ill.  
Unfortunately, there were over 200 fatalities. This was because the medicine that 
was used for the treatment of individuals with cardiac problems, contained 14 times the 
recommended volume of pyrimethamine (WHO 2013).  
Ultimately causing the patients to suffer from severe folate deficiency, which later 
triggered heavy internal bleeding after the bone marrow platelets were destroyed (Guo 
1999). 
Medicines are always changing and adapting due to the knowledge and 
experience that is gained, processed and developed from the testing and the 
application of them. Not only that, but the distribution of them is also adapting and 
having a wider reach.  
With the access to the Internet more people have access to the medicinal 
products. This in turn means there are more access points within the supply chain for 
counterfeit medicines to be procured (Khan et al. 2011). 
Multiple studies have been conducted regarding different counterfeit products, 
(Assi 2011) and (Moffatt 2010) focused on counterfeit pharmaceuticals with the use of 
spectroscopy. Others such as (Quayle 2016) are more focused on counterfeit tobacco.  
Fourier Transform Near Infrared (FT- NIR) has been proven to be among the most 
common approaches to analyse the pharmaceutical products. This, being because it is 
non-destructive to the materials it is measuring, can be used to build quantitative 
regression models as well as being used for the creation of a reference library of 
materials (Assi 2011).  
The reference library constitutes chemical fingerprinting in the sense that each 
chemical is unique in functional groups that are represented in overtones. It is also a 
beneficial tool to use because it can be used in conjunction with multivariate analytical 
tools such as Principal Component Analysis (PCA) for example. 
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1.6 The Monitoring of Medicines Sales within the Market 
When a failure in the manufacturing process causes a defect to occur, such 
defects can be considered accidental within the supply chain (Almuzaini et al. 2013). 
When such problems take place, the product can be ultimately removed/ withdrawn 
from the market by the manufacturer. 
One example of a medicine having undesired results when available on the 
market would be the use of thalidomide, which of course infamously was used as an 
anti-emetic almost 60 years ago. After many incidents, it was discovered to be the pre-
cursor for almost 10,000 babies to be born with various birth defects.  
Even though the medicine itself was preventing women from suffering with 
morning sickness which was its main goal. The mothers suffered from peripheral 
neuropathy (Vargesson 2015). 
This was due to the inability of the drug to perform the desired result without 
causing harm. Consequently, thalidomide was removed from the market. Thalidomide 
has now been modified in recent years to successfully treat multiple myeloma, some 
cancers and even Crohn’s disease (Gupta 2017). 
With regards to other medicines, there are different types of defects that are 
catalogued that cause different responses to occur; i.e. contamination, deflect in API,  
delivery, minor packaging defect, major packaging defect, potency, stability failure, and 
other possible defects. 
Various types of defects are assigned by the Medicine and Healthcare Regulatory 
Agency (MHRA) into drug alert classes1-4 depending on the risk associated with the 
defects the medicines were found to have. 
Drug alerts classes 1 ,2 and 3 require the relevant medicine batches to be 
recalled, whereas drug alert class 4 does not require a recall of the batches, it does 
however advise caution when dealing with a defective medicine.  
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Depending on the severity of harm caused by the medicines, that occur within 
different time frames, various action is required. 
The European Union Council (EUC) on the other hand classifies a falsified 
medicinal product as (EMA 2020): 
“Any medicinal product with a false representation of: 
 Its identity, including its packaging and labelling, its name or its composition 
about any of the ingredients including excipients and the strength of those 
ingredients; 
 Its source, including its manufacturer, its country of manufacturing, its country of 
origin or its marketing authorization holder; or 
 Its history, including the records and documents relating to the distribution 
channels used. This definition does not include unintentional quality defects and 
is without prejudice to infringements of intellectual property rights.”  
And classes a substandard drug as: 
“Substandard drugs are manufactured with the intent of making 
a genuine pharmaceutical product, but the manufacturer saves costs 
by not following GMP (Good Manufacturing Practice) or using poor 
quality raw materials. Another potential problem relates to inadequate 
storage or transport conditions, leading to deterioration of the 
product. The performance of such medicines is questionable” (EMA 
2020) 
With regards to other medicines there are different types of defects that are 
catalogued which cause different responses to occur, they are as follows (Gov.UK 2020):  
Contamination: A defect that is in relation to microbial contaminations and issues 
that are related to the sterility as well as the chemical and particulates (e.g impurities) 
contamination 
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Deflect in API: Are defects that are the product of the API being either inadequate 
or excessive in the formulation. 
Delivery: A physical or technical such as a broken capsule or leaking bottle. 
Minor Packaging Defect: Are the defects that occur such as the printing/ labelling 
of the packaging, these printing box errors can involve missing batch number or either 
a missing of incorrect expiry date of the medicine. Minor packaging defects also 
includes any errors that are occur in the patients’ information leaflet and even the 
summary of the products characteristics. 
Major Packaging Defect: Are defects that involve missing or incorrect name or 
strength of the medicine dosage, as well as the packaging of a medicine in the 
incorrect box or carton. 
Potency: The failure of the medicine to produce a desired effect within the stated 
strength. 
Stability Failure: Are defects which result from the failure of the medicine 
attempting to remain within the established standards throughout the expiration 
period. An example of this would be the low assay of an API prior to the product expiry.  
Other Defects: Deviations which concern non-compliance with the good 
manufacturing practice (GMP) at manufacturing site. 
Different types of defects the Medicine and Healthcare Regulatory Agency 
(MHRA) assign different classes of drug alerts categories 1-4 depending on the risk 
associated with the defects the medicines were found to have (Gov.UK 2020): 
Drug Alert 1:  The defective medicine is life-threatening and there is a serious risk 
to patient health. 
Drug Alert 2: The defective medicine is not life-threatening and but there is a still 
a harmful risk to patient health. 
Drug Alert 3: Alert issued due to problems relating to the compliance with GMP 
or marketing authorities, even though the medicine is unlikely to be hazardous.  
Drug Alert 4: Advises “caution in use” as it is the least critical alert. 
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Classes 1 ,2 and 3 drug alerts require the medicines batches to be recalled, 
where-as drug alert 4 does not require a recall of the batches however caution is 
advised when dealing with defective medicines. Depending on the scale of harm that 
can occur results in different time frames of actions (Gov.UK 2020): 
Drug Alert 1:  CLASS 1 MEDICINES RECALL  
Action Now – including out of hours Pharmacy, Dispensing Clinic, and Wholesale 
Level Recall  
Drug Alert 2: CLASS 2 MEDICINES RECALL  
Action Within 48 Hours Pharmacy, Dispensing Clinic, and Wholesale Level Recall  
Drug Alert 3: CLASS 3 MEDICINES RECALL 
 Action Within 5 Days Pharmacy, Dispensing Clinic, and Wholesale Level Recall  
Drug Alert 4: CLASS 4 MEDICINES DEFECT INFORMATION  
Caution in Use Distribute to Pharmacy, Dispensing Clinic, and Wholesale Level  
One example would be Valsartan, that was used to treat high blood pressure, and 
subsequently was withdrawn from the market in 2018 due to impurities that were found 
(Farrukh et al. 2019). However, many poor-quality products go unreported.  
 
1.7 Regulations 
Regulations, which include laws and policies, are fashioned in a way that adapt to 
change and are there to safeguard the problem of counterfeits. In most cases they 
work. 
However, just like any created rule and regulation, there is always someone who is 
willing to break that ruling and generate a loophole in the justice system. These specific 
loopholes give way to the rise to the sale and production of counterfeits, that can be 
bought Over the Counter (OTC) or on the Internet. 
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Many government authorities over the years have been created to uphold and 
create new rules and regulations to help battle counterfeiting in various areas such as 
medicines, clothes and even toys.  
Unfortunately, there is no single governing body that has created a solid 
definition on what can be classed as a counterfeit or substandard imitation of a 
product. Due to this, loopholes are created, and counterfeits can be passed on to the 
consumers. 
The International Conference of Drug Regulation Authorities (ICDRA) was 
established to create countermeasures and is organised biennially by WHO.  
Those that have a governing body that regulates and polices the problem of 
counterfeits are the European Union (EU) who has the European Medicines Agency 
(EMA), the United States (US) that houses the Food and Drug Administration (FDA), and 
Japan with its Japanese Pharmaceutical and Medical Devices Agency (PMDA) 
(Stationary Office 2017).  
Together these authorities brought about the formation of the Centre for Drug 
Evaluation and Research (CDER). 
As Zou (2006) suggested, there are six main categories for regulating medicines, 
each of which contain several subsets. These resulted from Zou synthesising a clear and 
precise representation of the laws regulating them. 
 Assessing the safety, efficacy and quality of medicines. 
 Assessing the issuing and marketing authorisation of the individual 
products. 
 Controlling/ monitoring the medicine quality on the market. 
 Analysing the adverse reactions in reports and therefore monitoring 
the safety of marketed medicines. 
 Regulating the licencing of the import, manufacture, distribution, 
export, advertising and promotion of medicines. 
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 Overall inspection of the manufacturers, wholesalers and importers, 
as well as the dispensers of medicines. 
One important fact that always needs to be considered with medicines is that they 
need to pass/meet three criteria: they must be safe, effective and to be of good quality. 
The terms effective and efficacy can be interchangeable depending on the 
circumstances within Zou’s work.  
To combat counterfeit medicines various directives have been created, the most 
recent is the Falsified Medicine Directive (FMD) of 2019, this directive looks closely at 
the supply chain and how to regulate each step in the process.  
The regulations surrounding medicines, pharmacies and counterfeits are 
discussed further in Chapter Five with more details about the new FMD 2019 and the 
authorities that govern them. 
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1.8 Rationale 
The counterfeiting of medicines is a global threat that requires stringent 
monitoring. As shown earlier, antimicrobials are the primary counterfeited medicinal 
product with 38%. Within that category are antibiotics and antimalarials, both of which 
are covered within a vast array of literature.  
For the antibiotics the classes that are often regarded and analysed are 
antituberculotic agents, penicillin and antifolates, for antimalarials quinine and malarone 
(mixture of atovaquone and proguanil) are often the categories analysed.  
Antimalarials are often administered with an antibiotic acting as a secondary 
agent, with this being the case antibiotics will be the focus of this research.  It is not 
often that a subclass of antibiotics or other medicine is analysed as proven by the 
studies that are available to explore.  
Ciprofloxacin is an ideal choice for this purpose, the reason being that as shown 
previously it has varied and broad applications, whereas other antibiotics target specific 
aliments. 
By having such a range of uses it can be suggested that it would be more likely to 
be counterfeited as more profit can be gained from its production and use, as it would 
have a wider consumer base. 
This research investigates the chain of supply that the counterfeits are a part of. 
The next following chapters follow the next steps that the medicines themselves 
undergo.   
First is the creation of the counterfeits and how they can be chemically evolved. 
This is important to understand as a society, so that individuals can better arm 
themselves with the knowledge that the counterfeits on the market today, can be 
sophisticated, and only differ from the genuine medicinal products via their chemical 
properties.  
Page | 40  
Most analytical techniques that are used for the detection of counterfeit 
medicines are destructive of the sample, and require extensive sample preparation, 
thereby causing the cost and time spent on the research to increase. To prevent this 
eventuality occurring a FT-NIR Spectrometer will be used as the analytical instrument 
for this research.  
The reason for choosing to use the FT-NIR is that it can be portable in most forms 
and it also processes the data quickly, allowing further analysis to be completed in-situ. 
Thus, the use of a FT-NIR is beneficial in respect of finding a quick and inexpensive 
technique for the analysis of the chosen materials.  
The validation for using FT-NIR is that previous studies with similar parameters 
used has been successful in determining if counterfeit medicines are present.  
For more accurate results the use of multiple batches of ciprofloxacin is 
paramount, this gives more accuracy to what is classed as a counterfeit product and 
having a variety of country’s supplies opens the analysis to include various counterfeit 
properties that have been discussed in others published work. 
The next step would be the laws and regulations surrounding the medicines and 
the distributors as they are there to protect the public and make sure that the threat of 
counterfeits entering the supply chain has a minimal disruption to the chain and limited 
health risk to the end consumer.   
The laws and regulations that govern medicines are always changing and 
adapting to accommodate the changes and evolution of the problem that counterfeit 
medicines produce. 
By understanding the history of the laws, how they came about and what they are 
protecting against, a picture can be deduced as to what the next logical step will be in 
our evolution.  
Once the laws are in place the distributors are then the next step to be monitored 
and this is done via the internet and documenting how an online pharmacy functions, 
the potential risk they can cause, on top of how far their reach is.  
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 With how the law changes and adapts it is also important to understand that the 
distribution of counterfeits has also changed with the Internet being made accessible to 
anyone. Online pharmacies are the future as they are convenient and cost efficient, 
enabling more access points in the supply chain cannot be manipulated and taken 
advantage of.  
It is important to understand the expansion of online pharmacies and how they 
are monitored. The General Pharmaceutical Council (GPhC) and the MHRA are the two 
governing bodies for the UK with regards to online pharmacies and their directory of 
approved pharmacies will be analysed. 
Lastly how does the end consumer, the public justify self-prescription. What are 
the reasons that they use online pharmacies and do they have concerns for 
counterfeits?  
By knowing how society regards counterfeits and the use of online pharmacies, it 
can open more avenues of manufacturing practice that can help safeguard the 
consumer more.  
It can be used to appeal to the public and give knowledge to protect them to 
reduce future incidents. 
 Using public perceptions, counterfeit regulation and the physical properties of 
counterfeits, this research can help safeguard the future and outline the benefits and 
the limitations that are present. 
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1.9 Overall Purpose 
The issue of counterfeit medicines is a full circle, from production to consumption. 
This research is the link between the various steps within that circle  
The medicine that is the focal point of the research Ciprofloxacin is widely used 
for a variety of infections and it is a medicine that is not widely talked about in 
literature. Most pieces focus on the medicines that target a specific infection. 
The various methods implemented in this research follow scientific reasoning 
alongside legal reasoning with social science as a framework. 
By combining each of these distinctive methods in one piece of research a further 
understanding of the risk of counterfeits can be found. With the combinations of 
quantification, categorisation and public perception, it is possible to determine the risks 
posed by counterfeits and what aspects are most effected by them in everyday life.  
Currently each of these topics are focused on in a variety of different ways, 
however it is unlikely if not rare to see the different components that are listed in this 
research to be combined together to get a full picture of the problems that counterfeit 
medicines have on society.  
From the creation to the consumer following on through the laws and the 
distributors. This research can help aid in the prevention of counterfeit medicines and 
support the research that has already been conduct and will be in the future.  
By understanding each of the steps along the journey the separate limitations and 
strength can be uncovered but also the overall strategies that could arise.  
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1.10 Aims 
The purpose behind this research is to further understand and circumnavigate the 
prevalence, knowledge and regulations associated with counterfeit medicines.  
The main focus of this study is ciprofloxacin, why it is used, method of purchase, 
understanding risk of counterfeit duplication, determining a counterfeits presence and 
the preventive measures in place for public safety. 
This is conducted using exploratory, explanatory, quantitative and qualitative 
methods, in order to add to the body of literature surrounding counterfeit medicines. 
 
1.11 Objectives 
 To identify the most common classes of medicines that are known to 
be counterfeited with the use of quantitative meta-analysis and cross 
reference to literature. 
 To assess online pharmacies and identify the authenticity of the sites 
using statistical analysis of internet records. 
 To determine the public’s reasoning behind purchasing medicines 
and self-prescribing using quantitative analysis in the form of 
questionnaires. 
 To develop spectroscopic methods for determining the authenticity 
of some purchased medicines and how to visualised the 
discrepancies.  
 To discuss the new Falsified Medicines Directive and how appropriate 
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Chapter Two: Identification of Counterfeit Medicines 
Using Spectroscopic Techniques. 
After the public perspective and the knowledge of how the medicines are 
distributed, the identification of counterfeits and authenticating the medicines becomes 
an important stage of the distribution process. 
 This chapter investigates the analytical techniques used currently, the 
authentication of ciprofloxacin batches, what pre-treatment processes are used 
(chemometric analysis) and the tablet analysis with the aid of PCA and CWS. 
Within this chapter a quantitative approach with nominal data was conducted. 
This research was to determine the presence of counterfeit medicines. Quantitative 
analysis is a proven methodological process to analyse large sample sizes that contain 
numerical data.  
With this approach FT-NIR was used, as it is an established testing instrument for 
medicinal products as confirmed in Chapter One and Chapter Five. The reason that this 
research is important is so that individuals are able to understand and be confident to 
identify them. This is crucial with regards to understanding if the public are at risk and 
how to limit that risk (Sun 2009). 
2.1 Analytical Techniques 
Gas Chromatography (GC), High Performance/Pressure Liquid Chromatography 
(HPLC) and Mass Spectroscopy (MS) have recently been the most reliable and 
beneficial techniques available with regard to testing substances, in this case medicines.  
Often when coupled together these techniques produce a gold standard of 
analytical tools for analysis, for example GC – MS (Di Giulio & Bonamore 2008). Despite 
these techniques being accurate and precise due to high sensitivity, they can at times 
unfortunately be expensive.  
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This is due to the extensive preparation the samples must undergo before they 
can be scanned and measured, this process is time consuming and therefore expensive. 
However, this has led to more progressive techniques, such as spectroscopy, becoming 
more popular. Reasons for these techniques rising in popularity includes; they are rapid 
in producing a result, they require little to no preparation for the sample and they are 
also inexpensive compared to the other techniques (Manley 2014). 
Both qualitative and quantitative information can be obtained from the data 
collected with spectroscopic techniques. Despite the fact that the whole molecular 
structure cannot be determined, these techniques can be used to examine the 
following; determining atomic structure, partial molecular structure, stereo-chemical 
arrangements as well as the functional groups.  
The basis of these techniques is the emission or absorption of electromagnetic 
ration of a sample which can be either a discrete or a considerable amount (Whiffen 
1996).  The energy levels/states of the various fluctuations in radiation which are due to 
either the emission or absorption can be measured and recorded. The representation 
of such measurements is often in the form of a graph called a spectrum. 
Due to a variety of energy changes a range of spectroscopic methods are used 
for measurements (Cahtwal 2009; Howarth 1973) as seen in table 1. 
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Spectroscopy techniques can be conducted in tandem with other complimentary 
instruments as is the case of GC-MS, whereas others are better when they function on 
their own.  It is important to note that for this study NIR will be used in conjunction with 
a Fourier-Transform (FT) instrument. (FT-NIR) will be used as the spectroscopic 
technique to analyse the medicines, to determine their authenticity.  
FT-NIR systems have the advantages of possessing higher resolutions and higher 
signal energy, are more stable, are easily repeatable and have better wavelength 
accuracy. They are not affected by stray light that is known to cause sampling 
challenges for dispersive systems such as individual NIR (Terrell 2019).  
By using the FT-NIR in this study, the data sets produced from analysing the 
medicines can be counted on to be accurate, reliable and less deficient that if solo NIR 
was used.  
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2.2 Principles of Near Infrared Spectroscopy 
Since the early 1940s Infrared (IR) spectroscopy has been in use. This was later 
adapted with the aid of interferometers to create advancements in measurements and 
analysis. 
 The basis IR spectroscopy is the interaction between a sample material and the 
electromagnetic radiation emitted from the instrument as seen in figure 3 (Stuart 2004). 
Figure 3: Visual representation of the  electromagnetic spectrum and wavelength seperation (Haynes 2016). 
The interaction between a sample and the IR radiation, can be classed into one of 
four categories, depending on the way in which a sample reacts with the IR radiation; ie 
absorbed, transmitted, scattered or reflected.   
Excited vibrations occur within a sample when IR radiation interacts with it, thus 
causing the molecules inside to be placed in a higher state of vibrational energy (Jee 
2016). 
One type of IR spectroscopy would be that of NIR, which is composed between 
the red end and the Mid- Infrared (Mid-IR) region of the visible light on the 
electromagnetic spectrum.  
This particular region lies in the location of 780 – 2,500 nm, which is then further 
divided into two more subsections; the longer wavelength is represented in the range 
Page | 48  
of 1,100 – 2,500 nm and the Hershel region which houses the shorter wavelengths 780 
– 1,100 nm. 
 In the last 35 years NIR has been the majority usage, regardless of being 
discovered over 200 years ago. This is mainly due to the recent advancements made in 
analysis, such as chemometrics, that allows spectral interpretation to be much easier as 
well as being to a high quality.  
A benefit of using NIR for sample analysis is that it is non-destructive and requires 
little to no sample preparation (Salganicoff 1998; Lennard 2004; Jee 2016). 
NIR instruments collect data that are the result of the molecular vibrations, by 
examining the vibrational characterises of a sample that is being measured. This is 
based on the principal theory of ‘ideal’ diatomic harmonic oscillation.  
The basis of the theory is that due to bonds between two atoms (for example H2) 
stretching, vibrational energy is experienced. When atoms stretch within a molecule, 
they obey Hooke’s Law (Equation 1) and as a result fundamental frequency are 
produced (Figure 4). 
 
Equation 1: Stretching Frequencies, the combination of Hooke's Law and fundamental 
frequencies. 
 
Where ‘k’ is the classical force constant, ‘c’ is the speed of light (is not always necessary 















Figure 4: Diatomic molecules obeying Hooke’s law. Transitions of the varying overtones and fundamental frequency 
(v = 0  v = 1). (v = 0  v = 2)the 1st overtone and  (v = 0  v = 3) the 2nd overtone and so forth, (Jee 2016). 
It is a known fact that overtones are more common within the NIR region, 
whereas fundamental frequencies are more used in Mid-IR regions (Figure 5).  
The difference of individual frequencies or the sum will be calculated when two or 
more vibrational modes occur simultaneously, this is typical with molecules such as 
polyatomic molecules when they exhibit energy changes.  
These energy changes produce subtraction and combination bands, which are 
weak bands. Subtraction bands are rarely observed to occur at room temperature even 
though it is possible, whereas combination bands also have a low probability for 
occurring (10-1,000 times smaller) compared to that of the Mid-IR fundamental 
frequencies.  
With this being the case there is a high chance of weak absorbance to occur. 
Despite this, it is classed as an advantage as a sample can be measured without any 
preparation. 
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Figure 5: Range of overtone markers created by the bonds between atoms in a molecule (Badr 2011). 
The values that are often found to be high value tend to be anharmonic 
constants. This is because they are encountered in bonds containing hydrogen such as; 
C-H, N-H, S-H, and O-H therefore they are the most dominating overtones (Figure 5 & 
6). 
The anharmonic oscillator potential energy level ‘E’ is defined by the equation: 
Equation 2: Anharmonic Oscillator Frequency 
 
Where ‘h’ is Planck’s constant, ‘v’ is the vibrational frequency, ‘w’ is the spacing 
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Figure 6: Hydrogen containing bonds in NIR and their respective overtone classes (Stationary Office, 2017). 
NIR is capable of multiple measurements from different source types. The two 
main types that are categorically measured are transmittance (TR) and reflectance (R).   
Transmittance measures the degree in which absorption of the wavelength 
occurs, once the radiation has passed through the sample. 
 Reflectance however is when the radiation does not pass through the sample and 
instead reflects off the substance and that is then measured. 
 Absorption alone is not measured as the result would be zero as no wavelength 
passes through the sample or reflects off (illustrated in figure 7). 
 
  
Figure 7: The differences between reflection, absorption and transmission and the basic scale of how the materials effect 
the radiation (Stationary Office 2017). 
When inside the material the radiation reacts in different ways as illustrated in 
figure 8. The difference between the types of interaction within the sample and the 
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Figure 8: The interaction between the radiation and the inside of the sample (Rinnan 2014). 
Transmittance is the ratio between the incident radiations (I0) to the transmitted 
radiation (It): 
Equation 3: Transmittance 
 
 
Whereas Reflectance can be defined as the ratio between the reflected radiation 
(Ir) and the incident radiation (I0):  
Equation 4: Reflectance 
 
 
There are two main categories of reflection: specular and diffuse as seen in figure 
9 
Figure 9: Comparison between diffuse and specular reflection with regards to the radiation within a sample:  where (- is ) 
the incident light, (- is the reflected light.)  
 
Specular radiation is when the radiation that is focused on a sample is simply 
reflected off in a uniform degree when it encounters the surface of a material, 
unfortunately very little information is gathered from this type of reflectance.  
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Diffuse reflection however is when unabsorbed radiation is reflected at various 
angles, this is often caused by the sample often having an uneven surface so the 
radiation may enter uniformly but will not reflect just so (Jolliffe 2010).  
There are multiple variants of vibrational/spectroscopy tools that are based within 
the electromagnetic spectrum. Working within the range of 400 – 4,000cm-1 is Fourier-
Transform Near Infrared (FT-NIR) spectroscopy. 
 The analysis of organic compounds and materials is the main use of the FT-NIR. 
The difference between the dispersive NIR techniques and the FT-NIR is that instead of 
prisms and gratings that the former relies on, FTIR uses a Michaelson interferometer as 
seen in figure 10.  
The main components of an interferometer are the two mirrors, one of which is 
stationary while the other moves in a parallel line to the light beam, and the beam 
splitter. The distance between the mirrors and the beam splitter can be controlled to 
utilise certain characteristics of the Infrared light beam.  
Polychromatic light (from the source) is split into two beamlets with the use of the 
aptly named beam splitter; one moves towards the stationary mirror while the other 
towards the mirror that I was able to move. Once reflected off their corresponding 
mirrors the beamlets are then combined once again at the beam splitter.  
Once combined they successively pass through the detector, depending on the 
combination phase, constructive or destructive, that the beams are experiencing this 
will affect the light intensity that is monitored as illustrated in figure 10. 
The subsequently detected intensity of the light when applied with the function of 
the offset mirror, which is measured with the use of a laser, is called an interferogram. 
After this the interferograms are mathematically transformed with the use of a FT to 
eventually obtain a spectrum that can be analysed further. 
Due to the polychromatic light, not being mono-chromicised all wavelengths can 
be measured (Hariharan 2007). 
Page | 54  
Figure 10: The inside working mechanism of the Michaelson interferometer (Shaw 1999). 
Either with the aid of a FT or not, any NIR can obtain both chemical and physical 
information about a sample. This can then be used equally for qualitative and 
quantitative analysis. Measurements of a sample can be accomplished in-situ due to 
little or no preparation being needed.  
Whereas the spectral collection method is considered simple, the interpretation of 
such spectra is more complex as before it can finally be used for chemometric 
modelling PCA it requires in depth mathematical transformation and editing (Data Pre-
treatment).  
The data pre-treatment is important on the basis that it corrects the offset 
baseline shift of a spectrum that is often caused by the scattering of light, known as 
diffuse reflection (Rinnan 2009; Jee 2016; Stationary Office 2012). 
2.3 Data Pre-treatment 
When spectra data is in its rawest form, untreated, an effect called spectral offset 
and overlapping can occur among the different spectra. Multiple factors can contribute 
towards this phenomenon: moisture content, temperature, sample thickness, optical 
properties of the sample, age of the sample (expiry date) and how the instrument 
performs (Einax 1995; Salaganicoff 1998).  
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Spectral pre-treatment methods are typically used to avoid these spectral quality 
deviations, these various types of spectral treatment are used to correct spectral noise, 
which is often the resulting factor of light scattering, it also removes any unwanted data 
variations/anomalies that are not caused by light scattering.  
Light scattering, in respect of a sample, can often be the main carrier of 
information ascertaining to that sample. Both the chemical properties of the sample 
and structural information (such as scattering and relative absorbance of light reacting 
with the sample) can be contained within the diffusively scattered light, which can be 
analysed with NIR spectroscopy techniques.  
There are two different forms of light scattering that avoid interaction with the 
energy that is contained within the molecules; Rayleigh, which is common with Raman 
spectroscopy, and Lorentz-Mie. Where Lorentz-Mie is used with particles of a larger 
size, Rayleigh is used with small sized particles.  
Both Lorentz-Mie and Rayleigh are processes which involve electromagnetic 
scattering; for example, some of these are; bubbles, cells, small particulates, crystalline 
defects, fibres and droplets, to name but a few of the variants. 
Where Rayleigh is wavelength dependent Lorentz-Mie is anisotropic and relies on 
the shape of the particles. There are two main types of data pre-treatment techniques 
used for NIR spectroscopy, scatter methods and spectral derivatisation (Rinnan 2009; 
Rinnan 2014). 
2.4 Scatter - Correction Methods 
There are various types of scatter correction methods, the most common being 
Standard Normal Variate (SNV) and Multiplicative Scatter/Signal Correction (MSC). With 
regard to MSC there are many variations that can occur; Inverse MSC (IMSC), Extended 
Inverse MSC (EIMSC) and Extended MSC (EMSC). Others, such as de-trending and 
normalization, also are effective in certain circumstances (Rinnan 2009).  
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The interferences that can be caused by the light scattering as well at the particle 
size within the samples, can be corrected with the use of SNV. SNV scales the 
absorbance values that are found within the NIR spectra automatically (Van Bambeke 
2017), thus enabling a result to occur more quickly without manually entering the 
constraints of the pre-treatment process. The equation below illustrates the correction 
process for SNV. 
   
Equation 5: SNV Pre-treatment 
 
Where ‘a0’ is the average value from the sample spectrums that are to be 
adjusted and ‘a1’ is the standard deviation of those sample spectrum values, ‘Xorg’ is 
the original spectra sample that was measured, and ‘Xcorr’ is the corrected spectra.  
With regard to ‘a1’, multiple vector-norms such as the positive length of the 
vector, or the square root of the sum of the squares, even the overall sum of the 
absolute values of the vector elements being the most commonly used.  
For SNV it is not necessary for a reference signal to be obtained, in its place each 
observation of the data is isolated for the remainder. Due to not using the least squares 
regression parameters for any estimations it is believed that this makes the SNV more 
sensitive to the entries in the spectrum that identify as noisy entrees (Guo 1999).  
Both spectral offset and absorbance scale that are caused by the scattered light, 
can be corrected with the use of MSC (Einax 1995; Lennard 2004). The scattered light 
that is shown is relative to the reference sample, meaning that when the same 
reference sample is used the same scatter pattern will be seen.  
With MSC, artefacts (undesirable scatter effects) or other imperfections are 
removed prior to any data modelling, resulting in a more pronounced result. Unlike 
with SNV, MSC consists of two steps (Brereton 2006). 
Step (1): Coefficient’s correction (multiplicative and additive contributions) 
estimations. 
Page | 57  
Equation 6: Step 1 in MSC 
 
Step (2): Recorded spectrum that has been corrected. 
Equation 7: Step 2 in MSC 
 
Where ‘e’ is the un-modelled part of ‘Xorg’, ‘Xorg’ is the original spectra sample that 
was measured, b0 and bref,1 are the scalar parameters, that are different for each sample 
‘Xref’ is the reference spectra used for pre-processing the data and ‘Xcorr’ is the corrected 
spectra. 
2.5 Spectral Derivatisation Methods 
Norris-Williams (NW) derivatives and Savitzky-Golay (SG) polynomial derivatives 
filters are main representatives for the spectral derivatisation methods. Both methods 
for full optimisation require smoothing the spectra prior to the derivatives being 
calculated.  
This reduces the damaging effect on the Signal/Noise ratio (S/N ratio) that other 
conventional methods would create. For the correction of NIR spectra 1st and 2nd 
derivatives (D1 and D2 respectively) are used, due to their innate ability to correct the 
baseline shifts and offsets within the NIR spectra (Lennard 2004).  
Whereas the 2nd derivative removes the offset, the 1st derivative reduces the 
offset effectively to a much similar one that can be understood more clearly.  
The more popularised method of the two is SG derivatisation as is uses a vector 
that includes a smoothing step (Savitszky 1964). It is based on orthogonal projections 
that alter and reshape spectrums using either the D1 or D2 derivatives.  
More commonly a polynomial of the orders 2 – 4 are fitted by least squares to 
the data using a certain amount of data points that range between 3 and 10 to make it 
more accurate in correlating the data. 
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 To limit the errors that could occur this process is applied to the complete 
spectrum rather than individual sections (Barnes 1989;  Rinnan 2014).  Polynomials are 
added within a symmetric window of raw data for a derivative to be found at the centre 
points.  
However, this is accomplished after the parameters have been calculated. Once 
this is achieved the derivatives of any order can then be identified more easily in the 
future.  
The degree of polynomial is directly proportional to the derivative that can be 
found e.g., a 4th order polynomial can be used to estimate up to the 4th order 
derivative. 
The NW method on the other hand was developed to reduce if not completely 
avoid the noise inflation that can occur on a spectrum between finite differences. NW is 
a twostep method (Standcliffe 1991) as follows:  
Step (1): An average over several given points with the aim to smooth the spectra 
is performed using the equation below: 
 
Equation 8: 1st step in NW derivatisation 
 
With ‘m’ being the number of points that are contained within the window of 
smoothing, which are centred on the current measurement points within the data.  
Step (2): For the 1st order derivative to occur the difference between two 
smoothed values is calculated with the difference being greater than zero. For the 2nd 
order derivatisation at point ‘i’ the smoothed value is multiplied by two which is then 
compared to the value that is smoothed either side. Which is illustrated in equations 
below: 
Equation 9 + 9a: Step 
2 in NW 
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Within this project Savitzky-Golay Derivative 1 and Multiplicative Scatter/Signal 
Correction are the data pre-treatment methods used for this study. This is because 
when the data is constructed with these data pre-treatment methods it is more readily 
readable and can be understood more clearly. 
 
2.6 Chemometric Qualitative Data Analysis 
A fundamental part of the analysis for NIR spectra is chemometrics due to it being 
difficult to interpret. Chemometrics is when statistical and mathematical methods are 
used in tandem for data selection and optimal experimental analysis.  
“Chemometrics is a chemical discipline that uses mathematics, 
statistics and formal logic (a) to design or select optimal experimental 
procedures; (b) to provide maximum relevant chemical information by 
analysing chemical data; and (c) to obtain knowledge about chemical 
systems” (Westad 2005). 
Test assumptions, modelling and the design of the experiment are some of the 
several (information extraction methods) aspects that chemometric group together 
(Komsta 2018). 
A variety of different qualitative analysis methods including: PCA, Mahalanobis 
Distance in PCA (MDPCA), Soft Independent Modelling of Class Analogy (SIMCA), 
Principal Component Regression (PCR), Principle Least Squares Regression (PLSR), 
Correlation in Wavelength Space (CWS) and lastly Maximum Distance in CWS 
(MDCWS). 
PCA is a multivariable analytical technique which evaluates the variation within a 
data set collected by the uncorrelated components that endeavours to analyse the 
structure inside the data set (Parsale 2015). 
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The expression of orthogonal values – principal components (PCs) – after being 
extracted from within a matrix table (data set) is the aim of PCA. Using mathematical 
arguments, which can optimise several algebraic criterions the PCs can be identified 
(Jolliffe 2010).  
PCA is also used to help explain the variations that are found within the data that 
is collected. For this reason, significantly smaller data sets can be analysed by linear 
transformation of the original data variables. This is common in the use of PCR and 
PLSR (Dunteman 2016). 
Score vectors and loading arrays are the two pieces of information that are the 
basis for PCs to be fully functional (Wold 1987). The scores illustrate the dominant 
matrix patterns whereas the loading arrays demonstrate the variable patterns (Andalo 
2004) 
For PCA to work the number of PCs for a matrix should be equal to the number 
of the matrix components. The PC variability is directly proportional to the PC order.  
For instance, the first PC, known as PC1, will contain the highest set of variances 
within the models whereas PC2, the second PC, will contain the second highest set of 
variables (Zou 2006). 
Therefore, PCA can be determined by:  
Equation 10: The equation for PCA 
 
Where ‘M’ is the data table of the matrix, ‘L’ is the loading arrays within the matrix 
which has an equal value to the matrix columns, ‘S’ is the score vectors which also has 
an equal value to the matrix columns, and finally ‘E’ is the error rate identified within the 
matrix. 
Simple PCA is the method used in this study for chemometric analysis. The reason 
being, it can identify trends and clusters within the data, visually thus making the 
analysis clearer and more accurate.  
Page | 61  
CWS is a mathematical technique that compares the coefficient of the correlation 
between the sample spectrum (A) and the reference spectrum (B) (Lennard 2004).  
It can be estimated by using the dot product ‘rd’ produced by the calculated 
product momentum ‘rp’ between A and B. 
This can be seen in the following equations: 
 
   Equation 11: Dot Product of CWS 
  
 Equation 12: Momentum Product of CWS 
 
The resultant correlation coefficient can be either positive or negative. If the result 
is positive then that suggests that the spectra being compared have similarities, with a 
result of +1 meaning that the spectra that are compared are practically identical in 
properties.  
However, the reverse also stands true, if a negative value is present, it suggests 
that the spectra compared are dissimilar, the closer the value is to -1 the more 
dissimilarities between the spectra are occurring. 
Unfortunately, due to noise interference being present in NIR spectra it is rare that 
a correlation coefficient would have a result of +1. As a result of this rarity occurring, 
the value ‘r’ of 0.95 is used as a threshold for two or more pharmaceutical products 
being classed as being the same, due to the spectra being the match.  
If a result of ‘r’ being lower than 0.95 is found, it is said that the products being 
compared are not the same as the spectra are not a match, even if they have strong 
similarities (Brereton 2006). 
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2.7 Tablet Components 
2.7.1 Ciprofloxacin 
In the past 35 years, clinical practices have struggled to properly integrate the 
antimicrobial agents that have been introduced to the market at an inflated rate (Lee & 
Ronald 1987; Dax 1997) 
Like many of their predecessors, fluoroquinolones, since their introduction to 
society, have become a pillar of treatment for some serious bacterial infections (Patrick 






Figure 11: The structural illustration of Nalidixic Acid. 
The reason they are so favourable for treatment is due to some of their ideal 
properties such as; relatively low incidence of toxic and adverse effects, good tissue 
penetrability and lastly an excellent bioavailability. Which together makes a model 
medicine for use (Ruizdiaz et al. 2006). 
Ciprofloxacin, which was patented in 1983 by Bayer A.G (company based in the 
Germany - rank 17th in the world), is one of the most successful and widely used 
compounds of the fluroquinolones class 
(Appelbaum & Hunter 2000). 
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Figure 12: The structural illustration of Nalidixic Acid. 
Bayer A.G is also responsible for the creation and patent for Aspirin [1963], Heroin 
(diacetylmorphine), Phenobarbital, Prontosil (the first antibiotic to be widely used - 
which won them the Nobel Prize in Medicine in 1939) and finally Yaz - drospirenone 
(birth control pills). 
With a range of over 300 brands to its name, ciprofloxacin is a marketed medicine 
worldline. Since the introduction to the world market, the value of fluroquinolones has 
been recognised for their respective uses (de Almeida et al. 2007). 
One of the reasons behind this is due to the broad uses of ciprofloxacin and the 
wide range of activity and pharmacokinetic properties. 
With such a wide success, ciprofloxacin has become a high money maker for 
Bayer A.G, gaining over a billion (American) dollars in additional revenue and a 
respectable reputation.  
Turn of the century ciprofloxacin based on new prescriptions ranked number 11 
in the United States, and ranked 20th in total for sales in the United States. In total the 
gross sales of ciprofloxacin gained Bayer’s a total of $1.04 billion in revenue.  
Whereas after just five years levofloxacin and ciprofloxacin together controlled 
65% of global sales, proving that the purchase of antibiotics particularly fluroquinolones 
were on the rise. 
After being a steady profit with marginal increase over the year, it can be seen 
that after the anthrax scare that was recorded in 2001, there was a dramatic increase in 
ciprofloxacin sales.  
The recorded sales included the deal that was made between the Us government 
and Bayer Pharmaceuticals for the purchase of over 100 million tablets of ciprofloxacin.  
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This deal in turn gave Bayer a foothold on the global share market for 
pharmaceuticals and to be known as one of the top players in the industry. The deal 
also regained the company a respectable reputation after losing the patent of Aspirin 
after WW1 due to the companies’ origins. 
The reason that the U.S is a one of the pillars of this research is due to who the 
key players are in the pharmaceutical industry.  
Below is a list of the top 20 ranked companies based on their revenues/share 
holds in the pharmaceutical industry  
[ Key: Company Name – Revenue - % Change (Decrease) / % Change (Increase) – Location of HQ] 
1. Johnson & Johnson - $372.2 bn – 7.5% from Q4 2018 – America [New Jersey] 
2. Roche - $239.6 bn – 12.7% from Q4 2018 – Switzerland [Basel] 
3. Pfizer - $235.8 bn – 6.9% from Q4 2018 – America [New York] 
4. Novartis - $226.3 bn - 14% from Q4 2018 - Switzerland [Basel] 
5. Merck & Co. - $213.3 bn – 7.3% from Q4 2018 - America [New Jersey] 
6. Eli Lilly - $133.6 bn – 9.0% from Q4 2018 - America [Indiana] 
7. Novo Nordisk - $132.1 bn - 17% from Q4 2018 – Denmark [Bagsværd]  
8. AbbVie - $119.1 bn - 14.7% from Q4 2018 - America [Illinois] 
9. Amgen - $116.8 bn – 5.9% from Q4 2018 - America [California] 
10. Sanofi - $115.7 bn – 3.9% from Q4 2018 – France [Paris] 
11. GlaxoSmithKline - $105.7 bn – 7.2% from Q4 2018 – United Kingdom 
[Brentford] 
12. AstraZeneca - $103.7 bn – 4.5% from Q4 2018 - United Kingdom [Cambridge] 
13. Gilead Sciences – $81.2 bn – 0.3% from Q4 2018 - America [California] 
14. Bristol-Meyers Squibb - $78.1 bn – 7.9% from Q4 2018 - America [New York] 
15. CSL - $65.9 bn – 5.4% from Q4 2018 – Australia [Melbourne] 
16. Takeda Pharmaceuticals - $53.4 bn – 141.8% from Q4 2018 – Japan [Tokyo] 
17. Bayer A.G - $63.4 bn – 4.9% from Q4 2018 – Germany [Leverkusen] 
18. Celgene - $61.4 bn – 37.1% from Q4 2018 - America [New Jersey] 
19. Merck KGaA - $52.2 bn – 13% from Q4 2018 – Germany [Darmstadt] 
20. Allergan - $48.7 bn – 8.1% from Q4 2018 – Ireland [Dublin] 
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(Note these ranks were collected on Q1 of 2019 – BioSpace  2019) 
Together these 20 companies reported a collective market cap of $2.63 trillion in 
Q1 2019, which was an increase of 6.2% from 31st December 2018.  
As shown nine of the top 20 pharmaceutical companies in the world are based in 
the United States (U.S), Meaning that they have an important influence on market 
trends, what medicines are produced and also more importantly they are more likely to 
be a country that is a target of counterfeit medicines.  
Below in table 2, is just some of the representations of ciprofloxacin medicines 
that are branded in each country. 










The reason behind the classification of fluroquinolones is due to their wide range 
of activity and the chemical composition or sometimes known as the pharmacokinetic 
profile. Ciprofloxacin is a second-generation fluroquinolone. 
Out of the fluroquinolone class ciprofloxacin is the most potent. It can be used 
against a wide range of bacteria. The most vulnerable bacteria against ciprofloxacin are 
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Neisseria and Enterobacteriaceae, which are aerobic gram-negative bacilli (Farhi et al. 
2009).  
It is a very successful, capable and effective drug due to its well-established safety 
aspects and alongside the widely acclaimed potency against a vast number of bacteria.  
With more than 250 million patients treated ciprofloxacin is a worldwide success 
that has been extensively studied, part of that research was into its safety profile that 
has been documented in numerous publications over the years (Brunner et al. 2004). 
Children with cystic fibrosis have been treated with ciprofloxacin as an alternative 
for antimicrobial therapy. Over 1500 patients treated with ciprofloxacin has identified a 
safety profile for adults, adolescents and children (Kubin 1993). 
The minimum inhibitory concentration (MIC) of ciprofloxacin compared to the 
other fluroquinolones used commonly for in vitro susceptibility illustrated a distinct 
superiority when tested against multiple Gram-negative bacterial strains. 
Due to ciprofloxacin’s broad-spectrums antibiotic properties is used for treatment 
in cancer patients. It is mainly used because of its apoptotic and antiproliferative 
activities that are present in several cancer cell lines.  
It was detected that the dose-dependent and time – dependent growths caused 
in a variety of leukaemia cell lines, osteosarcoma and carcinoma were inhibited by 
ciprofloxacin (Herold et al. 2002). 
2.7.3 Mode of action 
Fluroquinolones inhibit the bacterial enzyme Deoxyribonucleic acid (DNA) gyrase 
by nicking/slicing the double stranded DNA introducing the negative supercoils then 
finally reseals the nicked end of the DNA strand.  
This process is necessary to avoid excessive build-up of positive supercoiling 
strands, when they are separated to allow transcription and replication of the DNA 
(Cozzarelli 1980; Schmitz 1998). 
Page | 68  
An enzyme called helicase is used in the process for transcription and replication 
to unwind the double helix DNA strand. Whilst uncoiling the DNA tension builds due to 
the surplus supercoiling of the outstanding DNA double helix.  
For the overall process to continue and be successful the tension needs to be 
relieved. The release comes in the form of topoisomerase II enzyme which allows the 
supercoiled DNA. It breaks both strands of the DNA, overlaps them reforming the 
double helix structure then reseals them (Patrick 2017). 
Ciprofloxacin impedes the activation of DNA gyrase (which is an essential 
adenosine triphosphate-hydrolysing topoisomerase II enzyme) or ciprofloxacin can 
prevent the detachment of gyrase from the DNA strand. 
When the topoisomerases interact with the DNA it uses its bactericidal ability 
(Walters et al. 1999).  
2.7.4 Current synthetic developments 
As ciprofloxacin is a commonly used antibiotic that’s used to treat a wide range of 
infections there has been extensive efforts to modify and optimise its potency and 
activity. Synthetic developments were used to derive an array of a variety of potent 
analogue candidates of this drug. 
The molecular modifications were created by a variety of useful techniques such 
as branching of the side chain, homologation of the side chain, bio isosteric 
replacements or stereochemistry to name a few (Abraham & Burger 2003). 
A collective of derivatives of ciprofloxacin have been illustrated to have a 
successful improvement for potency and activity. 
A list of derivatives include: 
(A)   1-cyclopropyl-6-fluoro-3-(5-(4-nitrophenyl)1,3,4-oxadiazol-2-yl)-7-(piperazin-1-
yl) quinolin- 4(1H)-one  
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(E) 1-cyclopropyl-6-fluoro-7-(4-(2-(5-(methyl thio) thiophen-2-yl)-2-oxoethyl) 
piperazin- 1-yl)-4-oxo-1,4-
dihydroquinoline-
3- carboxylic acid 
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2.7.11 Analytical aspects 
Following on from the introduction of Quinolones, the research and development 
thus far has been rapid in progress and has resulted in a variety or important 
fluroquinolones.  
These fluroquinolones have been under immense scrutiny to understand their 
physiochemical properties, the uses those particular dosages of ciprofloxacin in certain 
forms and biological fluids.  
Due to this many analytical and assay methods have been used to determine 
such features of ciprofloxacin and similar compounds.  
2.7.12 Physical properties 
In its purest form ciprofloxacin arises as a white powder that is thought to have a 
bitter taste. To minimize the potential for photolytically induced degradation 
ciprofloxacin should be stored in a dark cool place at ~4°C. the melting point of 
ciprofloxacin is between 313–315°C. one of the benefits of ciprofloxacin is how freely 
soluble it is, it can be dissolved in methanol, ethanol, acetone and acetic acid, but 
partially soluble in water. 
The coefficient for the octanol/water partition for ciprofloxacin is known to be less 
that one (Hirai et al. 1986). 
pI = 7.14 (isoelectric point, which is the average of pKa1 and pKa2)., pKa1 = 6.09 
and pKa2 = 8.62 are some of the pH-solubility profile dissociation and isoelectric 
constants for ciprofloxacin. 
 These levels suggest that the N-4 of the piperazine substituent and the 6-
carboxylic group are the two ionizable functional groups.  
Since the ammonium group tends to be the weaker of the two groups, the 
second ionization constant pKa2 (8.62) corresponds to the N-4 in the piperazinyl group 
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proton dissociation, whereas the 6-carboxylic group is represented by pKa1 (6.09) which 
is the first ionization constant (Varanda et al. 2006). 
pKa2 value is 8.25 when the ciprofloxacin is at its most physiologically relevant pH, 
significant dissociation occurs for both the ammonium and carboxylic groups, thus 
causing substantial fractions of zwitterionic species. 
2.7.13 Pharmacokinetic aspects 
The pharmacokinetic characteristics of ciprofloxacin are the main reasons why it is 
commonly used as treatment today.  
The primary factors are described in more detail below are as follows; the 
absorption, distribution, metabolism and finally the elimination of such compound.  
2.7.14 Absorption 
Even though ciprofloxacin is normally readily absorbed, when administered orally, 
its complete absorption is typically not achieved via this method. 
First pass metabolism does not cause a considerable loss of bioavailability of 
ciprofloxacin when administered orally. Via oral consumption the complete 
bioavailability is within the range of 70% - 80% (Morgan 1997). 
When intravenously administered (IV) it had a higher bioavailability similar to 
other medicines. As seen the IV dosage required is less than the equivalent dosage of 
oral to have a similar effect. 
For example, a 500mg tablet given every 12 hours produces an area under the 
serum concentration-time curve (AUC) equivalent to a 400mg IV infusion given over 
60-minute period every 12 hours. Other such comparisons are illustrated in table 3 
(Morgan 1997). 
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Table 3: Examples of how oral dosages compare to the equivanlent IV dosages. 
The pharmacokinetics of Ciprofloxacin within cerebrospinal fluid (CSF) has been 
described in many studies, it has been found that the penetration when compared to 
the corresponding serum concentrations was exceptional.  
However, the absolute CSF concentration was often at times thought to be 
subtherapeutic (Leone 2002). 
Within the blood-brain barrier there is a slow flux of ciprofloxacin which is 
suggested by the relative consistency of the CSF level (Lipman et al. 2000). 
It is believed that even though a drug-food interaction is known to prolong 
amount of time needed for the maximum plasma concentration (tmax) to be reached, it 





Ciprofloxacin’s pharmacokinetic are expected in table 4 
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 One of the reasons ciprofloxacin is superior to that of other fluroquinolones is 
because there is little to no binding to plasma proteins. 
After oral administration and except for the central nervous system (CNS) it has a 
good amount of penetration in numerous tissues and fluid of the body. 
Except when the meninges are inflamed there is a poor penetration into the 
cerebrospinal fluid. The liver, kidney, lung and prostate show a substantial drug level 
that has been achieved. 
One of the primary reasons it is used for urinary tract infections is due to the 
urinary drug concentration which is higher than the minimal inhibitory concentration 
(Appelbaum & Hunter 2000). 
As only a very small fraction of ciprofloxacin passes from mother to unborn child 
it is suggested that there is a barrier within the human placenta which slows down if not 
inhibits the transport of fluroquinolones (Polachek et al. 2005). 
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The bioavailability within the interstitial target site for ciprofloxacin is considered to 
be a determinant for the efficiency and successfulness of the antimicrobial therapy. 
2.7.16 Metabolism and elimination 
There is a variety in which the degree of metabolism and elimination of 
ciprofloxacin via the liver or renal excretion occurs within patients treated.  
Even though the primary route for elimination of ciprofloxacin is via the 
glomerulus filtration and tubular secretion renal route (Davis 2007), eliminations occur 
both via renal and non-renal routes.  
Therefore, if a patient was to have renal impairment their second path of 
elimination would be via the liver and the dosage would be changed accordingly 
(Morgan 1997). Unfortunate ciprofloxacin is not cleared from the bodies system 
substantially well especially by both haemodialysis and peritoneal dialysis.   
There is also known to be a reduction in from the metabolism of ciprofloxacin to 
oxo-ciprofloxacin by hepatic cirrhosis (Wolfson & Hooper 1991). 
2.7.17 Adverse effects 
When compared to the benefits you gain from using ciprofloxacin the adverse 
effects are no too severe. At therapeutic doses ciprofloxacin has a mild toxicity, and the 
adverse effects are generally limited to gastrointestinal incidents such as vomiting, 
nausea and diarrhoea (Sárközy 2001). 
However, skin photosensitivity has also been proven to be a reaction to the use of 
ciprofloxacin (Appelbaum & Hunter 2000). 
Over the years there has been an increasing amount of resistance in 
pneumococci even though usually that is quite rare (Ho et al. 1999). 
Aseptic meningitis (Kepa et al. 2005) and arthritis damage (Mao et al. 2005) are 
just some of the consequences of ciprofloxacin being used to treat anthrax (Liu et al. 
2008).  
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Due to the higher dosage required to pass through the blood-brain barrier (BBB), 
therefore there is now a need to increase the managed uptake to the brain for 
successful treatment (Feliciano et al. 2008). 
As with resistance in pneumococci, there has been a growing resistance and 
infective complications when ciprofloxacin is used as an antibiotic prophylaxis for 
prostate biopsies (Feliciano et al. 2008). 
2.7.18 Drug interactions 
Antacids containing sucralfate, aluminium and other agents such magnesium 
have been known to reduce the absorption of ciprofloxacin after being digested 
(Sárközy 2001). 
For this reason, it might be hazardous to use together whilst treating a serious 
infection (Dollery 1999). 
The interaction between methylxanthines such as caffeine and ciprofloxacin have 
a disturbing if not more fatal interaction with each other than the interaction with 
antacids. 
During this interaction there is a rise in serum theophylline concentration to a 
significant amount, which involves the isoenzyme 1A2 of the cytochrome P-450 
pathway becoming more pronounced the more it is used. Consequently, the 
monitoring of the xanthine’s is needed along with required dose reduction 
(Efthymiopoulos et al. 1997) 
The use of ciprofloxacin has also been associated with the elevation in serum 
levels of cyclosporine.  
However, an increase in the serum concentration along with a significant decline 
in the clearance of ciprofloxacin throughout the system when an interaction is observed 
when it is paired with cimetidine, azlocillin and probenecid.  
On the other end of the spectrum due to the interaction with the ciprofloxacin the 
serum concentration of antineoplastic drugs lowers significantly (Lubasch et al. 2000) 
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Citrates, carbonic anhydrase inhibitors and sodium bicarbonate, impede the 
solubility of ciprofloxacin thus causing the urine to become alkaline and consequently 
leading to crystalluria (Efthymiopoulos et al. 1997; Dollery 1999; Boy et al. 2004). 
2.7.19 Clinical indications 
As suggested earlier Ciprofloxacin is effective against a broad range of bacterial 
infections, even those that are often deems difficult to treat. 
Due to the wide-spectrum nature of ciprofloxacin oral efficacy, bactericidal and 
the general good tolerability, it is being used widely for blind therapy infections. 
However, if a Gram-positive organism is suspected to be the cause of infection. It 
should also not be used for minor cases (Efthymiopoulos et al. 1997; Dollery 1999; Boy 
et al. 2004). 









2.8.1 Medicine Dosage Forms & Excipients  
Ever since medicine was first discovered and used to ease the wounded or cure 
illness, the route it has been administered has always been evolving. The evolution of 
this pathway is to find the optimal dosage and environment for the drug to be given 
(Williams 1996; Rowe et al. 2003; O'Shaughnessy 2015; Abrantes et al. 2016). 
There are two main factors that determine if a drug will or will not reach the 
intended site of action within the body and if it has an impact.  
1. The bioavailability of the drug – the extent at which the drug/metabolites 
become completely available to its intended biological destinations e.g. the site 
of action within the body. 
2. How the drug is given to the patient – the route of administration 
Combining these factors are vital in determining the correct treatment for the 
patient.   
The way a person reacts to a drug entering the body impacts whether they can 
effectively use the medicine. By understanding the different routes and what the 
medicine is made of can help determine what the best course of treatment is.  
This section focuses on the medicines themselves, how they are administered, the 
forms of administration and what they are comprised of.  
All of these points together form a picture of how society can be deceived into 
buying a counterfeit which seems genuine, over its real counterpart.  
Page | 79  
 
2.8.2 Route of Administration  
There are various routes of administration that each have their own advantages 
and disadvantages. The reason being that once the drug enters the body it is 
metabolised in different sections of the body. This causes different speeds of action 
within the patient e.g some medicines are known to have slow-release mechanisms 
allowing for the medicine to work over a few hours rather than a quick release which 
has an almost immediate and short effect.  
The routes of administration are as follows (Williams 1996; Rowe et al. 2003; 
O'Shaughnessy 2015; Abrantes et al. 2016): 
 Oral – via the mouth  
 Injection  
o Intravenously,  IV  – into the vein 
o Intramuscularly,  IM – into the muscle 
o Intrathecally – into the space around the spinal cord 
o Subcutaneously,  SC – beneath the skin 
o Implantation – inserted into the body 
 Sublingual – under the tongue 
 Buccal – between the cheek and gums 
o Inserted 
 Rectally – into the rectum 
 Vaginally – into the vagina 
o Placed  
 Ocular – into the eye 
 Otic – into the ear 
 Nasal – sprayed or absorbed through the nasal channel in the nose 
 Nebulization – breathed into the lungs 
o Inhalation - usually through the mouth 
 Cutaneous – applied to the skin 
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o Topical – local effect 
o Systematic – body wide effect 
 Transdermal – normally a patch on the skin 
 
2.8.3 Types Dosage Forms 
The term dosage relates not only to the strength of medicine given but also the 
physical form by which the drug molecules are delivered to the desired site of action.  
There are four categories which the forms are split into similar to everyday life (Williams 
1996; Rowe et al. 2003; O'Shaughnessy 2015; Abrantes et al. 2016): 
Solid Dosage Forms 
1. Semi – Solid Dosage Forms 
2. Liquid Dosage Forms 
3. Gas Dosage Forms 
The most common dosage form is that of the solid variety.  
There are two sections in which drugs are categories in when focusing on the strength 
and volume of the dosage. 
1. Unit Dose 
2. Bulk Dose 
2.8.4 Solid Dosage Forms 
Solid Dosage Forms are aptly names as they occur in a solid state, they are often 
used for the therapeutic effect either via and oral or nebulization/ inhalation route. 
Examples of Solid Dosage Forms (O'Shaughnessy 2015): 
 Tablets/Pills – Are compressed solid dosage forms that contain the excipients 
and active ingredients. (Unit Dose). 
 Capsules – Unlike tablets where the particles are compressed, the particles are 
placed into a soft or hard soluble shell. (Unit Dose). 
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 Granules – An agglomeration of much smaller particles of powders. (Unit Dose). 
 Sachets – A small bag or pouch packet that contains small sized spherical 
granules. (Unit Dose). 
 Lozenges – A solid dosage form that when placed in the mouth dissolves slowly.  
(Unit Dose). 
 Powders – Are the base forms of all solid dosage forms. (Bulk Dose). 
 Dry Powder Inhalers – Small powder particles that are delivered to the lungs by 
making a similar characteristic to gas. (Unit Dose). 
 Chewables – Are solid forms that are similar to tablets and capsules but needed 
to be chewed for the desired effect. (Unit Dose). 
Advantages:  
 More stable than other dosage forms. 
 Easy to handle. 
 Most accurate over the other dosage forms. 
 No preservation required. 
Disadvantages:  
 Expensive Machines used in their creation. 
 Hard for kids and patients to swallow if unconscious or nil by mouth  
2.8.5 Semi – Solid Dosage Forms 
Semi – solid dosage forms are solids that can act like a liquid, they are mainly 
used for topical treatment via the skin, nasal, vaginal and rectal cavities (Rowe et al. 
2003).   
Examples of Semi - Solid Dosage Forms (Williams 1996; Rowe et al. 2003; 
O'Shaughnessy 2015; Abrantes et al. 2016): 
 Ointments – A smooth Oily substance created from a mixture of ingredients. 
(Unit Dose). 
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 Pastes – Either a hard or smooth thick mixture that can be spread over 
treatment area. (Unit Dose). 
 Cream – Emulsions of oil and water, either oil-in-water (O/W) or water-in-oil 
(W/O). (Unit Dose). 
 Plasters ( treatment within)  – A relatively thick smooth mass that has a strong 
adhesive that becomes solid over time. (Unit Dose). 
 Gels – They range from being soft and weak to hard and tough, they are dilute 
cross-linked system that exhibits no flow when in a steady state, otherwise it acts 
like a liquid. (Unit Dose).  
Advantages:  
 Suitable dosage form for bitter drugs  
 It is used externally 
 Local action and Site-specific action of the drug on the affected area. 
 The probability of side effects can be reduced 
 First, pass gut and hepatic metabolism is avoided. 
 More stable than a liquid dosage form 
 Convenient for unconscious patients or patients to have difficulty in oral 
administration. 
Disadvantages:  
 May cause staining. 
 Physicochemical is less stable than a solid dosage form. 
 The accuracy can't be measured, for the semisolid dosage form.   
 Application with a finger may cause contamination. 
 They are bulky to handle. 
 May cause irritation or allergy to some patients 
Ideal Properties:  
 Non-gritty 
 Smooth texture 
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 Non-greasy and non-staining 
 Elegant in appearance 
 Non-hygroscopic 
 Non-dehydrating 
2.8.6 Liquid Dosage Forms 
Liquid Dosage Forms occur in a liquid state, they are often used via oral, subcutaneous, 
intravenous, intramuscular, cutaneous (topical and systematic), Ocular and Otic.  
Liquid dosage forms can be divided into two sections according to their phases 
and both have either external or internal use (Rowe et al. 2003): 
1. Monophasic – Only one phase that is liquid. 
a. Internal Use:  
i. Syrup – Either a thick or runny sweet liquid made from boiling 
sugar and other constituents in water. 
ii. Mixture – One or more liquids that blend together smoothly to 
form a solution.  
iii. Linctus – A syrup or sticky preparation that is used for a local 
therapeutic action on the mucous membrane within the throat. 
iv. Elixirs – A hydro-alcoholic solutions that contains at least one 
active ingredient. 
v. Parenteral preparations – Solutions, suspension and emulsions 
that are prepared for injection. 
 
b. External Use: 
i. Gargle – The action of using a non-digestible liquid used as an 
intraoral wash.  
ii. Mouthwash - A non-digestible liquid used as an intraoral wash 
iii. Lotions – A thick, smooth or gritty liquid preparation. 
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iv. Nasal Drops – A solution of ingredients that are used in the nasal 
passage, they can be converted into a spray for inhalation and 
local effect.  
v. Ear Drops – A mixed solution of excipients that are used in the ear 
cavity. 
vi. Eye Drops - A blended solution of ingredients that are used in the 
eye cavities.  
2. Biphasic – Two phases one liquid and one solid.  
a. Internal Use: 
i. Suspension – Two or more substances one the solvent and the 
others solid particles that do not mix with each other and the 
particles are left suspended in the solution. 
b. External Use: 
i. Emulsion – Similar to creams they are made of two or more 
(liquid) substances that do not cohesively mix without forced 




 The rate of absorption of the liquid dosage form is so faster than the solid 
dosage form. 
 Very useful for those patients who have trouble swallowing. 
 Liquid dosage forms are flexible to take a proper those than solid dose 
Disadvantages:  
 The problem of container breakage. 
 Affected by microorganisms: Due to the presence of sweetening and flavouring 
agents. 
 It needs a lot of special storage conditions. 
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 Less stable than other doses. 
 
2.8.7 Gas Dosage Forms 
Gas Dosage forms are particles that are in a gaseous state. They are stored in 
containers and are released upon applying pressure. The containers have valve systems 
that allow for limited or continuous delivery. 
Examples of Gas Dosage Forms (Rowe et al. 2003): 
 Vaporizer – A device that vaporizes the liquid based into it to create a gas so 
that it can be inhaled. 
 Sprays – Liquid droplets that are dispersed in a large surface area, usual for 
local topical effect.  
 Aerosols – A colloidal suspension of a particles dispersed in the air via a gas. 
 Nebulizer – A device used to create a gaseous spray from a liquid by means of 
compression, oxygen or ultrasonic vibrations (it is sometimes referred to as an 
atomizer). 
 Atomizer – An instrument that reduces a liquid into a spray (disinfecting, 
cooling, medicinal use or perfumes). 
 Inhalers – Solutions, suspensions or emulsions of drugs in mixtures of inert 
propellants held under pressure in a gaseous dispenser such as inhalers and 
aerosols.  
There are no advantages or disadvantages that specifically apply to gas dosage 
forms but apply to the medicines they carry such as the liquids that are pressurised.  
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2.9 Pharmaceutical Excipients  
Within a medicine there is a variety of components to make sure it functions 
correctly, each of the components has a specific job. In this section the different types 
of excipients will be explored; the category, properties and examples of chemicals 
within the category. 
An Excipient is: 
“An excipient is any constituent of a medicinal product that is 
not an active substance used in the creation of pharmaceutical 
products. The desired effect of an excipients is to guarantee 
physiochemical and biopharmaceutical success” – (British 
Pharmacopeia 2017) 
2.9.1 Excipient Classification 
Excipients are broken into three classifications; Standard, Mixed and Co-
processed.  
Standard Excipients:  Either compendial or non-compendial inactive substances 
(Compendial means that the substances are indexed in the pharmacopeia.  
Mixed Excipients:  A mixture of two or more compendial or non-compendial 
substances, this mixture can be either in a liquid or solid form.  
Co-processed Excipients:  A combination of two or more compendial or non-
compendial substances, in a variety of methods such as melt extrusion, granulation, 
milling and spray drying. 
Following on excipients are separated into four source points; animal, vegetable, 
mineral and synthetic. 
Animal Sources:  Extracted from animals such as Lactose, Beeswax and Gelatine  
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Vegetable Sources:  Extracted from plants and vegetables such as Peppermint, 
Starch and Guar Gum. 
Mineral Sources:  Extracted from the earth such as Silica, Talc and Calcium 
Phosphate.  
Synthetic Sources:  Man-made (via combination methods) such as Lactic Acid, 
Polyethylene Glycols and Saccharin. 
2.9.2 Characteristics of Excipients 
For an excipient to be successful in use it must have the following characteristics 
(Abrantes et al. 2016): 
1. It must be physiologically inert. 
2. Stable both physically and chemically - either by themselves or in combination 
with other excipients or drugs. 
3. Available commercially within an acceptable physical and chemical grade. 
4. Accepted by the FDA/ regulatory agencies and non-toxic. 
5. Compatible with drugs. 
6. Have organoleptic properties that are accepted such as odourless and 
colourless. 
7. Impurity and microbial hazard free. 
8. Aid not hamper the bioavailability of the overall drug. 
9. Economical  
10. The quality must not be put into question. 
2.9.3 Excipient Functionality 
Along with the characteristics the excipients also have a purpose e.g., the 
functionality. These functions together combine to make the medicines we know as a 
society.  
Pharmaceutical Excipient Functions are as follows; Fillers, Binders, Disintegrants, 
Glidants, Organoleptic Additives - Colouring Agents, Flavouring Agents and 
Page | 88  
Sweetening Agents, Anti-adherent, Lubricants, Coatings, Preservatives, Antioxidants, 
Sorbents, Solvent & Co-Solvent, Buffering Agents, Chelating Agents, Viscosity Imparting 
Agents and Humectants. 
Filler/Dilutants:  Also known as fillers or bulking agents, dilutants are components 
within a solid dosage form to increase the volume or weight of the medicine 
(O'Shaughnessy 2015).  
Examples of Dilutants are as follows:  
Binders:  Also known as granulators, binders are substances that are used in 
formulations to facilitate the agglomeration of loose powder to clustered granules This 
often occurs in the presence of a granulating liquid such as hydroalcoholic mixtures, 
dihydrogen monoxide (water) and other solvents (Williams 1996).  
Examples of Blinders are as follows:  
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Disintegrants:  A substant or a mixture of multiple substances that are added to a 
formula to facilitate the breakdown/ disintegration of the medicine into smaller 
fragments allowing for faster dissolution (Abrantes et al. 2016).  
When a disintegrants interacts with a liquid such as water, intestinal or stomach 
acid, they can absorb said liquid causing them to dissolve, swell of even form gel like 
substances. Consequently, the medicine form (often a tablet) will disintegrate or rupture 
thus increasing the surface area of the drug substance for improved dissolution (Rowe 
et al. 2003). 
Examples of Blinders are as follows:  
Coatings: Are Substances that coat a medicine in the form of a tablet, capsule and 
other particles. Not all tablets need coatings (O'Shaughnessy 2015).  
A successful coating formula most commonly consists of: 
 Colourants 
 Solvents 
 Opaquant – Extenders  
 Plasticizers 
 Film Formers – Enteric or Non-Enteric 
 Miscellaneous coating solution components 
Solvent & Co-Solvent:  A solvent is the base of a solution formed by combining 
with a solute. A co-solvent is a substance that is added to the primary solvent in a 
solution to aid in increasing the solubility of a poorly-soluble compound (Rowe et al. 
2003).  
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Examples of Solvent include: 
Examples of Co- Solvent include: 
 Ethanol 
 Propylene Glycol 
 Glycerine 
 Glycofural 
 Polyethylene Glycols 
 
Polymers:  A substance that consists of very large molecules or macromolecules 
comprised of many repeating subunits (Abrantes et al. 2016). 
Examples of Polymers include: 
 
Plasticizers:  A substance that is added to compound to increase its plasticity, 
decrease its viscosity and friction to ultimately make the compound softer and more 
flexible (Williams 1996).  
Examples of Plasticizers include: 
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Film Formers:  They are used as protection against environmental factors such as 
the air, light and moisture. The layer coating the drug helps to increase the mechanical 
strength, aids the patient in swallowing the drug, helps in product identification e.g., a 
bright or unique colour, texture and taste (O'Shaughnessy 2015). 
The coating also enables to mask the taste and smell, furthermore it can be used 
to modify the release of the active ingredient.  
There are four types of Film Coating: 
1. Conventional Film Coating 
2. Modified Release Film Coating 
3. Sustained Release Film Coating 
4. Enteric Film Coating & Non-Enteric Film Coating 
Examples of Enteric Film Coating: 
 Hydroxyl Propyl Methyl Cellulose 
 Sodium Carboxy Cellulose 
 Ethyl Cellulose 
 Acrylate Polymer EudragitE 
 Povidone 
 Propyl Ethylene Glycol 
Examples of Non-Enteric Film Coating: 
 Cellulose Acetate Phthalate 
 Acrylate Polymer EudragitL, S 
 Hydroxyl Propyl Methyl Cellulose Phthalate 
 Polyvinyl Acetate 
Anti-adherent: Used to prevent the tablets/pills from sticking to the insides of the 
dies and to the punches during the compression process. They also go by the name of 
anti-sticking agents (Williams 1996).  
Examples of Anti-adherent include: 
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 Starch (Corn-starch) 
 Talc 
 DL – Leucine 
 Sodium Lauryl Sulphate 
 Magnesium Stearate (Stearates) 
 Colloidal Silicate 
Emollients: They are used to adjust the texture of the products, such as ointments, 
creams and lotions. They are also used to aid in the smoothness and softness of the 
skin. Typically, they are used in conjunction with emulsifying agents for far better results 
(O'Shaughnessy 2015).  
Examples of Emollients include: 
 Glycerine 
 Glyceryl Mono Stearate 
 Polyethylene Glycol 
 Petrolatum 
 Isopropyl Myristate 
Emulsifying Agents: Used to reduce the surface tension between immiscible 
liquids or in a mixture between solids and liquids. It is a biphasic preparation that is a 
combination of two or more liquids that’s are forced to mix and remain together, it is 
successful when the kinetic energy in the mixture is decreased (Abrantes et al. 2016). 
The agents that are used are surface active, meaning that they absorb to the 
freshly made oil-water combo interface during the emulsion process. This absorption 
characteristic enables the formula to remain a emulsion and not recoalesce or cream.  
Examples of Emulsifying Agents include: 
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Humectants:  They are used in the prevention of product drying such as creams 
and gels, this is successful due to the ability to attract and retain water vapour (Rowe et 
al. 2003).  
Humectants can be categorised into three sections: 
1. Organic – Carbon based compounds occurring in natural environments.  
2. Metal Organic – An organic-inorganic hybrid crystalline porous material.  
3. Inorganic – Compounds that contain no carbon elements. However elementary 
carbon (graphite or diamonds) is considered inorganic alongside Nitrogen, 
Oxygen and Silicon. 
Examples of Humectants include: 
Preservatives:  a substance that is added to prevent decomposition of the product 
by undesirable chemical changes or unwanted microbial growth. Consequently, they 
improve/ amplify the shelf life of the products (Abrantes et al. 2016).  
Examples of Preservatives include: 
Antioxidants: Are substances that protect the Active Pharmaceutical Ingredients 
(APIs) that would normally degrade in the presence of either oxygen or peroxides 
(Rowe et al. 2003). 
Examples of Antioxidants include: 
 Butylated Hydroxy anisole 
 Butylated Hydroxytoluene 
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 Sodium Metabisulphite 
 Citric Acid 
Sorbents:  Are an insoluble substance used to absorb gases and liquids. 
There are four types of pharmaceutical sorbents: 
1. Activated Alumina 
2. Activated Carbon 
3. Polymeric Adsorbent 
4. Silica Gel 
Buffering Agents:  Used to adjust the pH of the drug to optimise its stability, they 
are also used to keep a constant hydrogen ion concentration (Williams 1996). 
There are three types of buffers available: 
1. Acidic Buffers / Acidifying Agent– Buffers that contain a weak acid and one of 
its salts. They are used to increase the metabolic acidosis of the patient and the 
gastric hydrochloric acid. 
2. Basic Buffers / Alkalizing Agent  - Buffers that contain a weak base and one of 
its salts. They are used to increase the pH within the body.  
3. Double Salt Buffers - Buffers that comprises of two salts. 
Examples of Buffers include: 
Examples of Double Salt Buffers include: 
 Monobasic Potassium Phosphate 
 Dibasic Potassium Phosphate 
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Chelating Agents:  A chemical compound that reacts with the metal ions in the 
body to forma a stable water-soluble complex. The reason they are successful is that 
they have a ring-like centre structure which allows it to form at least two bonds with 
the metal ions flowing in the body, allowing for it to be excreted (O'Shaughnessy 
2015).  
 
Viscosity Imparting Agents:  A substance that is added to a mixture to increase 
the viscosity without modifying a compounds characteristic. These types of agents 
improve the suspension of added ingredients, provide a body and increase stability 
(Abrantes et al. 2016). 
Examples of Viscosity Imparting Agents include: 
 Hydroxy Ethyl cellulose 
 Hydroxy Propyl Methyl Cellulose 
 Methyl Cellulose 
 Polyvinyl Alcohol 
Lubricants:  Are non-toxic and are pharmacologically inactive substances that are 
usually added to formulas to reduce if not prevent frictional forces between particles 
to each other and between particles and (metal contact surfaces) manufacturing 
equipment such as dies and punches (Williams 1996).   
Liquid lubricants are used before compaction as they are absorbed by the solid 
dosage forms.  Lubricants are also known to improve the flow rate of granulation.  
Examples of Lubricants are as follows:  
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Glidants:  Also known as anticaking agents are similar to lubricants in the way 
that they are non-toxic and are pharmacologically inactive substances used to 
promote the flow rate of granulation (Rowe et al. 2003). 
 It also decreases particle friction and unity when powders in particular are 
stored in bulk. Glidants are added during lubrication but in the dry stages before 
compaction (Rowe et al. 2003).  
Examples of Glidants are as follows:  
Surfactant:  Have well defined polar and non-polar regions on the substances 
that allow for aggregation in the solution that forms micelles. The non-polarised drugs 
can eventually be partitioned into micelles that can ultimately be solubilised.  It acts 
similar to a lubricant and decrease the interaction/ surface tension occurring between 
a solid and liquid, a liquid and gas or even between two liquids (Rowe et al. 2003).  
Examples of Surfactants are as follows:  
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Colouring Agents:  An inactive substance which are added to produce a 
significant appearance to help differentiate products from each other that would 
otherwise may have similar physical appearances (Abrantes et al. 2016).   
Colouring agents are placed into four categories: 
1. Lakes:  Insoluble forms of dyes that are a consequence of its irreversible 
adsorption onto a hydrous metal oxide. 
2. Natural Colourants:  Colouring Substances that are not considered to be dyes. 
3. Dyes:  Water – Soluble Colouring substances 
4. Inorganic Pigments:  Compounds such as metal oxides e.g., Iron Oxide and 
Titanium Oxide. 
Examples of Colouring Agents are as follows:  
Flavouring Agents:  Can be a single or combination of chemicals be it natural or 
synthetic in origin that help make the medicine more palatable for the patient thus 
increasing their compliance.  They produce an aroma or a taste when orally smelled 
or consumed (Williams 1996).  
Examples of Flavouring Agents are as follows:  
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Sweetening Agents:  They are used to also mask the usual unpleasant taste and 
flavours that medicines have. The sweeteners bind to the receptors on the tongue that 
are responsible for the sweet tastes that the body experiences (O'Shaughnessy 2015).  
Examples of Sweeteners are as follows:  
Release Modifying Agents:  Are substances that are used to control the speed at 
which the dosage is released. The most common is a prolonged release or a 
controlled release (Rowe et al. 2003). 
Examples of Release Modifiers are as follows:  
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2.10 Instrument – Fourier Transform Near Infrared 
Spectrometer  
The instrumentation that was the basis on the work in identifying the counterfeit 
medicines was the PerkinElmer Spectrum Two N Fourier-Transform Near Infrared 
Spectrometer (figure 13).  
The PerkinElmer Spectrum Two N FT-NIR fully equipped with a highly sensitive 
temperature stabilized In GaAs detector for quantitative use and low light applications 
as well as a LiTaO3 (lithium tantalite) NIR Detector.  
Alongside this it is also equipped with, for more repeatable and accurate results, 
standard Atmospheric Vapour Compensation (AVC), Absolute Virtual Instrument (AVI) 
and Automatic Performance Verification (APV). It also has OpticsGuard for humidity 











Figure 13: PerkinElmer Spectrum Two N Fourier-Transform Near Infrared Spectrometer in the process of scanning a 
ciprofloxacin tablet. As shown in on the computer screen the Spectrum 10 ES IR operating software illustrating the spectra as the 
sample is scanned. 
The collected spectra contained, at intervals around 1cm-1, over the 
wavenumber range of 4000 - 10,000cm-1, roughly 6,000 different data points.  
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The spectra graphs were produced by the Spectrum 10 ES IR operating software 
that was fitted on the computer whilst it was attached to the instrument.  
Spectrum 10 ES IR software was only used when the sample was tested, this was 
due to it showing the raw data and observations of the sample set could be seen.  
Therefore, if a sample was tested but did not follow the pattern of the same 
sample from previous scans it would be tested again. 
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2.11 Materials Used for Analysis: 
For this research, 40 different materials/excipients were used for analysis. 296 
ciprofloxacin tablets were inclusively used from a combination of 28 various batches. 
 All the batches were purchased and acquired from various countries, from 
different sources, most of which are deemed reliable. The source of purchase sources 
includes online pharmacies and brick and mortar versions. 
42 raw materials were scanned and analysed in this project, are listed below, 
three of which are combined as they are commonly found together in medicines. 
These are the Amoxicillin + Clavulanic Acid as well as the Amoxicillin + Potassium 
Clavulate.  
The raw materials were chosen as the majority of them are found to be 
excipients in the antibiotic tablets scanned and others show similar properties and 
were scanned for comparison. 
These materials are used in the PCA comparisons of the antibiotics and the 
binary mixtures and the CWS comparisons containing the raw materials and 
antibiotics as illustrated further on in this chapter.  
Within the APPENDIX illustrates all the details of the various ciprofloxacin batch 
samples, including product name, average weight of the tablet with the m/m%, batch 
number, the API that was involved, the manufacturer and the place of purchase 
(country) were recorded. 
The medicines collectively were gathered in a variety of ways, some were 
remaining tablets from various individuals’ treatments. Some were purchased over the 
counter in multiple abroad countries, some were purchased via the internet and 
delivered, where others needed to be collected. 
 By having multiple collection methods, it greatly improves the validity of the 
tests conducted as not just one area in the supply chain was focused on.  
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The information gathered as highlighted in the APPENDIX such as different 
Manufactures, Country of Source, Excipients, and volume of API were tested and 
recorded. This overall method of approach means that the exploration of counterfeit 
medicines can be expanded and separated for future in depth analysis.  
A list of the raw materials that were used for this study all of which were 
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2.12 Method 
2.12.1 pre-scanned: 
All materials that were measured were in a variety of states, these included; 
tablets, solutions, crushed powders and liquids. To enable an accurate measurement 
to be taken each state had a different process that it underwent. 
The solutions and liquids were placed into a 4mL water glass vial (transparent). 
These vials protect the samples from environmental influence such as humidity. The 
empty vials (EV0) mass was measured first and recorded. The vials were then filled with 
the various materials using pipette due to the varying viscosity of the solutions, and 
the mass was re-measured and recorded (EV1).  
The measurement originally recorded, Evo, was subtracted from EV1 to calculate 
the mass of the material itself. The properties of the materials found within the vials, 
such as the name, manufacturer and batch number, were recorded and attached to 
the vials for future indication of what lay inside. 
For the powders the same 4mL water glass vials were used, the empty vials were 
weighed, and the measurement recorded. Once the vial was filled with the correct 
material mass using a spatula they were re-weighed, and the measurement was once 
again recorded. The mass from the empty glass vial was deducted from the overall 
mass.  
The antibiotic tablets (all 296 ciprofloxacin and the comparative antibiotics) 
however were individually weighed, their mass’ were recorded, and then placed into a 
clear zip bag, which were then labelled with the tablet’s properties including the mass, 
name of tablet, the API, expiration date, batch number, manufacturer and the tablet 
number within the batch. 
2.12.2 Weight Validation  
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For the powders and solutions, an optimum volume of material within the vials 
needed to be calculated. The reason being that a uniform mass could then be used 
with all materials and a clear result could then be examined further.  
For this to happen the top five excipients, discovered in literature to be within 
the tablet categories that were researched in this project, were scanned at various 
volumes.  
The excipients measured were; Magnesium Stearate, Microcrystalline Cellulose, 
Maize Starch, Talc and Lactose, the volumes measured ranged between 0g – 1g at 
intervals of approximately 100mg.  
Once scanned the spectra from each of the excipients were pre-treated with SG 
D1 and treated with MSC. The spectra were then examined, and the main seven peaks 
were identified and the wavenumber corresponding to the peaks was recorded as 
illustrated in figure 14.  
For Microcrystalline Cellulose there were seven main peaks that were discovered; 
4298cm-1, 4342cm-1, 4800cm-1, 5216cm-1, 5628cm-1, 6664cm-1 and 8192cm-1 as seen 
to be identified in figure 15. The Signal/Noise Ratio for each of the wavenumbers for 
each of the volumes were grouped for further analysis.  
Figure 14: Seven main peaks of Microcrystalline Cellulose (MCC) highlighted by a red circle for illustration. 
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Visual aids were then created to help in the comparison between the 
Signal/Noise Ratio and the volume of excipients for each of the wavenumbers that the 
main peaks identified. Most commonly the data represented in the visual aids were of 
a normal distribution characteristic making it easier to identify the optimum volume 
needed as seen in figure 15 
Figure 15: Visual Representation of one Wavenumber for MCC with its corresponding Signal / Noise Ratio when scanned at 
various volumes. 
All wavenumbers that were found to be a main peak were examined and the 
results recorded for each to identify which volume gave the maximum Signal/Noise 
ratio for that wavenumber.  
The overall volume that produced the optimum Signal/Noise ratio for all 
excipients was 300mg. Therefore, 300mg was the volume that the powders 
(excipients) and mixtures (binary mixtures) were measured to throughout this project. 
2.12.3 Pilot Study: 
Originally the tablets that were to be scanned were contained within glass vials, 
however when the spectra collected from those tablets were analysed it illustrated a 
variety of noise present.  
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To correct this, adjustments were made to limit the noise impacts, the tablets 
were removed from the vials, with the use of gloves/ tongs, and placed directly on the 
FT-NIR for scanning. 
 As a result, the spectra showed defined peaks. Accordingly, the tablets 
throughout the project were placed directly onto the NIR plate during the scanning 
process.  After each tablet was scanned the plate was wiped carefully with solution 
and dried with a soft tissue to help prevent contamination. 
The tablets orientation was the next to be tested to further validate the method 
that would be used. A variety of tablets were scanned in multiple ways; each side was 
scanned and rotated 90˚ and re-scanned, a total of four scans were taken for each 
tablet two on each side. 
 When the results were examined, it was shown that the side scanned caused 
variation within the spectra, however, the rotation did not cause any variations to 
occur. It was concluded that the minimum number of scans that were needed for the 
project was two.  
However, with the powders and solutions not being compacted like the tablets 
two methods for validation ensued. The first being when the samples were stagnant 
and scanned, the second being when the powders and solutions were placed in a 
vortex mixer and scanned. 
 When the data collected was examined and compared it was seen that when 
placed in the vortex various readings would occur. This illustrated how a powder, or a 
solution is formed with regard to the particulates within it.  
By using the vortex throughout the project more accurate results were gained. 
For each powder and solution three to four scans were taken to ascertain a more 
reliable result due to the general properties within the sample. 
A benefit from using the Spectrum Two N Fourier-Transform-Near Infrared 
Spectrometer rather than another NIR, is that is does not require manual background 
or reference scans as the instrument itself completes those before a scan occurs.  
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2.24.4 Scanning Process: 
For the tablets two scans were taken, one on each side (plain side and then the 
pharmaceutical side). For more accurate and reliable data collection, multiple samples 
were taken from a single batch, up to ten tablets from each batch were used and 
multiple batches were used to show correlations within the data.  
For the powders and solutions, now measuring at 300mg, these were scanned 
three to four times depending if the sample was a pure standard or a mixture created 
for testing. The solutions and powders were both vortexed between individually scans.  
2.12.5 Data Input 
When scanned each sample had the spectral wavenumber range of between 
4,000 cm-1 and 10,000 cm-1 which had ~ 6000 data points at scanning intervals of 
1cm-1. The data that was collected was saved using three different extensions for 
further analysis (Sing Point [.sp] , JCAMP-DX [.DX] and Excel [.csv]). 
2.12.6 Data Pre-treatment & Analysis 
After the data had been saved using the various extensions, it was imported into 
Unscrambler 10.5.1 for data manipulation (pre-treatment) to take place and then 
imported into Excel for further spectral analysis.  
For this project, the data was derivatised to the first order using SG D1 and 
treated with MSC for spectral quality to be more accurate. The reason that SNV was 
not used was that, for the data that was collected, SNV did not show variation within 
the data points that made further analysis impossible. 
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2.13 Results & Discussion of Analysis 
2.13.1 Spectral Quality 
The NIR spectra had to be optimised for the noise present in the spectra to be 
reduced with the aim of making interpretation of the spectra easier to understand. This 
is also called curve fitting. 
MSC and the D1 of SG were used to treat the spectra with the aim of reducing 
the noise caused by the scattering. By using this method, the total number of peaks 
increased, enabling higher discrimination margins when completing further multivariate 
data analysis as illustrated in in figure 16.. 
Maximum absorbance, minimum absorbance, wavelength range, signal to noise 
ratio (S/N) and the number of peaks were some of the many factors that were 
considered when examining the spectral quality see APPENDIX.  
When some of the ciprofloxacin batches are compared - as shown in figure 17 & 
18 for some there is a peak at ~ 7100cm-1 which can be converted to 1408.45nm. 
The conversion of wavenumber to wavelength is illustrated below: 
Equation 13: The conversion between wavenumber and wavelength 
 
Where ‘k’ is the wavelength, ‘λ’ is the wavenumber.  
When the 1408nm peak is examined further and compared to the overtones in 
Chapter Five it represents a CH2 or CH3 bond.  
Due to the particulars of the C-H bond it is hard to determine the cause of such a 
bond appearing in the ciprofloxacin and where the contamination came from.  
The reason for calling it a contamination is that the peaks are only found within 
the ‘counterfeit’ samples. The authentic and generic samples do not contain the extra 
peak at 7100cm-1/1408nm. 
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Due to the comparisons of the raw materials to the ciprofloxacin samples, this 
bond and the excipients used in the tablets – from the medicine’s leaflets - it can be 
assumed the peak comes from Talc, as it has a strong peak at ~ 1408nm - as shown in 
figure 16. 
For future research the use of other instruments such as gas chromatography can 
be used to isolate the compound responsible for the C-H bond appearing at ~ 1408mn 
to confirm the assumption of Talc being the main contributor to this peak being 
present.  
 














Figure 17: MSCD1 Ciprofloxacin comparison of some of the batches used. 
 
 
Figure 18: MSCD1 Talc, with a distinguishable peak at ~7100cm-1. 
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2.14 Binary Mixtures Data Analysis: 
Within the pharmaceutical industry the use of powders for the intermediate or 
final products is widespread practice, and the mixing of those powders is one of the 
most common pharmaceutical operations.  
Most pharmaceutical products have a mixing stage and it would be difficult to 
find one that does not use this technique at some stage of production. 
Mixing can be defined as the process in which one product is created with two or 
more constituents that are mechanically blended or mixed together. The constituents 
are chemical substances, either elements or compounds.  
When mixed together chemical bonding or other chemical changes do not occur 
and each constituent of the mixture retains its chemical properties or make up (Atkins 
et al. 2002). 
With regard to pharmaceutical mixing, it often occurs on a large scale, for 
example: 
 The mixing of powders in a variety of proportions prior 
to tableting or granulation. 
 The dry mixing of various materials for direct tablet 
compression. 
 The dry blending of powders within compound 
powders (insufflations) and capsules. 
Solids such as powders can be divided into two types depending on the flow 
properties of the materials themselves, as illustrated in figure 19; cohesive which have a 
resistance to flowing through other materials e.g. wet clay or non-cohesive which are 
materials which flow readily such as sand, grain, even plastic chips (Smalley 1970).  
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Figure 19: Comparison between (A) cohesive and (B) non-cohesive material mixtures 
Flow ability must be mastered such and the understanding of free-flowing 
particles within powder mixtures must be achieved to enable successful production 
(Teunou et al. 1999).   
The reason for this is that within dry powders van der Waals forces are the main 
inter-particle force that causes the particulates to adhere to each other. This occurs 
especially when the contact distance between particles ~ 0.4 nm and the particle 
distances below that of 50 nm (Krupp 1967).  
The reason that van der Waals are so important within powder mixtures is that 
the size of the van der Waals force is directly proportional to the size of the particle 
itself (Yang & Evan 2007).  
Therefore, it is easier to produce a mixture with powders that have similar density 
and fineness, than to produce a mixture of a large mass of coarse powder combined 
with a small proportion of fine powder.  
Other than the density and the size of the particle, the adhesive properties of the 
constituents are also important factors that are taken into consideration when 
producing pharmaceutical products.  
For instance, in one tablet there are a variety of different types of powders/ 
compounds that when compressed form the tablet. These include but are not limited to 
the APIs, the bulk components, coating and some components which enable a slow 
release of the API into the blood stream. 
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For that reason, in the testing of tablets and other pharmaceutical compositions 
the knowledge of mixture behaviour is vital. 
As explained by Sun (2016) a classification for binary mixtures are theoretical 
considerations based on tableting behaviours. Using various systems of classification, 
binary mixtures can be used as a guide for efficient tablet formulation that are 
developed based on the different mechanical properties of the APIs and the excipients 
used. 
For this reason, the examination of binary mixtures is a key element in the 
discovery of fraudulent behaviour and counterfeit products being produced and sold 
around the world. 
What should be shown when a binary mixture is subjected to PCA is a parabola 
effect, for as one excipient increases in volume the other excipient decreases in volume.  
To test this theory five excipients will be combined in 10 various combinations and 
then analysed with FT-NIR. After they are analysed, they will be subjected to both PCA 
and CWS analysis. This is because the visual representation of the data that both 
produces is clear and concise.  
Table 6: The classification of each binary mixture (BM) model with the various components, where (A) is Magnesium 
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The excipients that are used for the binary mixtures within this research are as 
follows; Magnesium Stearate, Mg(C18H35O2)2, Microcrystalline Cellulose, C18H32O16, 
Maize Starch, Ca2H5O12P3, Lactose, C12H22O11, and finally Talc, H2Mg3O12Si4. As 
shown in figure 20, the various excipients have significantly different signatures.  
Each of the models have 13 vials within which there is a varying quantity of 
excipient. As stated previously, as one excipient increases in volume the other 
decreases. The ratio of the vials in each model are; 100% + 0%, 90% + 10%, 80% + 
20%, 75% + 25%, 70% + 30%, 60% + 40%, 50% + 50%, 40% + 60%, 30% + 70%, 25% 
+75%, 20% + 80%, 10% + 90% and finally 0% + 100% with excipient 1 and excipient 2 
respectively. 
2.14.1 Binary Mixtures PCA: 
As illustrated in table 7, there are 12 different PCA Binary Mixture models, which 
when combined illustrate why mixture definition is important. It also has the benefit of 
understanding the structures of the chemicals themselves.  
Table 7: The collection of Binary Mixture (BM) PCA Models and their respective Principle components (PC) on MSC-D1 pre-
treated FT-NIR data. Where (A) is Magnesium Stearate (MgS), (B) is Talc (Talc), (C) is Microcrystalline Cellulose (MCC), (D) is Maize 
Starch (MzeS) and lastly (E) is Lactose (Lact). 
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Figure 20 illustrates the FTNIR raw spectra of the excipients in the binary mixtures 
over lapping each other, it aids to illustrate clearly defined peaks and broad bonds 
shown in each constituent.  
Each of the excipients featured in the graph below represent the most common 
available in the ciprofloxacin tablets.  Within the graph it can be seen that there are 
strong sharp peaks related to the talc excipient, one at ~7100 and one at ~4400. These 
peaks transfer over to the ciprofloxacin tablet spectra as illustrated in the MSCD1 
Ciprofloxacin comparison graph (figure 18)  
The magnesium stearate excipient has a defined peak at ~5800. the other 
excipients in this model illustrate broad peaks overlapping the ~4500-7500 range. 
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This broad range makes it difficult to certifiably distinguish the different excipients 
from each other as they behave similarly to each other when place in the infrared 
beam.   
Figure 20: The raw spectra of Magnesium Stearate, Microcrystalline Cellulose, Maize Starch, Lactose and finally Talc 
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2.14.2 Binary Mixtures CWS: 
As illustrated in table 8, there are 10 different PCA Binary Mixture models, which 
when combined illustrate why mixture definition is important. It also has the benefit of 
understanding the structures of the chemicals themselves.  
Table 8: The collection of Binary Mixture (BM) Correlation Wavelength Space (CWS) Models on MSC-D1 pre-treated FT-
NIR data. Where (A) is Magnesium Stearate (MgS), (B) is Talc (Talc), (C) is Microcrystalline Cellulose (MCC), (D) is Maize Starch 
(MzeS) and lastly (E) is Lactose (Lact). 
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2.14.3 Binary Mixture 1 (A) + (B) 
Binary mixture 1 is comprised of (A) Magnesium Stearate and (B) Talc.  
Comparison of similarities found within the mixture illustrated both with PCA and 
CWS analysis. 
Figure 21: PCA – BM1  & CWS – BM1 respectively comprised of  Magnesium Stearate & Talc. 
PCA – BM 1 as shown in figure 21 demonstrates a clearly defined relationship 
between the ratio mix comprised of compound (A) and (B).  
This illustrates the sensitivity of the FTNIR instrument used. The reason being that 
each ratio sample mix within the model is shown to be comparable and the level of 
ratio able to be determined.   
This is supported by the CWS-BM1 model in figure 21. The ratio mix shows to 
have a strong correlation when the various sample mixtures are compared to 
themselves as you would expect. When the ratios are compared against each other the 
level of excipient within the ratios is more noticeable.  
The overall ‘r’ value ranges from 0.88 to 1. This indicates that the binary model for 
mixtures (A) & (B) are a success, as the percentage of the mixtures are able to be 
distinguished and calculated.  
For instance, the orange section of the CWS graph represents the 88% ratio mix 
that has a correlation of 0.88, whereas the light green section indicates 0.96 ‘r’ value for 
a 96% correlation match. 
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2.14.4 Binary Mixture 2 (A) + (C) 
Binary mixture 2 is comprised of (A) Magnesium Stearate and (C) - MMC -
Microcrystalline Cellulose.  
Comparison of similarities found within the mixture illustrated both with PCA and 
CWS analysis. 
Figure 22: PCA – BM2 & CWS – BM2 respectively 
comprised of  Magnesium Stearate & MCC. 
PCA – BM 2 and CWS – BM 2 as shown in figure 22 demonstrates a clearly 
defined relationship between the ratio mix comprised of compound (A) and (C).  
BM2 demonstrates an ideal model for the ratios when analysed as it clearly shows 
50% to 100% mixtures which is how the whole binary mixture is comprised of as one 
excipient increases and the other decrease at a identical rate. It is a directly proportional 
relationship. 
The overall ‘r’ value for the CWS model ranges from 0.5 to 1. This indicates that 
the binary model for mixtures (A) & (C) are a success, as the percentage of the mixtures 
are able to be distinguished and calculated.  
For instance, the dark blue section of the CWS graph represents the 50% - 60% 
ratio mix that has a correlation of 0.5, whereas the yellow section indicates 80% - 90%.  
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2.14.5 Binary Mixture 3 (A) + (D) 
Binary mixture 3 is comprised of (A) Magnesium Stearate and (D) Maize Starch.  
Comparison of similarities found within the mixture illustrated both with PCA and 
CWS analysis. 
 
Figure 23: PCA – BM3 & CWS – BM3 respectively comprised of  Magnesium Stearate & Maize Starch. 
PCA – BM 3 and CWS – BM 3 as shown in figure 23 demonstrates a clearly 
defined relationship between the ratio mix comprised of compound (A) and (D).  
The overall ‘r’ value ranges from 0.4 to 1. This indicates that the binary model for 
mixtures (A) & (D) are a success, as the percentage of the mixtures are able to be 
distinguished and calculated.  
For instance, the dark blue section of the CWS graph represents the 40% ratio mix 
that has a correlation of 0.40, whereas the light blue section indicates 0.80 ‘r’ value for 
an 80% correlation match.  
BM3 has the largest ‘r’ value range within all the binary mixtures this could be and 
also it is the only model for the binary mixtures that has an inverted parabola, there is 
no reason that can be determined for this effect as the mixture itself is definable.   
More investigation would be needed to understand what could cause this change 
apart from the possibility of commination or axis reversal. 
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2.14.6 Binary Mixture 4 (A) + (E) 
Binary mixture 4 is comprised of (A) Magnesium Stearate and (E) Lactose.  
Comparison of similarities found within the mixture illustrated both with PCA and 
CWS analysis. 
Figure 24: PCA – BM4  & CWS – BM14 respectively 
comprised of  Magnesium Stearate & Lactose.. 
PCA – BM 4 and CWS – BM 4 as shown in figure 24 demonstrates a clearly 
defined relationship between the ratio mix comprised of compound (A) and (E).  
The overall ‘r’ value ranges from 0.40 to 1. This indicates that the binary model for 
mixtures (A) & (E) are a success, as the percentage of the mixtures are able to be 
distinguished and calculated.  
For instance, the orange section of the CWS graph represents the 50-60% ratio 
mix that has a correlation of 0.50-0.60, whereas the light green section indicates 0.90-1 
‘r’ value for a 90-100% correlation match. 
BM4 is similar to BM3 in how the ratio mixtures are illustrated, only one ratio 
sample within the model seems to be out of the parabolic trend set for PCA analysis, 
the CWS illustrates the correlative effect similar to the PCA model.  
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2.14.7 Binary Mixture 5 (B) + (C) 
Binary mixture 5 is comprised of (B) Talc and (C) - MMC -Microcrystalline 
Cellulose.  
Comparison of similarities found within the mixture illustrated both with PCA and 
CWS analysis. 
 
Figure 25: PCA – BM5  & CWS – BM15 respectively comprised of  Talc & MCC. 
PCA – BM 5 and CWS – BM 5 as shown in figure 25 demonstrates a clearly 
defined relationship between the ratio mix comprised of compound (B) and (C).  
The overall ‘r’ value for the CWS model ranges from 0.5 to 1. This indicates that 
the binary model for mixtures (B) & (C) are a success, as the percentage of the mixtures 
are able to be distinguished and calculated.  
For instance, the dark blue section of the CWS graph represents the 50% - 60% 
ratio mix that has a correlation of 0.5, whereas the yellow section indicates 80% - 90%.  
The mixture ratios and success rates of identification of excipient amounts, are 
similar to models BM2, BM6 & BM7, as the parabolic effect of the PCA models show 
how the ratio of the mixtures change within a model compared to the percentage of 
the mix.  
Similarly, the CWS models show clearly defined bands of correlations between 
50% and 100% and the respective ‘r’ values of 0.5 1.  
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2.14.8 Binary Mixture 6 (B) + (D) 
Binary mixture 6 is comprised of (B) Talc and (D) Maize Starch.  
Comparison of similarities found within the mixture illustrated both with PCA and 
CWS analysis. 
 
Figure 26: PCA – BM6  & CWS – BM16 respectively comprised of  Talc & Maize Starch 
PCA – BM 6 and CWS – BM 6 as shown in figure 26 demonstrates a clearly 
defined relationship between the ratio mix comprised of compound (B) and (D).  
The overall ‘r’ value for the CWS model ranges from 0.5 to 1. This indicates that 
the binary model for mixtures (B) & (D) are a success, as the percentage of the mixtures 
are able to be distinguished and calculated.  
For instance, the dark blue section of the CWS graph represents the 50% - 60% 
ratio mix that has a correlation of 0.5, whereas the yellow section indicates 80% - 90%.  
Just as with BM5 the binary mixture analysis is a success as the PCA illustrates a 
definitive curve/trend and the CWS demonstrates a clear correlation for each of the 
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2.14.9 Binary Mixture 7 (B) + (E) 
Binary mixture 7 is comprised of (B) Talc and (E) Lactose.  
Comparison of similarities found within the mixture illustrated both with PCA and 
CWS analysis. 
 
Figure 27: PCA – BM7  & CWS – BM7 respectively comprised of  Talc & Lactose 
PCA – BM 7 and CWS – BM 7 as shown in figure 27 demonstrates a clearly 
defined relationship between the ratio mix comprised of compound (B) and (E).  
The overall ‘r’ value for the CWS model ranges from 0.5 to 1. This indicates that 
the binary model for mixtures (B) & (E) are a success, as the percentage of the mixtures 
are able to be distinguished and calculated.  
For instance, the dark blue section of the CWS graph represents the 50% - 60% 
ratio mix that has a correlation of 0.5, whereas the yellow section indicates 80% - 90%.  
BM7 has a similar result to BM2, BM6 and BM8 with regards to how the PCA and 
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2.14.10 Binary Mixture 8 (C) + (D) 
Binary mixture 8 is comprised of (C) - MMC -Microcrystalline Cellulose and (D) 
Maize Starch.  
Comparison of similarities found within the mixture illustrated both with PCA and 
CWS analysis. 
 
Figure 28: PCA – BM8 & CWS – BM18 respectively comprised of  MCC & Maize Starch. 
PCA – BM 8 and CWS – BM 8 as shown in figure 28 demonstrates a clearly 
defined relationship between the ratio mix comprised of compound (C) and (D).  
The overall ‘r’ value ranges from 0.88 to 1. This indicates that the binary model for 
mixtures (C) & (D) are a success, as the percentage of the mixtures are able to be 
distinguished and calculated.  
For instance, the orange section of the CWS graph represents the 88%% ratio mix 
that has a correlation of 0.88, whereas the light green section indicates 0.96 ‘r’ value for 
a 96% correlation match. 
The reason for the interrupted parabola for the mixture of (C) & (D) could be that 
an error occurred when the vials were filled with and the ratio mix was incorrect and the 
m/m% were out of proportion.  
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2.14.11 Binary Mixture 9 (C) + (E) 
Binary mixture 9 is comprised of (C) - MMC -Microcrystalline Cellulose (E) Lactose.  
Comparison of similarities found within the mixture illustrated both with PCA and 
CWS analysis. 
 
Figure 29: PCA – BM9  & CWS – BM9  respectively comprised of  MCC and Lactose 
PCA – BM 9 and CWS – BM 9 as shown in figure 29 demonstrates a clearly 
defined relationship between the ratio mix comprised of compound (C) and (E).  
The overall ‘r’ value ranges from 0.7 to 1. This indicates that the binary model for 
mixtures (C) & (E) are a success, as the percentage of the mixtures are able to be 
distinguished and calculated.  
For instance, the grey of the CWS graph represents the 80-85% ratio mix that has 
a correlation of 0.80-0.85, whereas the dark blue section indicates 0.70-0.75 ‘r’ value for 
a 70-75% correlation match. 
Similarity to BM8 the disruption to the ratio determination could be the result of 
incorrect m/m% and ratio mix measured or contamination to the sample itself.  
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2.14.12 Binary Mixture 10 (D) + (E) 
Binary mixture 10 is comprised of (D) Maize Starch and (E) Lactose.  
Comparison of similarities found within the mixture illustrated both with PCA and 
CWS analysis. 
 
Figure 30: PCA – BM10  and CWS – BM10  respectively comprised of  Mazie Starch & Lactose. 
PCA – BM 10 and CWS – BM 10 as shown in figure 30 demonstrates a clearly 
defined relationship between the ratio mix comprised of compound (D) and (E).  
The overall ‘r’ value ranges from 0.6 to 1. This indicates that the binary model for 
mixtures (D) & (E) are a success, as the percentage of the mixtures are able to be 
distinguished and calculated.  
For instance, the dark grey of the CWS graph represents the 90-95% ratio mix 
that has a correlation of 0.90-0.95, whereas the light blue section indicates 0.70-0.75 ‘r’ 
value for a 70-75% correlation match. 
As with BM8 & BM9 the binary mixture interruption could again be the result of 
miscalculation or measurement, contamination of such samples.  
  
Page | 129  
2.15 Binary Mixture Comparison: 
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Figure 31: The collection of PCA binary mixture models from 1 - 10. Where [1] is the mixture of A+B, [2] is A+C, [3] is A+D, 
[4] is A+E, [5] is B+C, [6] is B+D, [7] is B+E, [8] is C+D, [9] is C+E, [10] is D+E. Where (A) is MgS, (B) is Talc, (C) is MCC, (D) is MzeS 
and lastly (E) is Lact.. 
As seen in figure 31 PCA – BM 1 - 7 show clear parabola effects between the two 
main excipients shown in colours and the various ratios within the model in black. By 
having a clear parabola effect, it can be suggested that volumes of excipients within a 





Figure 32: PCA - BM 1, where MgS and Talc are in a comparative ratio mixture. As the MgS volume ratio decreases and the 
Talc volume increases the data points start to bend towards Talc. 
Not all the binary mixtures illustrate a perfect parabolic effect. There are several 
reasons why this could have happened. The first is that the samples themselves could 
have been contaminated with other substances if the spatulas were not cleaned 
thoroughly between mixtures being produced. 
 Another reason being that the percentages of the samples within the mixture 
where not accurate enough, thus the percentages of volume where disrupted.  
However, PCA – BM 8 – 10 show a scattering of data points rather than a clear 
parabola effect like the other models. The reason in this case is most likely due to the 
chemical structures of the excipients in models 8 – 10. 
 The chemical composition of MCC, MzeS and Lact, could be interfering with the 
readings as they are similar in structure. Also, it is illustrated that as one excipient’s 
volume increases, the inverse is true for the remaining excipient in the mixture and the 
volume decreases as seen on closer inspection in figure 25. 
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Microcrystalline Cellulose 
As can be seen in figure 34, when the Binary models are combined in one PCA 
the clusters start to be seen. With the pure excipients being at each end of a model the 
mixtures of various percentages in volume can be found along a line between the two 
excipients that contribute to the mixtures. 
As can been seen in figure 35, between the black dots representing MCC and the 
purple dots representing MzeS, the two mixtures represented by the orange dots are in 
a linear line connecting the two. This shows that PCA can distinguish the percentages in 
the mixtures and which excipients they belong to. 
As indicated in the black circle there is a cluster of three models and three 
excipients, which can be examined further in figure 34. When the cluster is examined 
more closely it can be seen that a triangle of mixtures form, and each side of the 
triangle is a batch mix of a binary mixture. 
 The peaks of the triangle are three of the excipients used.  As shown in figure 33 
the chemical compounds of C, D and E are of similar structure, whereas A and B are 
different.  
Figure 33: The Chemical Strcuture of the Excipeints found in the binary mixtures. Where (A) is MgS, (B) is Talc, (C) is MCC, 
(D) is MzeS and lastly (E) is Lact.. 
  
Lactose 
Maize Starch Talc 
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This is the cause of the cluster triangle being close together and the larger 
triangle seen in PCA-BM 1. This triangular cluster is made of the same components that 
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2.16 Binary Mixtures Implications: 
The binary mixtures created, demonstrate on a small scale the excipient structure 
that is found within tablets. By using the various mixtures of the common excipients 
found, a satisfactorily method of analysis and the correct instrument can be 
determined.  
 Not only does the mixtures aid in the spectra analysis, but the ratios between the 
excipients in the various mixtures also help determine how accurate and sensitive the 
FTNIR is.  
This sensitivity when understood, factors in the effects that the surroundings and 
other variables have on the instrument and how accurate the spectra is that is 
produced. Therefore, the FTNIR and PCA are able to distinguish between the various 
excipients in a mixture and a compacted tablet.  
The spectra that were then treated by an illustrative analysis, in this case PCA, can 
determine if correlation and similarities can be found within the binary mixtures of 
different ratios and thus determine the same properties in the tablets.  
For the CWS analysis only 4/10 models demonstrate the ideal data to be 
illustrated with ‘r’ values between the ranges of 05 to 1. Whereas the other models the 
‘r’ values are ranging from as low as 0.4 to 1.  
By knowing that similar compound structures group together it can be suggested 
that overall similar compounds will also group together as the structural integrity is 
virtually identical if not for a slight variation.  
For further analysis to determine the margin of accuracy tertiary mixtures and 








Figure 34: PCA-BM 11, the comparison for all 10 binary mixtures models with the 13 vial ratios within. 
 
 
Figure 35: Closer examination of the cluster found in figure 34 
Page | 135  
 
 
2.17 Data Analysis - PCA: 
2.17.1 Antibiotics 
PCA was the chosen method of analysis with regard to distinguishing groups in 
the NIR data. The reason for the others mentioned previously, such as SIMCA and CWS, 
not being used was due to software incompatibilities.  
PCA was the chosen analysis tool because it is helpful in distinguishing different 
groups and can give a visual representation of them. 
To gain a more accurate representation of all the data clusters 11 PCA models 
were created as illustrated in table 9. Of these, 10 focuses on the groupings of 
ciprofloxacin, whereas the remaining model illustrates the relationship between 
different classes of antibiotics and the raw excipients that are present in medicines.  
Table 9: The collection of PCA Antibiotic (AB) Models and their respective principle components (PC) percentages on MSC-
D1 pre-treated FT-NIR data. Where 'A' is authernitic Ciprofloxacin, 'G' is tested generic Ciprofloxacin and 'C' is counterfeit 
ciprofloxacin. 
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By having AB 2 –7 it can be seen that the use of the averages rather than the 
complete data set would have little to no effect on the PCA data. As shown the PC 
percentages do vary from the same groups in different models. The discrepancies 
however are not significant enough to warrant excluding the use of averages.  
 
Figure 36: Illustrates how PCA can correlate and cluster the various MSC - D1 treated antibiotics where PC1 is 63% and 
PC2 is 14% 
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Figure 37: Illustrates PCA- AB1 with a smaller number of various MSC - D1 treated antibiotics with PC1 being 59% and PC2 
is 21%. 
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The groups/ clusters that are shown in figures 36 and 37 are the result of the 
variations with regard to the intensity of the absorbance at different wavelengths being 
grouped together due to similarities found.  
The reason for the groupings is that the same type of medicines would have the 
same or similar chemical compositions. When exposed to the NIR radiation the 
chemicals that have the same type of bonds, such as O=H, N=H and C=H, show the 
same results.  
The bonds present in one type of compound would then respond differently at 
varying wavelengths, compared to the same type of bonds in a more diverse 
compound.   
PCA is also a valuable tool to use when trying to identify manufacturers as the 
compounds created with the same chemical makeup cluster together. With the cake 
scenario, if a group of friends were to cook Victoria sponge cakes, with multiple 
repeats,  
PCA would be able to cluster and identify who made which cake. This being due 
to the recipes varying from person to person, even though the sponges made are 
fundamentally the same thing. 
When PCA was used to analyse the ciprofloxacin batches it was successful in 
categorising the variations between A&C, G&C and C&C within the multiple grouped 
PCA models. 
 When analysing the PCA models some clusters were found to be distinct, 
whereas others are broader in appearance (illustrated in figure 38). 
Five batches were identified as counterfeit, 9 were identified as generic and 14 
were identified as authentic. 
 







Figure 38: (A) PCA-3 MSC-D1 pre-treated FT-NIR spectra of counterfeit (black), generic (red) and authentic (green) where 
PC1 is 43% and PC2 is 38%. (B)  PCA-6 MSC-D1 pre-treated FT-NIR spectra of counterfeit (black) and authentic (green) where PC1 








Figure 39: (C) PCA-5 MSC-D1 pre-treated FT-NIR spectra of generic (red) and authentic (green) where PC1 is 59% and PC2 
is 24%. (D) PCA-4 MSC-D1 pre-treated FT-NIR spectra of counterfeit (black) and generic (red) where PC1 is 54% and PC2 is 30 
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Figure 40: PCA-AB6 MSC-D1 pre-treated counterfeit ciprofloxacin batches where PC1 is 48% and PC2 is 31%. 
Unfortunately, as seen figure 39, there are no set clusters, which means that the 
CC PCA model was unable to distinguish between the sources correctly. Even if they 
are not from the same manufacturer the countries themselves have different 
manufacturing restrictions, meaning that countries of origin would be seen on an ideal 
model. 
The three that should be grouped together are C3, C4 and C5 as they are from 
sources in Lebanon. However, C2, C3 and C5 seem to be groups, whereas C2 is from 
Ghana.  
One of the problems that PCA has is when there is a heavy bias in the sampled 
date. Due to the way PCA works it ‘explains’ the cause of most of variation in the data.  
 Therefore, if most of the samples are deemed to be from one part of the 
population such as C3, C4 and C5, the PCA will calculate a component that mostly 
spans this population and will pull the remaining data inline such as C2. 
 Due to only having five samples there were confirmed to be counterfeit, there is 
not a sufficient amount of mappable data. Another reason for the samples data being 
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skewed is that as they are counterfeiting, the regulations that would be in those 
countries may not be followed completely so similarities could be found where there 
should be none.  
AC and GC were able to separate for the main part the manufacturing sources 
and cluster them together as demonstrated in figure 41 for AC and figure 42 for GC. 
Figure 41:PCA- AB5 MSC-D1 pre-treated authentic ciprofloxacin batches where PC1 is 37% and PC2 is 28%. 
PCA-AB5 figure 41 was able to shoe the manufactures in a country but separation 
of those countries as well, even if the clusters did not seem to be clear and concise. A7 
was a product from Lebanon, whereas A14 and A6 were produced in Ghana. The 
remainder of the ciprofloxacin batches were produced in the UK.  
As is with a majority of countries the UK has different manufacturers. This is shown 
with A4 being for the most part separate to the rest of the batches. A4 was produced 
by Telanc Pharma, whereas the UK batches were produced by Bayer AG Germany and 
grouped together. 
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Figure 42:PCA-AB7 MSC-D1 pre-treated generic ciprofloxacin batches where PC1 is 87% and PC2 is 2%. 
PCA-AB7 figure 34 also demonstrated the ability of PCA distinguishing countries 
of origins. Just like with PCA-AB5, PCA-AB7 shows the variations of manufacturers 
within the countries. 
In figure 41, batches G3 and G8 are detached from the main group and from 
each other. G3 and G8 are from Lebanon, they are however from different 
manufacturers. The manufacturers of those two batches are Pharma International Co, 
an unknown source.  
G1 was produced in Tanzania and shows separately from the main group that 
were produced in the UK.  
When examining the UK batches, a separation of manufacturers has occurred with 
G7, which was manufactured by Karib Kemi Pharma compared to Bayer AG Germany 
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2.18 Data Analysis - CWS 
With PCA being successful in determining counterfeit medicines another method 
that was deployed for analysis was CWS for the comparison between multiple different 
vectors. 
Eight comparison models were created as shown in table 10 for a more accurate 
representation of the data. 
Table 10: Table of correlation models and their respective 'r' values. 
CWS is capable of determining how similar one product is to another, it 
determines correlation comparison by finding how often a similarity appears 
throughout a spectra’s wavelength range when compared to another sample (Bewick, 
Cheek and Ball, 2003). Within this project the correlation occurs between the range of 
4000cm-1 and 10000cm-1.  
The reason for using CWS in this study is that when comparing antibiotic samples 
to raw materials it can be determined if the material is contained within the medicine.  
The reason behind the separate models is to illustrate a broad understanding of 
similarities found between antibiotics, excipients and other raw materials. A variety of 
materials were used in these comparisons – for a list of materials used please see 
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Section 2.23. The comparisons ultimately test how each compound or material 
compares against themselves, materials of similar properties and the same type of 
compound.  
The value ‘r’ is used to determine how strong a correlation comparison is between 
two samples. If it shows 0.65, it suggests that there is a 65% match between the 
samples compared.  
The ‘r’ value can be used in the case of medicines and raw materials to determine 
if an API is present in the mixture. For a similarity to be observed it must show an ‘r’ 
value of 0.95 and above for a consideration of correlation to occur. 
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Figure 43: CWS -1 showing MSC-D1 pre-treated Antibiotic FT- NIR data being compared against each other with a max ‘r’ 
value of 0.94 and a min ‘r’ value of 0.21. 
CWS-1 illustrated in figure 43, illustrates the similarities found when comparing 
the antibiotic samples to each other. 
The overall ‘r’ value range for the various antibiotics are compared to themselves 
ranged from 0.94 to 0.21. When an antibiotic was compared against itself it illustrated a 
strong correlation as demonstrated by the diagonal dark blue line the ‘r’ values for the 
comparisons ranged from 0.8 to 1.  
When different types of antibiotics were compared to each other there was not a 
defined high correlation, but some similarities appeared the ‘r’ value ranged between 
0.4 to 0.8. Certain antibiotics match characteristic of others when they should not. Some 
of the samples that illustrated a correlation ‘r’ value of 0.8 or above when there is no 
reason for a high correlation are azithromycin, cefuroxime and ofloxacin.  
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Figure 44: The chemical structures of azithromycin, cefuroxime and ofloxacin. 
As illustrated in figure 44 the chemical structures of these three API compounds 
that show a high correlation, are structurally unsimilar, so the high correlation identified 
could be due to contamination of the samples.  
Another reason for the high correlation is due to the excipients contained within 
the tablets being the same if not similar as each other. One such excipient that is the 
same throughout the batches is Talc.  
By having Talc in a large quantity as a filler the CWS would not be able to 
distinguish between the API that was need to be correlated and the small percentages 
of other materials involved in the tablets.   
  
 
Page | 148 








Figure 45: CWS -2 showing MSC-D1 pre-treated Ciprofloxacin FT- NIR data being compared against each other with a 
max ‘r’ value of 0.99 and a min ‘r’ value of 0.21. 
CWS-2 illustrated in figure 45, illustrates the similarities found when comparing 
the ciprofloxacin samples to each other. 
The ‘r’ value range for the authentic ciprofloxacin batches matching against 
themselves ranged from 0.99 to 0.87. Similarly, the ‘r’ value range for the counterfeits 
when compared to each other range from 0.90 to 0.50.  
Whereas when the counterfeit medicines are compared to the authentic 
medicines the overall ‘r’ value ranges from 0.62 to 0.85. Therefore, the overall ‘r’ value 
range for the ciprofloxacin batches compared to themselves ranged from 0.99 to 0.62 
on average. 
As illustrated in figure 45 there are some ‘r’ values that are as low as 0 to 0.2, this 
demonstrates that even though the tablets are all classed as ciprofloxacin, the 
counterfeits compared to authentic have significant differences to each other. This 
could be caused by different excipients present or different amounts of APIs. 
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Unlike the other models there is no clear distinction of correlation when a sample 
is compared to itself. There are however two ciprofloxacin batches that show clear 
comparisons for all the other samples (illustrated in yellow).  
The grid lines demonstrate that there is a 0.6-0.8 correlation between the two 
ciprofloxacin samples and the other samples when compared. These batches are the 
counterfeit ‘it502bz’ and cf1h0005.  
These particular characteristics suggest that there is a component within the 
tablets that are shared throughout the different batches.  
Unfortunately, there is not a way to distinguish the particular characteristic 
component involved in the correlation. 
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Figure 46: CWS -3 showing MSC-D1 pre-treated Raw Material FT- NIR data being compared against each other with a max 
‘r’ value of 0.99 and a min ‘r’ value of -0.47 
CWS-3 illustrated in figure 46, illustrates the similarities found when comparing 
the raw materials to each other. 
The ‘r’ value range for the raw materials compared to themselves ranged from 
0.99 to -0.47. The ‘r’ values demonstrated by the grey line range between 0.5 to 1.  
The ‘r’ values are split into such a wide range, for example -0.5 to 0, 0 to 0.5 and 
0.5 to 1, is due to how different the materials are structurally in their raw form when 
compared to each other. 
As shown in CWS -1 there is a medium to high correlation demonstrated when a 
sample is compared to itself. This is illustrated in figure 46 by the clear diagonal line (in 
grey).  
When the raw materials are compared to each other there are a limited number 
of high correlations, except when the samples are compared to themselves. The main 
similarities occur between the sodium containing compounds and the sugar-based 
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compounds. This is mainly due to the similarities in structures and the behaviours they 
present when the FTNIR is used for analysis.  








Figure 47: CWS -4 showing MSC-D1 pre-treated Raw Material FT- NIR data being compared against one batch of each 
type of antibiotics with a max ‘r’ value of 0.99 and a min ‘r’ value of -0.41. 
CWS-4 illustrated in figure 47, illustrates the similarities found when comparing 
the raw materials to the antibiotic samples. 
The ‘r’ value range for the raw materials compared to the various antibiotics 
ranged from 0.99 to -0.41. The sections segregated in figure 47 illustrate the different 
comparisons, (1) & (4) the raw materials compared to the antibiotic batches, (3) the raw 
materials compared to themselves and (2) the antibiotics compared to themselves.  
Once again as similar to CWS-1 & 3 there is a correlation demonstrated when a 
sample is compared to itself. This is illustrated in figure 47 by the clear diagonal line (in 
grey).  
Often seen when the sample is compared to themselves. As shown in CWS -1 
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discrepancies illustrated where some of the excipients are not common across the 
antibiotics.  
When the comparisons between the antibiotics and raw materials are examined 
further it can be seen that there are some high correlations in the groups. The main 
correlation found are those that represent lactose, talc and titanium dioxide, this is 
expected as they are excipients in the antibiotic tablets. What is unusual and would 
need to be explored further is that they are the only excipients showing a high 
correlation when there are other known excipients in the model.  
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Figure 48: CWS -5 showing MSC-D1 pre-treated Raw Material FT- NIR data being compared against all of the ciprofloxacin batches 
with a max ‘r’ value of 0.99 and a min ‘r’ value of -0.47. 
The overall ‘r’ value range for the raw materials compared to the ciprofloxacin 
batches ranged from 0.99 to -0.47. 
Similar to CWS-4 the sections segregated in figure 48 illustrate the different 
comparisons, (1) & (4) the raw materials compared to the ciprofloxacin batches, (3) the 
raw materials compared to themselves and (2) the ciprofloxacin batches compared to 
themselves.  
When inspecting the CWS-5 model as a whole the ciprofloxacin batches illustrate 
an extremely high correlation rate, even when they are a mix of authentic, generic and 
counterfeit samples.  
In retrospect, because the raw materials are so diverse, they illustrate clearly the 
differences when they are compared.  
However, when the raw materials are compared to the ciprofloxacin there are rare 
similarities shown and they cannot be distinguished easily in the visual model. 
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correlated square. Thus, any slight differences in the correlations would be hard if not 
impossible to distinguish.  
To reduce this issue, the examination of separate classes of ciprofloxacin batches 
with comparisons to the raw materials would reduce the conformity issues of 
correlating such a large scale.  
Those models that aid in distinguishing the conformity issues are illustrated in 
CWS 6-8. 
CWS 6-8 also help to separate the correlative value of 0.99 max and -0.47 
minimum. These values are from the overall model where high correlation occurs for 
the ciprofloxacin batches compared to the raw materials. 
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Figure 49: CWS -6 showing MSC-D1 pre-treated Raw Material FT- NIR data being compared against the authentic 
ciprofloxacin batches with a max ‘r’ value of 0.99 and a min ‘r’ value of -0.42. 
CWS-6 illustrated in figure 49, illustrates the similarities found when comparing 
the authentic ciprofloxacin samples to the raw materials.  
The overall ‘r’ value range for the raw materials compared to the authentic 
ciprofloxacin batches ranged from 0.99 to -0.42. The sections segregated in figure 49 
illustrate the different comparisons, (1) & (4) the raw materials compared to the 
authentic ciprofloxacin batches, (3) the raw materials compared to themselves and (2) 
the authentic ciprofloxacin batches compared to themselves. Similar to the visual 
representation show by models CWS – 4 & 5.  
It is hard to distinguish the rectangles that represent the comparisons between 
the authentic ciprofloxacin and the raw materials, again this is due to the wide range of 
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With the ciprofloxacin batches being highly correlated together with ‘r’ values of 
0.5 to 1, the comparisons between the raw materials and ciprofloxacin batches thus 
correlate at a lower rate with ‘r’ values of 0.5 and lower.  
However, there are a couple of hotspots of high correlation. These hotspots are 
representative of croscarmellose sodium, talc and lactose.  
For the most part high correlation is not apparent, probably because of the 
differences in the chemical composition.  
The lack of other high correlative peaks could be due to contamination of 
samples, with the wavelengths not being cleaned efficiently when comparisons were 
made. 
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Figure 50: CWS -7 showing MSC-D1 pre-treated Raw Material FT- NIR data being compared against the counterfeit ciprofloxacin 
batches with a max ‘r’ value of 0.99 and a min ‘r’ value of -0.49. 
CWS-7 illustrated in figure 50, illustrates the similarities found when comparing 
the counterfeit ciprofloxacin samples to the raw materials. 
The overall ‘r’ value range for the raw materials compared to the counterfeit 
ciprofloxacin batches ranged from 0.99 to -0.49. 
The sections segregated in figure 50 illustrate the different comparisons, (1) & (4) 
the raw materials compared to the counterfeit ciprofloxacin batches, (3) the raw 
materials compared to themselves and (2) the counterfeit ciprofloxacin batches 
compared to themselves. 
Despite PCA being able to distinguish trends within the counterfeit medicines, 
CWS had an issue determining correlations between the raw materials and the 
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Even though some of the raw materials used in the comparison are known to be 
in the tablets due to being written on the tablet information label, there are no 
definitive correlative peak of ‘r’ values higher than 0.5.  
This suggests that there is a high level of impurity in the samples of ciprofloxacin 
batches. The reason for this suggestion is that PCA was able to find differences with 
identification of the variables between samples, whereas CWS could not find significant 
similarities in the wavelengths. 
One high correlative match found in some of the counterfeit batches was that of 
talc when the model was expanded. This is supportive of figure 17 where the 
counterfeit medicines are distinguished by the talc peak. 
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Figure 51: CWS -8 showing MSC-D1 pre-treated Raw Material FT- NIR data being compared against the generic ciprofloxacin 
batches with a max ‘r’ value of 0.99 and a min ‘r’ value of -0.45. 
CWS-8 illustrated in figure 51, illustrates the similarities found when comparing 
the generic ciprofloxacin samples to the raw materials. 
The overall ‘r’ value range for the raw materials compared to the generic 
ciprofloxacin batches ranged from 0.99 to -0.45. 
The sections segregated in figure 51 illustrate the different comparisons, (1) & (4) 
the raw materials compared to the generic ciprofloxacin batches, (3) the raw materials 
compared to themselves and (2) the generic ciprofloxacin batches compared to 
themselves. Once again, the correlation shows between the samples and themselves 
has a ‘r’ value or 0.5 and above, illustrated via a grey line. 
It is easier to see that there are a few correlative peaks between generic 
ciprofloxacin batch samples and the raw materials. There are only four peaks that can 
be seen using CWS, when comparing the generic batches against the raw materials 
illustrating ‘r; values of 0.5 and above. These peaks correspond to titanium dioxide, 
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However, these peaks are only distinguishable because of the level of correlation 
(0.5 to 1), however it is not possible to determine how significant the correlation is and 
where the ‘r’ value lies within that range.  
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2.19 Medicine Identification Summary 
The consensus of the experiments and tests conducted is that they are able to 
show a trend in the data that can be used to determine points of focus for the future 
with a far greater sample set.  
FTNIR was able to distinguish the similarities of the binary mixture and also the 
volume ratio of each mixture, this validated the FTNIR being used for the analytical 
instrument of choice.  
 The binary mixtures that were used gave validity to the PCA being the primary 
illustration through being able to isolate the identity of chemical structures and how 
they are fundamental to the clusters being grouped.  
When PCA was used to analyse the ciprofloxacin data it was able to identify small 
trends and anomalies that at first thought should not be there. Such example is PCA CC 
as the origin of the medicines should show more commonality between samples, 
whereas another batch from a different source was intermingled in the data.  
This shows that even though PCA is a strong technique for large data set analysis 
it does still have flaws if not all parameters are met. The smaller the sample size the 
more variability there is in the components.  
On the other hand, CWS, even though useful for visualising the comparisons of 
the antibiotics to the raw materials or when compared to themselves, it was not found 
to be as useful as PCA.  
One reason being is that if failed to determine distinguishable features between 
the various classes of ciprofloxacin batches, either by comparison of the samples to 
themselves or the raw materials compared to the ciprofloxacin batches.  
This difference would be so minute that their significance would be 
overshadowed by the similarities identified instead. When compared batch 1 to batch 1 
it would show ~ 100% similarity whereas if you measured batch 1 to batch 2 there 
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could be a 99% match where only 1% of the chemical makeup of batch 1 differs from 
batch 2. Thus, CWS on its own is not strong enough to pick up that slight difference in 
a small data set.  
However, it is found that the overall analysis of medicines was successful, as the 
properties of the ciprofloxacin batches were determined and categorised. There was in 
total 14 authentic, 9 generic and 5 counterfeits identified.  
As close to 1:3 tablet batches were found to be counterfeit, with such a small 
sample set the number of counterfeits found is significant and a cause for concern. 
These medicines were screen by professionals and prescribed to the patients be it from 
a brick-and-mortar pharmacy or an online version.  
This cause for concern stems from the basis that the medicines that we as a 
society consume even though thought to be tested, some may miss the mark of 
standards set.  
As society grows and is ever evolving the standards of counterfeits in all walk of 
life have to adapt and become almost unrecognisable, only distinguishable under the 
microscope and tests.  
Even though FTNIR has its advantages such as its quick, efficient and does not 
degrade a sample when tested, it also has its draw backs that it takes knowledge to 
decipher the spectra and needs treating before the analysis is complete.  
Overall, this process would be time consuming and thus cost the industry a lot of 
money if it was to become standard practise for all batches to be tested before being 
released on market. However, spot checks, quality control of manufacturers and other 
measures are in place to help prevent and aid in counterfeit medicines from being 
pulled from the supply chain.  
If counterfeit medicines were to enter the market the threat to public health 
would be greatly increased. One way for counterfeits to be countered is for the 
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regulations regarding them to be updated and amended. The new FMA Directive is the 
next stepping stone on the path to fighting counterfeits.  
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Chapter Three: Policies and Laws governing 
Online Pharmacies and Counterfeit Medicines. 
 
3.1 The Falsified Medicine Directive (FMD) 
Following on from the quantification of counterfeit medicines in Chapter Two, it is 
clear that the only way to verifiably detect if a sample was indeed a counterfeit was to 
look in depth at the chemical composition of the samples.  
The medicines themselves are only one part of the problem, yet they cause the 
risk to the public’s health and the individual who consumes them. The problem with 
counterfeit medicines - as will be explained throughout this study – is that they have 
very little traceability, and presence that stands out.  
They are sophisticated enough to be hidden via normal means of detection such 
as the packaging or the continuity stamps for example the batch number or expiry 
date.  
Thus, this causes a wide spread problem not just nationwide but worldwide, the 
impact of which is felt throughout all demographics and cultures as no country is 
primarily safe from some description of a counterfeit being present.  
Apart from the counterfeits themselves another one of the issues in the supply 
chain that counterfeiters can take advantage of is the distribution and sites of the sellers 
if they sell through a third party.  
The individuals that are most at risk from being supplied a counterfeit in particular 
are those that shop online or those who use pharmacies that are overworked and not 
managed sufficiently as explained below. 
As ciprofloxacin – which is the focus of this research - is typically a prescription 
only medicine (POM), rather than a general sales list medicine such as ibuprofen, fall 
 
Page | 165 
under the scrutiny of the FMD. As is the directive that directly effects the security of 
counterfeit/ falsified POMs.  
In this chapter the FMD will be analysed via how it worked, how is it 
tested/implemented and also how its structure passes onto pharmacies either local 
brick and mortar or online.  
As stated previously in Chapter One, falsified medicines are fake/false medicines 
that are thought to be the genuine versions, with regard to the ingredients, the 
packaging or both among other things. Whereas counterfeits are “medicines that do 
not comply with intellectual property rights”. These are the definitions that will be used 
throughout this chapter. 
The European Union (EU) has developed legal frameworks for the licencing, 
distribution and manufacturing of medicines. The frameworks are centred around the 
directives on falsified medicines that are primarily for human use, so that only the 
authentic medicines are sold form licenced pharmacies and other approved retailers.  
3.2 FMD Brief History 
The FMD is EU Parliament legislation that has been passed with the aim of 
increasing the security of the manufacturing and delivery process of medicines across 
Europe, thus preventing falsified medicines from entering the supply chain. 
The FMD was originally created with the 2001/83/EC Directive in 2001 by the 
European Commission (EC). The 2001/83 Directive was created for the sole purpose of 
bringing the various directives already in use into one manageable place of reference.  
The directives placed in the 2001/83 Directive and the amendments that have 
been created over the years are as follows. 
The following directives which were placed within the 2001/83 directives 
guidelines; Council Directive 65/65/EEC, the Council Directives 75/318/EEC and 
75/319/EEC, The Council Directive 89/342/EEC, The Council Directive 89/343/EEC, 
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Council Directive 89/381/EEC, Council Directive 92/25/EEC, Council Directive 
92/26/EEC, Council Directives 92/27/EEC and 92/28/EEC, Council Directive 92/73/EEC.  
As stated in the 2001/83/EEC Directive ‘In the interests of clarity and rationality, 
the said Directives should therefore be codified by assembling them in a single text’ 
thus unifying the previous directives into one with the unified aim to ‘govern the 
production, distribution and use of medicinal products to safeguard the public health’.  
This unifying directive has subsequently been amended over the years with the 
following directives; Directive 2002/98/EC, Commission Directive 2003/63/EC, Directive 
2004/24/EC and 2004/27/EC, Directive 2008/29/EC, Directive 2009/53/EC, Directives 
2001/82/EC and 2001/83/EC, Commission Directive 2009/120/EC, Directive 
2010/84/EU, Directive 2011/62/EU. Which brings us to the most recent amendment 
Commission Delegated Regulation (EU) 2016/161.  
3.3 FMD Initiative 
A problem, that has been gaining traction across Europe and the globe is falsified 
medicines for human use (Houston 2012).  They first entered the market mostly for 
lifestyle medications; more recently however they have included other medicines such 
as antibiotics (Brady 2020). Consequently 2001/83 Directive was amended by the 
2011/162/EU Directive by the recently published Delegated Act 2016/161.  
The amendments that are imperative to this research are Commission Directive 
2003/63/EC due to the code relating to the human use of medicinal products, which is 
a cause of concern when investigating counterfeits as explored in Chapter Three.  
Furthermore Directive 2009/53/EC is an important amendment due to focusing 
on the terms of marketing authorisations for medicinal products, which relates to the 
importance of authentic pharmacies as discussed in Chapter Three.  
The nature of Directive 2011/62/EU makes a great solution for it to be used for 
the recognition and risk of falsified medicines form entering the supply chain, when 
working with Commission Delegated Regulation (EU) 2016/161 which regards the 
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implantation of safety features on medicinal products for human use, the FMD 2019 
was created.  
Due to the unifying properties of the 2001/83 Directive, it is thought that the FMD 
will enable wholesalers, manufacturers, distributers and anyone else who supplies the 
medicines to patients to have the ability to verify the authenticity of the medicinal 
product, the individual packets and even check whether the outer packaging has been 
tampered with. 
The FMD introduces and harmonizes safety and strengthens the various control 
measure across Europe to limit the risk to the public’s health.  
Essentially the FMD was created to provide safety measures against the entry of 
falsified medicinal products into the supply chain. This measurement is done by the 
‘mandatory’ placement of the new safety features, including an an ti-tampering device 
(ATD) and a unique identifier (UI) on the packaging of the medicinal products. Those 
products are for human use and the use of the safety features is to allow the 
authentication and identification of these medicinal products.  
In conjunction with these safety features the FMD also provides an ability to aid 
security when purchasing medicinal products on the Internet. Falsified medicine as 
stated by the FMD “poses a particular threat to human health and may lead to a lack of 
trust of the patient also in the legal supply chain”.  
Thus, it is paramount that the scope of 2016/161 Directive, to protect patients 
from the health consequences of falsified medicines is understood.  
Overall, it is estimated that the falsified medicinal products impact on the 
economics globally is €10.2 billion every year and increasing (EUIPO 2020). 
Unfortunately, the costly revenue produced from falsified medicines include all 
medicines, not just those that are covered by the FMD. 
Despite, the cost of implementing the safety features on the packaging the 
pharmaceutical industry is progressing forward with the execution of 2016/161/EU 
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Directive. In addition to the cost and safety features, another relevance to the FMD is 
the staffing availability, a lack of which impacts the ability to handle large amounts of 
packages, as this is where one of the risks for entering the legal supply exists.  
 
3.4 FMD Features 
1. Safety Features of medicines 
On and there after the 9th February 2019 the marketing authorised holders are 
obligated to place two safety features on the packaging of mostly prescribed 
medicines. However, some over-the-counter medicines in the EU are also obliged to 
have the safety features.  
The safety features are as follows; an anti-tamper device (ATD) and a unique 
identifier (UI) in the form of a 2D matrix (Barcode) as shown below in figure 52 for 
examples. The features are in accordance with Commission Delegated Regulation (EU) 






Figure 52: The two safety features now present on the packaging of medicines that is implemented due to the FMD. 
The UI code must include the product code, the unique serialisation number, the 
expiry date and batch number. If the pack size permits, the UI code and the information 
will be printed side by side. 
As mentioned previously, the manufacturer applies the ATD and the UI to the 
medicine containers and uploads the valid codes to the European Medicines 
Verification System (EMVS) via the European Medicines Verification Organisation 
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(EMVO). The EMVS will act as a hub that links all the national systems together allowing 
parallel trading of medicines to continue.  
The development of such verification systems is being led through stakeholder 
models that involve five main sectors of the supply chain; (1) the research-based 
manufacturer, (2) the generic manufacturer, (3) parallel traders, (4) the wholesalers and 
lastly (5) the pharmacies.  There are also five main areas which the new system 
identifies; (1) the manufacturer, (2) the pre-wholesaler, (3) the wholesaler, (4) the 
community pharmacy and finally (5) the hospital pharmacy.  
At each stage the medicine is scanned, the National Medicine Verification System 
(NMVS) will identify the status of the product, either ‘active’ meaning it can continue 
down the supply chain or ‘inactive’ mean ing it cannot be passed on. A product may be 
‘inactive’ if it has been stolen, withdrawn.  
It can also be ‘inactive – dispensed’ if the medicines have been dispensed already, 
this process prevents the same UI code from being authenticated and used by another 
dispensing entity.  
If a product when scanned is found to be ‘inactive’ the NMVS will alert the MHRA 
as a potential falsified/ counterfeit medicine may have been discovered, thus it should 
be withdrawn from the supply chain for more investigation due to the guidelines set by 
the 10 – day rule.  
Furthermore, when a medicine is found to be inactive it is decommissioned from 
the system. In regard to errors made and incorrect decommissioned UI codes the 
following can occur to reverse the status of the medicines in accordance to Article 22 of 
the FMD; the reversal is done not more than 10 days after the decommissioning 
(commonly known as the "10-day rule"), the product has not been supplied to the 
public, the product has not been marked by the NMVS as recalled, withdrawn, stolen or 
intended for destruction, the reversal takes place in the same location as the original 
decommissioning (ie, within the same dispensing entity) and finally the product has not 
expired. 
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2. Supply Chain and Good Distribution Practice 
Wholesalers are tasked with new responsibilities introduced by the directive as 
well as a definition of brokering activities as well as new responsibilities for the brokers. 
The agency’s good-distribution-practice (GDP) guidelines revised now included specific 





3. Active Substances and Excipients 
Commencing July 2013, all the active substances that are manufactured outside 
of the EU and those that are imported into the EU have had to be accompanied by a 
written confirmation from the current regulatory authority of exporting country.  
The statements that are produced and issued per manufacturing site and per 
active substance ensure that the standards of the good manufacturing practice (GMP) 
or those that are the equivalent in the EU to be upheld. When a country is called 
‘equivalent’ the regulatory framework of written statements will not be needed.  
Several countries have already implemented the status of being ‘equivalent’ 
including Japan, Australia, Switzerland and the US. Other countries such as Brazil, Israel 
and Singapore have also requested to be an equivalent. 
 
4. Internet Sales 
The FMD has also introduced an obligatory logo that will appear on websites of 
legally authorised online pharmacies and approved retailers in the EU as discussed in 
Chapter Four. The Implementing regulation that established the new logo entered into 
force in July 2014 
3.5 How effective is the UI Code? 
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In a recent study conducted by Dr Bernard D Naughton of Oxford University 
some concerns were raised with regard to the effectiveness of UI and ATD from the 
perspective of the patients. Firstly, the FMD is only responsible for prescription 
medicines, it does not cover over the counter (OTC) products (Naughton et al. 2016).  
There have been some exceptions to the rule, one being omeprazole and 
paracetamol being covered by the FMD. As discussed in Chapters 1 and 2, falsified 
medicines can contain little to no amount of API, they can also contain toxic substances 
which can cause a public health risk.  
Consequently, by description the FMD is primarily covering the interests of the 
pharmaceutical industry that produces the prescriptions drugs rather than the needs of 
consumers with the perspective of the patients (Naughton et al. 2016).  
Secondly in the study conducted by Naughton (2016) the reliability of the 2D 
codes were tested. After performing an examination on over 4,192 packages, 180 
falsified, expired or recalled boxes were found. Within those packages, despite 100% 
being detected with technical instruments, 64% of expired medicines, 58% of recalled 
drugs (product and batch) and only 31.8% of falsified medicines were excluded from 
dispensing. 
Furthermore, a pilot study conducted by St James Hospital, Dublin contained a 
programme that simulated the flow of pharmaceutical products through a serialised, 
global supply chain.  
The model proposed was supported by the delegated Act 2011/161/EC. Within 
this study known counterfeit products with barcodes copied from the originals 
in various forms were distributed alongside the authentic products.  
The results from this study were that within the simulation 18 of the 50 falsified 
medicines were incorrectly verified and dispensed to patients. However, when multiple 
authentication points were added to the chain the number of counterfeits that were 
supplied to the patients reduced to 10 (Systech 2020). 
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Consequently, it can be assumed that if the producers of the falsified/counterfeit 
medicines obtained a list of random codes, it can be presumed that these producers 
could use the UI on falsified packages thus enabling them to enter the drugs into the 
market. As a result of this, whether the first code entered to be authenticated is on the 
authentic or falsified medicine, the code will be decommissioned and classed as 
authentic.  
This makes the scenario of falsified medicines entering the supply chain still 
applicable, as the only hinderance to this situation is that the falsified medicines must 
enter the market before the authentic versions reach the pharmacies. Due to the 
complexity of the supply chain the falsified medicines will be dispensed as authentic 
and the public will be none the wiser to the risk. 
As mentioned previously in Chapter One, the MHRA have alert policies where 
medicines can be recalled by the manufacturer when the public report adverse effects.  
Due to the falsified medicines progressing through the supply chain to the patients and 
the authentic medicines being classed as falsified, this causes manufacturers to recall at 
least the whole batch, even if only just one code was misused. Unfortunately, this may 
cause an unintended shortage of medicines. 
Another issue that may arise from the serialisation of medicines and the use of the 
UI is technical error, including non-decommissioning of medicines when they are 
delivered to the pharmacies, malfunctioning of the scanners and staff misinformation of 
the codes. 
As a conclusion, from the combination of Naughton and St James Hospital 
serialisation alone is not adequate to eliminate diversion and counterfeiting risks in 
the supply chain.  
3.6 How effective is the ATD? 
The ATD, otherwise known as a tamper-indicating device (TID), is designed to 
leave unambiguous, non-erasable evidence of unauthorized access or entry of the 
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packaging. The ATD that is used in conjunction with the FMD is referred to as a seal 
(Appel 2011).  
A seal is used when recording of access is required, unlike a lock which is used to 
resist access. Thus, some seals are made of paper or plastic that can be easily removed. 
Seals must be inspected to determine whether an intrusion has occurred, and the 
device has been tampered with (Petersen & Johnston 1997).The ATD is a type of 
adhesive label seal. These types of seals are made with the consistency of tape (sticky 
labels) that become damaged if removed from what they are stuck to. Examples are 







Figure 53: Examples of Adhesive seals 
Adhesive seals are inexpensive, easy to use and able to mass produced. However, 
these types of seals do not offer or provide high levels of security, nor are they very 
robust. As discovered in a case study conducted by Andrew W. Appel from Princeton 
University when he was tasked with the testing, security and the use of seals on voting 
machines by the State of New Jersey (Appel 2011).  
Appel found that when the seal is first removed or ‘mostly pulled back’ it is 
successful in recording tampering as shown in Figure 54 with ‘open void’ being present.   
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Figure 54:Pressure-sensitive adhesive tape. At left, as first installed; at right, when (mostly) peeled back and pressed down 
again. 
To tamper with the seal Appel used a heat gun to remove the seal using the edge 
of a razor blade when the seal was softened enough by the heat. This method was 
successful in the fact that Appel could remove the seal completely without evidence 
showing tampering. All that it took was 80 seconds of heat to remove the seal and 2 
seconds to replace a new one in its place (Appel 2011). 
Therefore, it can be argued that the ATD alone is not enough to hamper falsified 
medicines from entering the supply chain and being detected. However, with the aid of 
the UI and the Frangible seals within the blister packs together, this should form the 
start of future attempts to stop falsified medicines from being supplied to the patients.  
3.7 Supply Chain & Risk 
As described in Chapter Four the use of online pharmacies poses a major risk to 
public health, due to the purchasing of falsified medicines. With comparison between 
Australia and the UK, Australia’s Health Authority found that 95% of prescription drugs 
purchased via the Internet were falsified (Auf der sicheren Seite 2020).  
On the other hand, within a 10-year period only 11 cases of falsified medicines 
were recorded to enter the supply chain, nine of which were due to parallel importing 
(Almuzaini et al. 2013). Whereas, according to overall global statistics, 30% of all 
purchases from the Internet are falsified as described in the introduction. 
To counteract this rising issue, the FMD includes a regulation that implements the 
authentication logo for Internet pharmacies. This is the MHRA logo described in  
Chapter Four. This regulation is a step along the road to protect patients form falsified 
medicines.  
Nevertheless, the successfulness of the regulation will be dependent on the 
patients being educated in how to distinguish fake pharmacies from real ones. Thus, 
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the relevance of the supply chain and the source of the medicines is important to be 
understood for patients and pharmacists, especially within hospitals. 
3.8 Who will Benefit from the FMD? 
Despite the issue of risk to public health, the FMD does not focus on the patients 
and offer them an opportunity to check the authenticity of the products they purchase, 
compared to the eTACT drug traceability system proposed by the European 
Directorate for the Quality of Medicines & Healthcare (EDQMH) (EDQM eTACT 2012).  
This is a surprising concept as the purchasing of medicines on the Internet is 
increasingly popular, and a major source of falsified medicines (Auf der sicheren Seite 
2020). 
Creating patient/public awareness of the opportunity to seek out the 
authentication logo for Internet medicine purchasing may limit the risk to their health.  
However, the effectiveness of this awareness has yet to be tested, compared to 
the discussion in Chapter Four which looked at online pharmacies that contained the 
various ‘authentic’ logos. 
After the manufacturer applies the ATD and the UI to the medicine containers 
and uploads the valid codes to the European Medicines Verification System (EMVS), via 
the European Medicines Verification Organisation (EMVO), the EMVS will act as a hub 
that links all the national systems together allowing parallel trading of medicines to 
continue.  
This data will be kept on the EMVO servers for several years, thus enabling recall 
of data if the need arises for inspection. It also allows for the respective authorities to 
keep track of reported incidents.  
Consequently, the FMD does not restrict access to this data as other parties may 
be granted permission to access the data for pharmacovigilance reasons. 
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A negative of the FMD is that the system it is implemented on is dependent on a 
stable and good Internet connection. In most cases this should not influence services, 
however when considering rural and remote hospitals, major problems may occur, 
therefore requiring extra financial investment that has not been currently budgeted.  
This is due to the technical prerequisites in hospital which is in accordance with 
the Association of Hospital Pharmacies. This means there is an insufficient amount of 
funding (Frontini et al. 2013). 
Furthermore, hospital pharmacies mass purchase medicines either by direct 
contact with the manufactures or through qualified wholesalers. It is known that the 
scanning of individual packages is time consuming and the workforce will be removed 
from daily duties to repackage single packages. 
In an ideal situation, with 2-3 second per scan using instruments such as the FT-
NIR used in Chapter One, that can easily be used in a large pharmacy delivering 
2.5million packages per year. The time taken to scan all the packages at the various 
hospitals would equate to at least one full time staff member. 
Due to the implementation of the FMD across the EU the intention is that it would 
be cost neutral for pharmacies. On the contrary, making the operation realistic with 
focusing on the cost of additional workforce and technology has yet to be determined 
(EDQM eTACT 2012). 
The FMD has not been assessed sufficiently in the case of its efficiency or its 
effectiveness. Furthermore, it has not been compared to other such initiatives e.g 
MEDICRIME Convention or the eTACT Healthcare (EDQM eTACT 2012) which justify the 
cost to be shared amongst the shareholders.  
Additionally, it should be noted that by excluding all the OTCs – except those 
mentioned earlier – the FMD could be seen as ineffective from the patients/public 
perception. 
3.9 Which Direction? 
 
Page | 177 
With regards to the time and work force resources required by the FMD and the 
Delegated Act 2016/161, a magnitude of pressure has been placed on the shoulders of 
the pharmacies. This is especially the case regarding hospital pharmacies, where an 
astronomical number of packages are supplied.  
These packages are normally delivered to the wards directly rather than to the 
patients. As mentioned earlier the time taken to scan the individual packages would be 
time consuming and a challenge. 
Ultimately it is important to ascertain if the FMD is beneficial and enhances the 
safety of patients. Concerning hospitals, this circumstance is highly questionable. As 
mentioned previously the hospital pharmacies usually purchase the medicines directly 
from the manufacturers or other reliable sources.  
The purchase from the original manufacturer is placed at the same level as supply 
via the Internet. This suggests that the complexity of the supply chain has not been 
considered by the FMD, nor is the source of the medicine’s purchase.  
This is cause for concern as it shows that little effort has been placed in 
distinguishing the sources of purchase and into differentiating the risks.  
Additionally, as proven many times over, no technical solution is without failures. 
Even if scanned packages emitted very low level false positive/negative output, the total 
number of incorrect scans would be considerable.  
The efficiency of the distribution process in pharmacies would be hindered due to 
the time taken in identifying and clarifying the incidents into appropriate groups, both 
communally and in hospitals. 
Despite purchasing from a reliable source, the safety of patients will not 
significantly increase. This is because purchasing from a reliable source does not mean 
that a falsified medicine cannot be purchased. To safeguard against this risk 
pharmacists are obliged to quality check the medicines they provide to patients.  
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Stronger controls and updates to the Good Procurement Practice (GPP) (WHO 
2018) and Good Distribution Practices (WHO 2018) will further help to prevent 
counterfeit medicines from entering the market, especially when placed in every 
pharmacy, community and hospitals. 
Fundamentally the FMD implements a bureaucratic system, which consumes a 
vast number of resources at every junction of the supply chain, especially in hospitals 
where there are staffing shortages.  
Even though the probability of a falsified medicine is minimal the result could be 
fatal. With regard to hospitals and the FMD there are arguments for and against. On 
the one hand it may prevent further harm to the public, on the other it could be a 
hindrance to already tired and stretched staff members. 
The FMD does not adequately protect patients who are purchasing from online 
sources where the risk of harm is greater. In addition, those patients are excluded from 
the verification process in spite of the technical possibilities that are available.  
Some individuals believe that the FMD illustrates a bias towards the 
pharmaceutical industry with its massive influence, rather than considering the needs of 
the hospitals or the patients.  
Unfortunately, hospitals must comply with the regulations that are set and are 
based on retail pharmacies. As explained earlier this notion is not feasible due to 
hospital pharmacies not supplying single packages like a community pharmacy does.  
At both national and European levels, the consequences of the FMD need to be 
examined further, with regard to the distribution and ramifications of the regulation.  
This is mainly for the hospital pharmacies as previously discussed in this chapter 
because some if not all of them have already secured and implemented an efficient 
supply chain by implementing GPP. 
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Codes that are specifically created for hospitals supplied directly from the 
manufacturer could be implemented to reduce the scanning process, and potentially 
the risk of codes being copied.  
This is just one example of how the directive could be adapted for a more 
practical aspect, especially with regard to hospitals.  
3.10 What’s the EMA Role? 
The European Medicine Agency (EMA) works with the EC and the EU Member 
States with regard to implementing the FMD. This cooperation includes the WHO 
International Medicinal Products Anti-Counterfeiting Taskforce (IMPACT), the European 
Directorate for the Quality of Medicines and Healthcare (EDQMH). 
The reason the EMA is important to this research is because the framework 
discussed further down is due to an incident being flagged by the safety features 
repository system. This is a requirement of Article 37 of Commission Delegated 
Regulation (EU) 2016/161, in which the medicine verification system is introduced.  
If any (suspected) falsified medicines are believed to have been discovered, it is 
the duty of the marketing and/or the manufacturing authorisations holder to report to 
the EMA, due to the risk to public health these centrally authorised medicines pose.  
In addition, the marketing authorisation holders of the centrally authorised 
medicines are to notify the country authorities where the falsified medicines are being 
distributed, whilst notifying the National Competent Authorities (NCA) of the Member 
States. 
The EMA is responsible for the inter exchange of information relating to falsified 
medicines, this is in conjunction with the information being supplied to the NCA of the 
EU Member States. These Member States are often responsible in turn for investigating 
the supply chain and thus making decisions on the action taken within the markets.  
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The way the EMA can maintain control over the flow of information is through its 
reporting system, which consists of a falsified medicinal product template. This template 
is the framework that marketing, and manufacturing authorisation holders are required 
to use. This framework can notify the EMA of suspicious offer(s) that have been 
received and suspected/ confirmed falsified medicines. 
Due to the success of the information exchange the EMA also cooperates closely 
with the international anti-counterfeiting trade agreements as well as other criminal-law 
instruments such as; Operation PANGEA, the Organisation for Economic Cooperation 
and development (OECD) and the Council of Europe's Medi-crime convention (OECD 
2020). 
During Operation PANGEA VII – that utilised the coordination of Interpol, customs 
and the health authorities in 2014, over 12,000 websites in the EU alone were 
disbanded and taken down. Over eight million counterfeit medicines were seized 
during this exploration. 
It is thought that 97% of all websites that sell medicines online operate illegally, as 
stated by the European Alliance of Access to Safe Medicines (EAASM). despite the 12, 
000 websites being shut down business is still going strong and increasing. Europe is 
thought to have over 30,000 ‘fake pharmacy websites’ according to the EAASM. 
Alongside the discussion in Chapter Three it is proven that the online pharmacies need 
to be monitored closely and with strict regulations. 
If a notified incident can cause serious risk to the public and/or animal health, the 
NCAs inform each other through a rapid alert system. The EMA in turn is responsible 
for the maintenance of the rapid alert list of contact points, which include the NCAs in 
EEA Member States, the international partner regulatory authorities, the European 
Commission and various other organisations. 
3.11 Will Brexit Effect the FMD?  
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When the UK ultimately leaves the EU, there is a risk factor that the FMD will not 
be regulated to the best standard possible, due to the FMD being a European 
approach to deal with the rising global threat of falsified medicines.  
This in turns paves the way for falsified medicines to be found in the supply chain 
due to the lack of enforcement and thus a risk to public health. 
For the EU and the EEA Member States, the Delegated Regulation and the 
European Directive are binding. The future of the FMD in the UK will be dependent on 
the relationship that the UK maintains with the EU.  
Even if the UK leaves the EU with less than amicable terms the UK is within its right 
to participate in the regulation of the FMD, as has been previously conducted by 
countries such as Norway, Iceland, Switzerland and Liechtenstein.  
As the FMD is a globally occurring process, manufacturers and regulators alike are 
adopting pack serialisation as a way of countering falsified and counterfeit medicines.  
Meaning that whilst the UK is still a major player in the supply chain of global 
medicines, and it retains a significant pharmaceutical manufacturing presence; the 
manufacturers and regulators may be reluctant to produce different packs for the UK 
medicines due to cost efficiency.  
To remain a ‘safe part of the medicine supply’ it is believed that the UK would 
need to adopt the medicine pack serialisation, just as the rest of the EU complies. 
Currently this safety measure is the FMD. 
At the present time, the MHRA and the National Competent Authorities for the 
UK have stated that they are ‘continuing to implement the FMD in the UK’. 
 
3.12 FMD Enforcement 
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The National Competent Authorities are responsible for the enforcement of the 
FMD in Member States. The MHRA and GPhC are responsible for the enforcement for 
manufacturers and wholesalers, and the enforcement for community pharmacies 
respectively, with the aid of the Pharmaceutical Society of Northern Ireland.  
3.13 FMD Brief Summary 
Overall, the FMD illustrates the progress we as a society have developed in the 
prevention of counterfeit/falsified medicines. It is a good basis for future adaptations of 
the directives that are used to regulate such discrepancies.  
As demonstrated, there are both strength and limitations of the FMD that impede 
on its ability to be as efficient and thorough as it could be.  
That being said the FMD and the other laws and regulations supporting the 
restriction place one medications and consumer good are only one part of an overall 
chain. The chain is only as strong as its weakest link. 
The next step in the chain is the distributional hubs, the pharmacies. What are 
their defining features and how do they affect the supply of counterfeits to the greater 
public?   
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Chapter Four: Monitoring Online Pharmacies: 
Authentic? 
Following on from the restrictions of medicine sales and use in Chapter Three, 
Chapter Four explores the differences between the sale of drugs online compared to 
physical shops.   
An investigation into the products sold, the quantities sold and the regional 
differences across the UK, as well as the level of authentication and approval of the 
pharmacies.   
4.1 Method 
This chapter illustrates the combination of categorical and nominal data, which is 
the quantitative analysis of pharmacies that focus on the cataloguing of online, and 
physical pharmacies throughout the UK. The reason for analysing the pharmacies is 
because they are a crucial part in the distribution of medicines, not only in the UK, but 
worldwide.  
This in turn causes a risk to public health through counterfeit medicines entering 
the supply chain. With the use of categorical and nominal data, regions can be 
clustered together, and a numerical value calculated as a result. This gives an added 
benefit from using a combined method (Bengtsson 2016).  
All pharmacies in the UK, whether they are online distributions sites, or the 
physical brick and mortar counterparts needed to be catalogued for this research.  
4.1.1 Pharmacy Data Collection 
In regard to the physical pharmacies, the following stages occurred for the 
categorisation of each one; (1) each county was searched with the aid of the yellow 
pages and the phone book to identify pharmacies or medicine providers, (2) physical 
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pharmacies were name searched by county again with the use of the Internet – various 
search engines were used for example Google, Bing and Internet Explorer etc.  
The search terms that were used included ‘COUNTY (X) pharmacy’ or ‘pharmacies 
in COUNTY (X)’.  
The counties that were categorised within the study of pharmacies included 
counties in England, Scotland, Wales and Northern Ireland. These counties are sub 












Figure 55: Visual representation of the UK and the counties it comprises of. The counties are sperated in multiple different 
colours to aid the seperation between them. 
 
ENGLISH COUNTIES 
BEDFORDSHIRE, BERKSHIRE, BRISTOL, BUCKINGHAMSHIRE, CAMBRIDGESHIRE, CHESHIRE, CITY OF 
LONDON, CORNWALL, COUNTY DURHAM, CUMBRIA, DERBYSHIRE, DEVON, DORSET, EAST RIDING OF 
YORKSHIRE, EAST SUSSEX, ESSEX, GLOUCESTERSHIRE, GREATER LONDON, GREATER MANCHESTER, 
HAMPSHIRE, HEREFORDSHIRE, HERTFORDSHIRE, HUMBERSIDE, ISLE OF WIGHT, ISLES OF SCILLY, KENT, 
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LANCASHIRE, LEICESTERSHIRE, LINCOLNSHIRE, MERSEYSIDE, MIDDLESEX, NORFOLK, NORTH SOMERSET, 
NORTH YORKSHIRE, NORTHAMPTONSHIRE, NORTHUMBERLAND, NOTTINGHAMSHIRE, OXFORDSHIRE, 
RUTLAND, SHROPSHIRE, SOMERSET, SOUTH GLOUCESTERSHIRE, SOUTH YORKSHIRE, STAFFORDSHIRE, 
SUFFOLK, SURREY, TYNE & WEAR, WARWICKSHIRE, WEST MIDLANDS, WEST SUSSEX, WEST YORKSHIRE, 
WILTSHIRE, WORCESTERSHIRE 
 
SCOTTISH COUNTIES  
ABERDEENSHIRE, ANGUS, ARGYLL & BUTE, AYRSHIRE, BANFFSHIRE, BERWICKSHIRE, BORDERS, 
CAITHNESS, CLACKMANNANSHIRE, DUMFRIES & GALLOWAY, DUNBARTONSHIRE, EAST AYRSHIRE, EAST 
DUNBARTONSHIRE, EAST LOTHIAN, EAST RENFREWSHIRE, FIFE, HIGHLAND, INVERCLYDE, KINCARDINESHIRE, 
LANARKSHIRE, MIDLOTHIAN, MORAY, NORTH AYRSHIRE, NORTH LANARKSHIRE, ORKNEY, PERTH & KINROSS, 
RENFREWSHIRE, SHETLAND, SOUTH AYRSHIRE, SOUTH LANARKSHIRE, STIRLINGSHIRE, WEST 
DUNBARTONSHIRE, WEST LOTHIAN, WESTERN ISLES. 
 
WELSH COUNTIES  
BLAENAU GWENT, BRIDGEND, CAERPHILLY, CARDIFF, CARMARTHENSHIRE, CEREDIGION, CONWY, 
DENBIGHSHIRE, FLINTSHIRE, GWYNEDD, ISLE OF ANGLESEY, MERTHYR TYDFIL, MONMOUTHSHIRE, NEATH 
PORT TALBOT, NEWPORT, PEMBROKESHIRE, POWYS, RHONDDA CYNON TAFF, SWANSEA, TORFAEN, VALE 
OF GLAMORGAN, WREXHAM. 
 
NORTHERN IRELAND COUNTIES 
ANTRIM, ARMAGH, DOWN, FERMANAGH, LONDONDERRY, TYRONE. 
 
The data that was collected from these searches was as follows: The Trading 
Name, The Owner Name, and the Address – Including the town, county and postcode. 
A total of 14,365 pharmacies were catalogued using the yellow pages and a further 200 
from online searches for pharmacies in each county as seen in Figure 56 (Online Vs 
Brick). 
For the online counterparts, multiple searches were conducted using various 
search engines on the Internet. The search terms that were used include ‘online 
pharmacies’, ‘online distribution sites’, ‘distance selling pharmacies’ and ‘online 
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pharmacy’. All results were used if they followed the criteria of residing in the UK or 
making shipments to the UK.  
The same data was collected for the online pharmacies/ distribution sites as was 
collected for the physical pharmacies. Alongside the data such as The Trading Name, 
The Owner Name, Address – Including the town, county and postcode, the URL was 
also included in the data. A total of 946 online pharmacies were identified and 
catalogued. 
For both sets of searches online 200 pages of results were checked when the 
same results started to appear multiple times in quick succession it could be assumed 
that no more unique results would appear. The last 150 pages were also checked as 
they were the most likely to hold unauthorised sites, they were searched until repeats 
showed. 
Once the data was found the information was input into an Excel document 
where further analysis could take place. 
 
4.1.2 Pharmacy Data Collection: Authentication 
Every pharmacy both online and brick alike have an authenticity to them that 
needs to be catalogued. To do that each pharmacy was checked against the MHRA 
and GPhC registry of authenticated and authorised dispatchers of medicine. This is 
explained further on in section 4.2. in Chapter Four as to how the pharmacies are 
authenticated. 
 
4.1.3 Pharmacy Data Collection: Method & Characteristics 
Due to the nature of this study the online pharmacies’ multiple characteristics, 
along-side those mentioned above, were collected. The reason for so many variables 
being collected was that over the years there have been many classifications and 
authentication processes that are used with regard to online pharmacies.  
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The online pharmacy characteristics that were categorised and recorded were 
separated into several sections including: 
1. The Pharmacies Brand 
2. Are they physical on or the internet? 
3. Geographical location 
4. Do online pharmacies offer consultations 
5. What are the medicines that are sold online? 
6. Can you purchase prescription medicines online? 
7. What reviews do the online pharmacies have? 
8. Do they have a shipping cost and what range of prices are there for a 
product? 
9. Do the online sites have a sales promotion advertised? 
10. Are the websites maintained? 
11. Is a privacy disclaimer available? 
12. What contact details are asked for? 
13. Are the pharmacies registered? 
 
When an online pharmacy was found all of the previous points were searched for 
over a nine-month period.  
The analysis of part seven and part nine recorded data was converted into 
averages for comparison. For example, if a pharmacy had a 3* review five out of 10 
times checked and had a 6* for two visits and 1* for three then the overall rating for 
that pharmacy would be the average rating of 3*s.  
For part nine if discounted items showed more often across the website 
compared to flash sales, then discounted items was used for primary analysis.  
The other sections if they showed to be present even once then they were 
categorised for that pharmacy. Such as if the pharmacy shows a privacy disclaimer or if 
a consultant was available.  
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The website maintenance was looked into both the website as they sometimes 
have a time stamp of last update or identified in the website code itself as a time stamp. 
This time and date were recorded each visit and a correlation was able to be 
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4.2  Authentication 
With regard to online pharmacies, there are two main regulatory bodies in the UK 
that govern them; the MHRA and the GPhC. These organisations have the ability to 
authenticate pharmacies both online and physical. 
Section 4.2.12 Quality Certificate highlights the mechanisms used for authorisation 
and provides evidence of how the public can verify authorised pharmacies.  
Furthermore, the creation, role or governance of each organisation is important 
when understanding how each of the organisations approve or deny authentication of 
a Pharmacy.  
4.3 Registry 
Both the MHRA and the GPhC have a record of authentic certified pharmacies, 
these are kept in a directory that is open to the public, this is explained further on in the 
chapter under ‘Quality certificate’. Online pharmacies and Brick & Mortar pharmacies 
are both required to register with either authority, the directory is updated every year, 
since the data was collected in March 2019, 35 online and brick & Mortar pharmacies 
have had their licences revoked and a further 20 licences have been suspended. This 
action took place on the 11th July 2019.  
Alongside the directory of pharmacies, the MHRA also has a register of the 
manufacturers that are licenced to sell certain active substances. Each of the licences 
are due to the ‘Written confirmation for active substances exported to the European 
Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) 
of Directive 2001/83/EC’.  
The 2001/83/EC is explained further in Chapter Three.  The register is updated on 
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4.3.1 What is the MHRA? 
The Medicines Control Agency (MCA) gained control of the General Practice 
Research Database (GPRD) in 1999, this was then combined with the Medical Device 
Agency (MDA) in 2003 to create the MHRA.  
In 2012 the Clinical Practice Research Datalink (CPRD) was and expansion of the 
GPRD. Later in 2013 the MHRA merged with the National Institute for Biological 
Standards (NIBSC), together they are the MHRA brand that is known today. 
4.3.2 What is the MHRAs Role? 
The MHRA takes on the role of supporting multiple governing committees, such 
as the British Pharmacopoeia Commission and the Commission on Human Medicine 
(CHM); previously referred to as the Committee on the Safety of Medicines (CSM).  
Operating as part of the Europeans System of Approval, the MHRA along with 
other organisations process and verify pharmaceutical applications for industry 
members. 
4.3.3 What is the GPhC? 
The GPhC is responsible for the regulation of those on the pharmacy premises 
including the pharmacists and the pharmacy technicians, it is also the body responsible 
for the independent regulation of the pharmacy profession within the UK. 
 It was created in 2010 when the regulatory functions of the pharmacy profession 
could be separated (GPhC 2020). 
 
4.3.4 What is the GPhC Role? 
The GPhC aim to maintain the level of standard in the industry. Therefore, follow 
principal functions, which are set out in The Pharmacy Order 2010.  
 To establish and maintain a register of pharmacists, pharmacy technicians 
and premises at which a retail pharmacy business is; 
 
Page | 191 
14656 
946 
Brick & Mortar Online
 To set and promote standards for the safe and effective practice of 
pharmacy at registered pharmacies; 
 To set standards to which registrants must demonstrate that their fitness 
to practise is not impaired; 
 To promote the safe and effective practice of pharmacy by registrants;  
 To set standards and requirements in respect of the education, training, 
acquisition of experience and continuing professional development that it 
is necessary for pharmacists and pharmacy technicians to achieve to be 
entered in the register or to receive an annotation in the register and to 
maintain competence; and 
 To ensure the continued fitness to practise of registrants. 
The implementation of this order ensures that the GPhC are setting suitable 
measures, but also that members are operating to the guidelines set.  
 
4.4 Pharmacy Analysis Results 
4.4.1 Online Vs Brick & Mortar 
A comparison of the numbers of online pharmacies and physical pharmacies 
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Figure 56: The visual comparison between online pharmacies and the brick and mortar versions. 
Despite the volume of physical branches of particular companies (pharmacies), 
the impact of the online distribution is considerably more extensive. 
  For example to name the top three, Lloyds Pharmacy has 1598 branches across 
the UK and two online channels for distribution, Well (Best Way National Chemist 
Limited) has 760 branches and has only one online channel and Rowlands Pharmacy 
has 519 branches and two channels. 
Now dispite having a limited number of online channels these companies can 
supply the whole country. This means that the number of distributional channels lessens 
for the counterfits to pass through, they only have to pass through tens rather than 
hundreds and thousands of branches.  
This overall suggests that counterfeit medicines will become more of a health 
problem to the greater public as there will less checks, less correspondance with 
pharmacist and a far greater reach for sales.  
It is known that counterfeit medicines can be bought from both types of 
pharmacies, however it is more difficult for counterfeits to be in the supply chain that 
are purchased from a brick and mortar pharmacy.  This is one of the reasons that 
online pharmacies should be closely monitored and checked regularly as well as being 
one of the key points in this research.  
As discussed in section 4.2.2, the location of the pharamcies may influence the 
number of branches, nevertheless online pharmacies have a distribution that spans the 
UK. 
If the public influence what items are avaliable to purchase online then it stands to 
reason that they are also responsible for the safe purchase of such items. 
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Figure 57: A visual representation of the regions across the UK that have be created - via collection of other counties -  for 
this research. 
Albeit online pharmacies have a presence on the Internet, for a company to be 
legally allowed to distribute any type of product it needs to be licenced under a 
physical address. 
 These addresses are recorded and are available to the public. These addresses 
were identified and documented, then categorised by region. The regions are depicted 
in figure 57. 
The quantities of both online pharmacies and the brick-and-mortar versions were 
catalogued for each of the UK regions as seen in figure 58. It is important to note that 
for this figure the brick and mortar quantity is divided by 10, the reason being that a 
direct visual comparison can be made.  
Alongside the various versions of the pharmacies the populace at each region 
was also calculated, the population was divided by 20,000. This is to illustrate that the 
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population does not account for how the pharmacies are spread out amongst the UK 
regions.  
For instance, the West Midlands is in the top 5 for the population count, however 
it is in the bottom 5 for the quantity of pharmacies both physical and online versions.  
The same can be said for the North West where the population is considerably 
more than the quantity of the pharmacies found with the region. Henceforth it can be 
assumed that even with a populace being of a sizeable quantity less pharmacies can 
operate and distribute to those customers. 
 
 
Figure 58: Online pharmacies (-) = 1:1 ratio, Brick and Mortar versions (-) = 1:10 ratio and the populace (-) = 1 : 20000  
ratio. The figures stated are in a calculated ratio for each reagion to aid in visual representation and so that all numerical data can 
be categorised on a clear compact scale. (Office for National Statistics (UK) 2019) at each region of the UK. 
4.4.3 Consultation 
When entering a physical brick and mortar pharmacy you can talk to a physician 
such as a doctor or at the very least talk to a pharmacist.  When looking closely at the 
 




Docotor Pharmacist Not Needed
online pharmacies it is noticeable that talking to a professional is not always an 
available option, as is the case in almost 50% of them.  
26% of online pharmacies have a doctor/physician available to chat with and 24% 
of online pharmacies a patient has access to a pharmacist.  
Figure 59: The availability of a professional consultatant in respect to the online pharmacy gthey are working with and 
which type of professional is on hand. 
As shown in figure 59 there is a significant difference in the number of 
pharmacies online that allow for a consultation and those that deem it not a necessity. 
When comparing those numbers, it illustrates that the idea of consultation regarding 
medicines is a dwindling practise for the future. 
 If the online channels do not offer this basic curtesy, can they be trusted to 
monitor the medicines that are to be purchase and distributed. The public use the 
available consultation service if they are unsure and hesitant about using the medicines 
offered to aid their treatment, and to also talk through their concerns.  
On the other hand if a patient can talk to a consultant before purchasing any type 
of medicine, is it then true that they can in turn trust that the consultant is authorised 
when speaking to them online rather than in a physical store. 
A simple way to check the authenticity of a consultant or to find if they are 
licenced is to check against the General Medicine Council (GMC) register. The medical 
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register is an online list of the doctors throughout the UK, it also shows the types of 
registration the doctor holds, what their individual training is and a variety of other 
information.  
The medical register also offers details such as whether the consultant is a GP or a 
specialist consultant, the date they registered and whether they have a fitness to 
practise history since 20 October 2005 (GPhC 2019). 
These registers along with the ability to talk to a professional aids the public’s trust 
in online pharmacies and thus will enable counterfeits to easily reach the consumer if 
they are not monitored and maintained. By having a registered consultant, the 
pharmacies are more likely to be a trustworthy source but also the company may feel a 
responsibility to the patients they aid.  
4.4.4 Medicines Sold 
There are three main categories of medicines that can be purchased from the 
various pharmacies that were analysed. They are as follows; prescription only medicines 
(POM) such as ciprofloxacin, penicillin and Vicodin, general sales list medicines (GSLM) 
such as paracetamol and ibuprofen and lastly pharmacy medicines (PM) such as sleep 
aids and domperidone (a high dosage of ibuprofen). 
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Figure 60: The comparison of medicines sold via online pharmacies. Prescription on Medicines (POM), pharmacy medicines (PM) 
and general sales list medicines (GSLM). 
As can be seen in figure 60, the most likely combination of medicines to be found 
on an online pharmacy is that of POM, PM and GLSM. However, the most common 
medicine to be sold on any of the websites is GSLM, which was the hypothesis at the 
beginning of the research due to GLSM being sold nationwide in supermarkets. 
It should also be noted that there were some websites that did not disclose what 
they were licenced to sell, see quality certificate later in this chapter for more 
information on licencing. 
By having such a wide range of medicines available for purchase that can also be 
delivered to your door gives rise to a profitable market that is a cause for concern. With 
such a variety of medicines having the ability to be purchased online rather than in a 
physical store means that ages aren’t checked for the purchaser if they were to be 
under the age of 16.  
More than one of a type of medicine can be purchased in one transaction which 
is normally limited to two if purchased in a supermarket or physical store. This means 
that the public can easily get their hands on medicines that should be regulated and 
that could have dire consequences to those who need the counter measure in place.  
4.4.5 Are there still restrictions on prescriptions? 
Most if not, everyone has heard of a prescription, but what is a prescription? A 
prescription (Px) is an implementation tool of a health-care program used by a 
physician or other qualified health care practitioners, within the form of instructions that 
govern the plan of care for the individual patient (Jameson et al. 2016).  
The term prescription often refers to a written authorisation of a health care 
provider for a patient to have the ability to purchase a prescription drug from a 
pharmacist. 
 




A prescription must include: 
 Name, address and telephone number of the prescriber, 
 The date, 
 The generic name of the drug, the strength, 
 The dosage form, the total amount, 
 The label, instructions and the warnings, 
 Name, address and age of the patient, 
 Signature or the initials of prescriber. 
Within the UK the Medicines Act 1968 as well as the Prescription Only Medicines 
(Human Use) Order 1997 contain within them the regulations and guidelines that cover 
the supply of sales, the use, the prescribing, and production of the medicines. As stated 











Figure 61: The comparison between the online pharmacies that require a prescription for purchasing a POM and those that 
do not. For every 1 pharmacy that does not require a prescription to sell a POM medcine 1.15 pharmacies that do. 
54% of the sites that medicines can be purchased over the Internet need a 
prescription, whereas 46% does not require a prescription for the medicines to be 
purchased by the patient. However, as described by the Medicines Act 1968 the 
possession of a POM without a prescription is legal unless it is covered by the Misuse of 
Drugs Act 1971 (Mutsatsa 2016). 
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One of the reasons for having a restriction on POM – that it should only be sold 
in the presence of a signed prescription- maintains the public safety as it makes it more 
difficult to use if the patient is self-prescribing and may not need the medicine 
purchased.  
The mindset that is apparent within society that purchasing for convenience 
rather than seeking out professional opinion, may lead to more dangerous outcomes. 
Not to say when purchasing GSLM that an individual would need a professional's 
opinion to purchase paracetamol or ibuprofen for their cold.  
However, when the POM includes antibiotics or strong painkillers the risks far out 
way the benefits if used in treatment that the medicines are not intended to be used 
for.  
To allow a POM to be purchased without a prescription endangers the consumer 
as there is not a safety check in place that would otherwise be. Limited if no instructions 
available, the dosage may be incorrect which could be fatal in some cases.  
By not having a prescription needed those medicines maybe more likely to be 
counterfeit as the pharmacy themselves may not be strictly monitored and thus their 
safety check regarding the medicines may not be up to par. If that is the case, then 
these pharmacies are aiding in the reach and destruction caused by counterfeit 
medicines.  
As of April 16th, 2019, the new guidelines set out by the GPhC and the MHRA 
state that patients will no longer be able to select a prescription only medicine without 
having an ‘appropriate consultation’ with the prescriber the online pharmacies state it is 
in collaboration with.  
Online pharmacies will now need to take a stricter policy when they carry out 
identity checks on the patient obtaining the medicines and thus identify the 
inappropriate requests such as placing multiple orders to the same address of delivery.  
 
Page | 200 
Alongside this the pharmacy staff must be able to verify the patient’s identity – 
following the Nation Health Service (NHS) digital identity verification and authentication 
standard – to obtain information to check that the supply of medicine is safe for use, 
the information can include; age, gender, other medications that may be taken.  
On top of the ID checks, online pharmacies will also need reassurance that the 
prescriber they are in collaboration with ‘will proactively share all relevant information 
about the prescription’ with the various and relevant healthcare professionals – such as 
the patients GP – after the medicines are prescribed.  
The online pharmacies that are found to not comply with the guidelines set out 
could face ‘enforcement action’. 
 
4.4.6 Public Influence 
When monitoring online channels, it becomes clear that the public has a major 
influence on what can be sold and what will make profit. This suggests that certain 
criteria need to be met for an individual to be happy to hand over money and purchase 
the product.  
These factors help determine if an individual is confident in the purchase and if 
that is the case, then more safety checks will need to implemented in the future to 
guard against counterfeit medicines from entering the supply chain.  
When categorising the data that was collected for monitoring online pharmacies 
the groups that stood out for public influence include but not limited to; customer 
reviews, the price of shipping and delivery and if there was a sale.  
4.4.7 Reviews 
As with most purchase sites on the Internet, reviews can often be left for future 
customers to see and form an opinion. The reviews can consist of delivery standards, 
quality of shipping, price of the product, and other various comments. 
 













Figure 62: Customer ratings for particular online pharmacies that have been reviewed. 
As seen in figure 62, the overall rating of a customer’s review is almost even 
across the board, being evenly distributed due to the stars rating. As can be seen, more 
than 30% of the online pharmacies do not have access for customers to give a review.  
Just as with any market site online the reviews have an impact on whether a 
person will trust them and purchase a product from them. Typically, the lower the 
review the lower sales made. These sites will normally try other tactics to gain support 
such as sales or reduced shipping and wait times. These factors are reviewed later in 
more detail. 
 However, what was interesting when looking at the sites was the percentage of 
online pharmacies that do not have the availability for review. Even those some sites 
have 1* reviews they still showed trustworthiness as they posted those reviews.  
Whereas not giving the ability to rate a service or give and opinion for others to 
see illustrates distrust and could cause a problem in the future if more sites take this 
route.  
If a site the way some reviews is based on difference experiences, did they find 
what they were looking for, could they purchase the medicine hassle free, could it be 
shipped to them and so forth.  
4.4.8 Price & Shipping 
 




Free Shipping Shipping Collection
When a customer is in the process of purchasing an item one of the staples of the 
site or item that seals the deal in the purchase is the price of the item and the shipping. 
The prices of the items that were searched for such as ciprofloxacin, ibuprofen and 
amoxicillin were relatively similar.  
Therefore, the price could not be used as a deciding factor in this scenario, 
however the price ranged from £3.50 to £5 without shipping involved for the antibiotics 
the GSLMs such as ibuprofen ranged from £0.99 to £1.50 without shipping included. 
So, one of the only factors comparable to those prices available is the price of a 
prescription from the pharmacy which is close to £9.00 per ingredient.  
Whether the online pharmacy has shipping, be it free or priced and collection was 







Figure 63: The types of delivery available to customers when purchasing medicines online. 
95% of the online pharmacies have a type of shipping, 80% have a priced 
shipping and 5% ask for collection. 
The pharmacies that offered free shipping were typically the big recognisable 
companies such as Lloyds Pharmacy, where as those who required a paid shipping fee 
were the less recognised pharmacies.  
This suggests that the shipping fee is one of the ways that they claim back the loss 
in product costs. It should be noted that some of the pharmacies that has a shipping 
 




cost attached would also promote free shipping as a sales tactic – illustrated in the next 
section.  
By having a relatively low shipping cost or no cost at all promotes a sale for that 
pharmacy. The reason being that we as a society will typically purchase the most for the 
least amount of money.  
So, if the shipping cost is saying £2 compared to £4 and the products were a 
similar price +/- £0.50 then the pharmacy with the £2 shipping cost would have their 
products purchased.  
Also, another reason that shipping cost comes into effect is that the idea of 
shipping or delivery to your door is convenient and you don’t have to remember to go 
to the store and pick up your medicines. This makes the process more comfortable and 
retainable in the future.  
When an individual uses an online pharmacy the shipping cost is sometimes a 
deterrent for a purchase. So, for the pharmacy to make profit they may need to raise 
the cost of the product and reduce the shipping cost if the shipping cost is what is 
losing the customers. This is where the sales tactics come in to play.  
4.4.9 Sales Promotions 
For any business to be successful they need to be able to sell, this can be in the 
form of merchandise, time, assets even advice. For sales to continue the market needs 
to be investigated and the top tip for sales to continue is to have promotions that gain 
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Figure 64: Comparison for if an Online Pharmacy use sales promotion techniques to promote custom. 
53% of online pharmacies use some type of promotion. The 10 most popular 
types of sales are as follows: Discounted Products, Free Shipping/ Free Returns, Flash 
Sale – limited time offers, Buy More, Save More, Products Giveaways/ Branded Gifts, 
Loyalty Points, Coupon Giveaways, Competitions, Price Match Promises and Holiday 
Promotions.  
The top four promotions that could be seen in the online pharmacies that used a 
method of sales when the data was collected are illustrated in figure 65. 
62% of the pharmacies on average use discounted prices to gain custom, 
whereas 6% entice customers with free or discounted shipping, 8% with flash sale (hurry 
now the offer ends in 24hrs – for example) and 4% with a buy more, save more mind 
set, such as buy 3 for 2. 
 
Figure 65: An illustration of which type of sales promotions are used by online pharmacies. 
By having a sales tactic, the pharmacy can promote the sale of their merchandise 
which is the name of game at the end of the day. For society money is a very sensitive 
subject, which we as a whole typically hold close to our chest, but if we can save money 
for essentials then purchases are more likely to occur.  
When offering discounts, the mark up price may never actually be the price that 
the medicine has sold for in the past. What this means is that the illustrated price for 
 
Page | 205 
say the 50% off at £3.50 and the RRP is a crossed out £7.00, the medicines price may 
never reach £7.00.  
In certain studies, this is shown to have an effect on the consumer as they think 
they are having a bargain when in actual fact they would be spending a similar amount 
to somewhere else that didn’t have the offer on.  
It is this practise that sometimes leads to distrust in the markets as the majority of 
compares in any type industry around the world use this as a sales pitch to gain more 
customers, but they are clearly being dishonest.  
When items are on offer and in the category of being in a flash sale the buyer 
feels panic that they may not get the best deal or they may lose out on purchasing the 
product they need. 
This causes a rush of sales that may not be just. The way a seller can promote this 
type of sale is with phrases such as ‘hurry now while stocks last’ or ‘offer ends in 
13hours’ sometimes ‘last one left’, these phrases reaffirm the point that buyer needs to 
purchase soon or lose out.  
 
4.4.10 Pharmacy Integrity & Discretion 
On the other side of public influence is the pharmacies duty of care, respect and 
integrity for the customers and the products they sell. The categories that illustrate 
these points are the website maintenance, privacy disclaimer for the public and how the 
contact details are held and processed.  
These details demonstrate if a pharmacy has taken care with what is given to 
them and if it can maintain its transparency. All these factors impact whether a site or 
pharmacy is deemed to be trustworthy. 
4.4.11 Website Maintenance 
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Whenever a website is created it leaves a digital fingerprint that when accessed 
you can see how often the site is maintained and updated. However, on some sites it is 
published in the print how often the site is maintained or updated. For the majority 
(27%) of sites it is not possible to determine the frequency of maintenance that the site 
undergoes 
This shows that with regular maintenance, the online pharmacies take care in their 







Figure 66: The frequency in which an online pharmacy site is maintained. 
As shown in figure 66 the most common update partaken was monthly this was 
demonstrated in 21% of the online pharmacies checked.  The others showed a normal 
distribution where an annual update (15%) occurred less often than a weekly update 
(18%) and quarterly updates which occurred 19% of the time.  
When any website is updated regularly and monitored it can be assumed that it is 
more trustworthy as the facts, data and settings are constant. Having a trustworthy 
website is a dependable factor when purchasing products or gathering information on 
the internet.  
For example, if you purchased a product on a 25% off offer but the price 
increased on receipt and you questioned it and the seller in return replied that the offer 
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ended last week and that product is not eligible for the deal so you need to pay full 
retail price, that annoyance and distrust grows.  
Overall, it is not good for business, so up to date websites and product checks are 
important for a business to stay in touch with the public to gain influence and profit.   
4.4.12 Privacy & Disclaimer  
A privacy policy or disclaimer is a legal document (in privacy law) or a statement 
that discloses some if not all the ways a party gains, uses, discloses or manages a 
customer’s/ client’s data.  Its duty is to fulfil a legal requirement that protects the client’s 
or customer’s privacy.  
The personal information can be any means that can help to identify an 
individual, this includes but is not limited to (Donaldson 1994): Client / Customer Name, 
Address, Date of Birth, Marital Status, Contact Information, ID Issues, Expiry Date, 
Financial Records, Credit Information, Medicinal History, Travel Information and lastly 
the intentions to acquire goods and services. 
With regard to a business a privacy disclaimer is often used as a statement that is 
a declaration of a party’s policy on how it collects, stores, and releases the personal 
information that it collects.  
The declaration informs the client or the customer what specific information is 
collected, and once it is collected whether it is shared amongst partners, sold to other 
firms or enterprises or whether it is kept confidential (Laurent & Levallois-Barth 2015). 
Depending upon the requirements across geographical boundaries and legal 
jurisdictions, the contents of the privacy policy may change. Most countries have their 
own legislations and guidelines as to what information is collected, who is covered and 
what it can be used for. The data protection laws in Europe in general cover the private 
and public sector (Laurent & Levallois-Barth 2015).  
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Thus, the right to privacy is a highly developed area in European law, as all 
member states of the EU are also known to be the signatories of the European 
convention on human Rights (ECHR). 
The Organisation for Economic Co-operation and Development (OECD) issued its 
‘Recommendations of the Council Concerning Guidelines Governing the Protection of 
Privacy and Trans-Border Flows of Personal Data’ to create a comprehensive data 
protection system throughout Europe (OECD 2020) The OECD’s seven principles that 
govern the protection of personal data are as follows (OECD 2020): 
1. Notice—data subjects should be given notice when their data is being collected; 
2. Purpose—data should only be used for the purpose stated and not for any other 
purposes; 
3. Consent—data should not be disclosed without the data subject’s consent; 
4. Security—collected data should be kept secure from any potential abuses; 
5. Disclosure—data subjects should be informed as to who is collecting their data; 
6. Access—data subjects should be allowed to access their data and make 
corrections to any inaccurate data; and 
7. Accountability—data subjects should have a method available to them to hold 
data collectors accountable for not following the above principles.  
The Data Protection Directive (DPD) - more commonly known as directive 
95/46/EC - that was created in 1995, was superseded by the General Data Protection 
Directive (GDPR) 2016/769/EC on the 25th May 2018 more commonly known as the 
Data Protection Act 2018, which harmonises the privacy rules across all the EU member 
states.  
 




The GDPR not only imposes the seven principles but is the reason for the 
implementation of more stringent rules on the collection of the client’s personal 
information.  
The EU data is required for the purposes of privacy policies to be concise, clearly 
worded and the transparent disclosure of any collect, storage, processing or the 
transfer of the personal information that could lead to the identification of an individual.  
The controllers of the data must also be able to erase the data under certain 
circumstances, and the data to be made portable in a common format follows.  
Unfortunately, not every site follows the regulations set by the GDPR, 16% of sites 
do not have the disclaimer, however 84% of sites have a privacy disclaimer, and state 









Figure 67: The representation of whether an online pharmacy has a privacy disclaimer 1in 6 pharmacies has a privacy disclaimer 
avalaible for the public to read.. 
Similar to having a website maintained, by having a privacy disclaimer for 
customers to read and question illustrates the transparency of the pharmacy’s intent.  
This gains the customers trust which in turn gains the pharmacies profit for the 
inevitable sales that will be conducted. Any customer has the right to know how their 
data is collected, how it is used, why it is being used and also where its being stored.  
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When a pharmacy refused to place a simple statement/disclaimer to acknowledge 
this basic right, then future issues will occur for those pharmacies as they are not 
cohering to the GDPR regulations set out and can be prosecuted. Not having a 
disclaimer is a definitely disadvantage for those pharmacies.  
If those pharmacies aren’t following the GDPR regulation, what other regulations 
aren’t they following and could they be a threat to the public health?  
All regulations, policies, guidelines are in place to prevent if not stop error and 
mistakes form occurring that can be a risk to society and have an impact on an 
individual.  
One of those risks are counterfeit medicines, if the GDPR is not followed can we 
safely assume that the counterfeits are monitored and routinely checked to protect the 
public? 
 
4.4.13 Contact Details 
Whenever there is a purchase over the web, various details are taken to procure 
payment. These details often have an overall recurring theme, such as the following: 
Title, Forename, Surname, Email, Password – often used when registration takes place, 
Country, Phone Number (+44), Postcode, Address and the County.  
However, what is often not recorded is whether privacy is maintained when 
payment details are taken. This includes if the customer can use PayPal or other 
payment methods that can give security to the customer with bank and card details.  
Card details that are often required include, name of the customer, the card 
number, the expiry date on the card and lastly the card verification code (CVC).  
More than 50% of online pharmacies recorded require the card details of the 
customer and do not offer payment security or protection.  
 
Page | 211 
511 
435 







Figure 68: The comparison of payment methods available to the customers when purchasing medicines on the Internet. 
For every pharmacy that has alternative payment method card details can also be used. 
A persons contact details need to be securely handled otherwise they can be 
used in cases of fraudulent activity. To not enable the user to pay with an alternative 
method is a risk to both the buyer and seller.  
The buyer has a risk that their details could be used without their consent if the 
details were to be stored for a later date, also when the details are collected there is 
nothing stopping the company from using the details in an automatic purchase process 
if it’s hidden in the fine print or programming.  
The seller has a risk as some customers may be put off purchasing any products 
as the payment method, they use is not available, also they may be concerned for 
identity fraud.  
4.4.14 Quality Certificate 
As explained previously for an online pharmacy to be authentic it must be 
approved either by the GPhC or the MHRA. The MHRA initiated a compulsory EU 
common logo, also known as the ‘Distance Selling Logo’ in July 2015.  
If there is intent to supply or sell any GSLM, POM or PMs on the Internet the 
MHRA logo - as shown in figure 69 must be applied and displayed on every page of 
the website. The Distance Selling Logo must also be shown on the websites of non-
pharmacy retailers of GSLMs.  
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For the MHRA to accept a distance selling pharmacy or online pharmacy and 
place it on the register, the pharmacy needs to meet all the conditions set out in the 
law before it can be registered. Another option for a pharmacy is to have the voluntary 







Figure 69: The MHRA Distance Selling Logo and the GPhC Voluntary Internet Logo 
The pharmacy should only be given the GPhC Internet logo after it has applied 
and been given the MHRA Distance Selling Logo. However, that does not appear to be 
the case where 9% of online pharmacies only hold the GPhC voluntary logo.  
The GPhC logo can only be used by pharmacies registered under that scheme. 
No third party is permitted to use that logo. However, 1% of the pharmacies are neither 
authorised by the GPhC nor the MHRA. Most sites (55%) are authorised by both the 
MHRA and the GPhC. General Pharmaceutical Council, 2020 & MHRA, 2020). 
By following the MHRA and GPhC registry, pharmacies illustrate that they are 
licenced and regulated by the correct authorities. This means that they are trusted to 
uphold the strict guidelines set in place for the pharmacies, regarding what is sold, how 

















Figure 70: The comparison between what each of the online pharmacies has as a quality certificate, if they have one 
readlily avaliable to check and how many onnline pharmacies do not demonstrate that they are registered pharmacys and legally  
allowed to sell medcines. 
By having this check in place helps the public to trust the pharmacies and thus be 
confident in the purchased products themselves. Those pharmacies that are not 
licenced or registered are essentially an endangerment to the public’s health as they do 
not hold any regard for the laws and regulations set out for them. 
 This in turn enables the market for counterfeits to have a footing in the industry, 
which also causes concern as the more they are enabled to be used for profit the more 
likely they will be. 
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4.5 Online Pharmacy Summary 
Society as a whole would be more likely to make purchases from a place that they 
have had a positive experience such as saving money, or a good review and had a 
show of authorisation.  
Having a consultant available for advice and consultations improved the 
productivity of the pharmacy and in the opinion of the public. If a pharmacy is to sell 
POM or other medicines that should often be confirmed with via a professional then a 
consultant should be available. By having a consultant means that the safety and 
concerns of the public are met.  
Furthermore, POM should only be available if a prescription is signed and 
checked by a medical professional, otherwise why would the medicine be so restricted 
for purchase. If POM do not have a prescription, then they either need to be revaluated 
to explore the health risks or all pharmacies need a prescription.  
The Medicines Act 1968 needs to be validated for the flux of online distributional 
channels as when it was created only brick and mortar pharmacies were available and a 
prescription was needed.  
As society increases its knowledge base the laws and regulation even the 
guidelines need to keep up with the change and evolve accordingly, otherwise it could 
be a potential to cause more harm than good.  
These sales promotions and other influences that are affecting the consumers are 
having on the market is crucial in understanding how the online pharmacies will change 
and adapt in the future.  
Will they need to be more closely monitored; can they only do certain sales in a 
strict period of the year and so forth.  
By constantly updating and maintaining the website demonstrates respect for the 
clientele and for their business market. Thus, enabling the counterfeit industry to take 
root within online distribution channels.  
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Together all the sales promotions, the distribution and integrity of the pharmacies 
cultivate an environment for counterfeits to be present in.  
Overall, it is believed that online pharmacies need to be more closely regulated as 
they have a far reach, they are convenient and, in the end, they seem to be the future 
of pharmacies.  
This next stage in development is the subsequent step in securing the safety of 
the consumers and aiding in the fight against counterfeit medicines.  
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Chapter Five: Knowledge and Experience of 




As explained previously in Chapter One, medicines are an essential part of today’s 
society, curing ailments that decades ago would have been thought to have been 
impossible or a miracle.  
As medicines became a crucial factor in society, counterfeit medicines arose to 
take advantage of the market for financial and personal gain. Counterfeit medicines are 
detrimental to a patient’s health and thus cause a public health risk. 
As it is the public that would be affected most of all by the presence of counterfeit 
medicines, it can be assumed that their view and perspective of them would be 
important.  
For this to be interpreted, various questions would need to be asked to gain the 
appropriate perspective of the public. In view of this, the questionnaire that is the basis 
of this chapter was created, to analyse the purchasing of medicines from online 
distributers.  
This included the trust placed in such distributers and the trust of the supply chain 
itself, alongside the types of medicines that are frequently purchased.  
 Understanding the public’s view and perception of such matters is important in 
preventing further risk caused by counterfeit medicines. If the public’s understanding 
can be analysed, then pre-emptive measures can be created to limit that risk.  
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5.2 Aim of the Questionnaire  
The purpose of this study is to further explore the knowledge and experience of 
pharmaceuticals with regard to online pharmacies and self-prescription using a semi 
structured questionnaire.  
The study will investigate the consumer perspective through their demography, 
the use of pharmacies, the reason behind using them and the public’s opinions of 
counterfeit medicines and online pharmacies. 
5.3 Objectives for the Questionnaire 
Allow me to introduce the following focal points that are pivotal to this study:  
1. Identifying the demographic factors of self-prescribing medicine 
users. 
2. Identifying a correlation between gender or age and the reasons 
for purchasing medicines. 
3. Exploring the motivation of the purchasing of medicines. 
4. Assessing the public’s opinion on counterfeit medicines. 
5. Investigating the public’s concern over the trustworthiness of 
online pharmacies.  
5.4 Methods 
Chapter 5, uses a semi structured questionnaire for extracting knowledge from a 
social environment. The use of semi structured interviews/questionnaires is a common 
methodological tool, used in cases where the goal is exploratory, discovery and 
interpretation of complex social events or trends such as the perception of counterfeit 
medicines and the use of online pharmacies (Morris 1984; Klandermans 2007). 
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5.4.1 Research Design 
The reason for this study being conducted with a semi structured questionnaire, 
was to maximise the data received from the participants, with the primary focus being 
on those who purchase medicines.  
A semi structured questionnaire is composed of two parts; the controlled 
questions and open-ended ones, compared to a fully structured questionnaire which is 
only comprised of ridged tick box answers (yes, no or categories).  
With having a structured questionnaire, the participants are limited in what they 
can give as a response. Yes, it does make the data easier to correlate as there is only a 
selection of answers available.  
However, a semi structured layout still incorporates some of the controlled tick 
box answer for easier correlation, but it also has open-ended questions such as ‘what 
gender do you identify with?’.  
By having these types of questions, it gives the participant freedom to come up 
with their own answers and comments, thus enabling their thoughts and feelings to be 
shown. The questions that had an open approach included the background and the 
opinions of the consumers, which are the primary interests of the study. 
At the beginning of the questionnaire, it also focuses on the point that there is no 
right or wrong answers, meaning that we truly are interested in what the public think 
and feel with relation to medicines, pharmacies and counterfeits.  
Participants were given the freedom to write a response to a question in their 
own word that would later be copied verbatim for analysis once the study had been 
collected. 
One disadvantage for using a semi structured layout is that the answers need to 
be analysed in a different way. They need to be examined to see if there was a theme 
to the answers that could be grouped together for further analysis.  
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Overall, this results in a minimalistic intrusive approach to participant privacy and 
into their lives. 
5.4.2 Data Collection 
The questionnaire was distributed online for the furthest possible reach of 
participants. The criteria of the participants were for anyone above the age of 18, 
however it could reach to those that are 16.  
The questionnaire was in circulation from February to May 2019. Any participants 
that did not answer the questions appropriately or did not fit the criteria set out for the 
participants, would be excluded from the data pool. 
 
5.4.3 Definitions 
For the purpose of the questionnaire, self-prescribing can be defined as 
prescribing medicines yourself. E.g., buying cough medicine when you have a sore 
throat. The rationale for using the WHO’s definitions of both a counterfeit and 
substandard drug/medicine is because WHO is an internationally known organisation 
and the definitions are recognised worldwide (WHO 2020).  
The reason that this is important is so that the knowledge and perhaps the 
perception of the definition is far-reaching and understood by more than solely the 
participants in the UK.  
Another motive for using the WHO’s definitions, is that numerous researchers 
over the years, of multiple specialities, have already been successful in informing others 
of such dangers, by having these definitions as a framework.  
(Zhou 2005) uses the WHO’s definitions to further the point that one definition 
can be used across multiple disciplines and be successful. 
In this survey the medicines that are being described are medicines such as 
Antibiotics, Antimalarial and such.  
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Furthermore, as stated by the WHO, a counterfeit is (WHOa 1999): 
“A product that is deliberately and fraudulently mislabelled with respect 
to identity or source. Counterfeiting occurs with both branded and 
generic products and counterfeit medicines may include products with 
the correct ingredients but fake packaging, with the wrong ingredients, 
without active ingredient or with insufficient active ingredients”. 
Whereas (WHOb 1999).... 
“Substandard drugs are manufactured with the intent of making a 
genuine pharmaceutical product, but the manufacturer saves costs by not 
following GMP (Good Manufacturing Practice) or using poor quality raw 
materials. Another potential problem relates to inadequate storage or 
transport conditions, leading to deterioration of the product. The 
performance of such medicines is questionable”. 
5.4.4 Data Analysis 
This pilot’s study consists of 76 questionnaires that were collected between 
February and May 2019. The studies were collected online and copied to excel 
verbatim. After numerical analysis and the coding of the data within excel, the data was 
then imported on RStudio for statistical descriptive analysis.  
The questionnaire consisted of four parts; (1) the demography characteristics of 
the consumers, (2) the use of pharmacies and medicines, (3) the reasons for using them 
and (4) public opinion of online pharmacies and counterfeits.  
Further investigation into the data created Comparison Models for the variables 
most relevant to the research question of counterfeit medicines and the use of online 
pharmacies. 
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Age groupings were created to be four/five years apart over a 60-year range. The 
reason for this is due to the belief that a change can become more apparent with the 
aid of a four/five-year range (Teater 2015).  
5.4.5 Data Validation 
Once the data was collected it was imported into RStudio and Excel, which was 
then used to analyse descriptive and numerical statistics. The data was interpreted with 
an unbiased and non-judgemental view, and an open mind and attitude was also used 
during the research to keep the results fair and accurate. 
Bias is when you illustrate prejudice, favouritism or preference for someone or 
something, where being judgemental or showing judgement suggests that you allow 
your own values and tastes to guide your discissions (Sitthi-amorn & Poshyachinda 
1993). 
A non-judgmental and unbiased view means that you disassociate yourself with 
what you think you know and what your own beliefs are about a topic when you are 
looking at someone else’s answers to a question that has been asked (Sitthi-amorn 7 
Poshyachinda 1993). 
By allowing the questions to be answered in a non-judgemental and unbiased 
environment you are more likely to get an accurate honest answer than someone 
trying to tell you what they think you want to hear.  
A good way to show non-judgmental and unbiased feelings or ask questions is 
for it to be conducted anonymously, for how can you be judged if you are not known.  
For example - this is in theory only! 
Two people are standing next to each other. Person A is against anything new, 
different and expressive such as (Race, Gender, Sexuality for scenario purposes). Person 
B identifies with one or more of those differences and expressive changes in life (Race, 
Gender, Sexuality for example).  
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Both individuals are asked by Person C to tell them what colour the sky is. Person 
A looks up and say its green. Person B looks up and says Blue.  
Person C shares the same belief as Person A and shows a biased view so they 
ignore the reason for Person Bs answer and sides with Person A and takes that as truth. 
Person B changes their answers to be more alike Person A. 
However, person D has an unbiased view and askes the same question, Person A 
and B answer again.  Person D ignores their own beliefs and listens to both and 
questions are either of you colour-blind. Person A answers well yes, I am and Person B 
answers no, not that I’m aware of.  
There is always a reason for someone’s answer. 
The reason that the data would be examined with an unbiased view is because 
multiple answers were needed for correlation to occur, this means that various opinions 
were needed for analysis and some of those would oppose the thoughts I had 
originally when conducting the study. Nevertheless, the bias and judgement needed to 
be removed for an accurate and just assessment to take place.  
With a variety of answers, no one answer or expected answer would be looked at 
more highly than others, thus an unbiased view. Also, to further avoid the problem of a 
biased viewpoint skewing the data, only the answers needed for analysis were 
examined together. So, the whole data was not interpreted at once, thus the answers 
were kept anonymous throughout. 
5.4.6 Ethical Considerations 
Before the questionnaire was distributed online, ethical approval was sought from 
Bournemouth University Internal Ethics Committee (Ref 24172).  
To protect those who completed the questionnaire, no data that would be able to 
be used to identify the participants were used or stored, such as full names.  
Also, the data that was collected in this study was not shared outside of the scope 
of the study. 
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5.5 Results 
5.5.1 Demography 
Due to the semi structure of the questionnaire the groupings for the demography 
are manually created. Also, for the purpose of this study the percentages have been 
rounded to whole integers. 
It should be noted that the data in this study is interpreted from a modernism and 
post modernism view. The reason being that the understanding on modernism and 
postmodernism is important for this study.  
The motive behind the use of a modernism view versus a post-modern view is 
because of the concept of each.  
Modernism can often class as the living in a qualified, new and different world 




Sarıbay (2001 cited by Gürkan 2012) states that modernism is; 
“A situation in which a differentiation of progressing, economic and 
administrative rationalization and social world opposite to traditional order 
in parallel with modern capitalist –industrial government and which has been 
started to be used in West with the Enlightenment in the eighth century”  
Meaning that modernism is the collection of individuals who are embracing 
various relationships that are the base for a world which is regularly formed due to an 
individual’s intellect and enlightened individuals and the organisations formed of such 
individuals (Kahraman 2015). 
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Whereas the postmodernism period, seen as a historical period which is the cause 
of a serious paradox. In addition to various individuals adapting to the countless 
changes and developments in every area of society, there is an increase in the status of 
societies lifestyles such as economic and social developments.  
Even though most accept postmodernism to be classed as an extension of 
modernism with the thought of a living situation, some believe postmodernism exists to 
be a reaction against the modernism global view in the context of mind and values, 
development of humanist ideological values and knowledge gained by the individual. 
As stated by Adak (2010) postmodernism can be classed and categorised in three 
branches. The first being the different styles in arts and architecture. The second branch 
being the historical period starting from 1900’s.  
Finally, the third branch is the ethical and philosophical view, due to the 
knowledge of an individual being tested as radical epistemological. 
With these views being considered, the understanding of a person’s perception 
can be focused on, and the identification of reasoning behind a view may become 
clear. Since no matter what changes society faces, creates or are presumed, we 
overcome them and adapt.   
This becomes crucial when focusing on the public perceptions of counterfeit 
medicines and medicine purchasing. As seen below the focus and ideals of each 
generation, alongside the modernism versus postmodernism view is expanded further.  
The ideals of each generation are as follows (Kahraman 2015): 
Baby Boomers (age 52-70) 
 Live to work 
 Self-worth = work ethic 
 Loyal to employer 
 Competitive 
 Goal-centric 
 Process oriented 
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 Focused 
 Disciplined 
 Enjoy working in teams and proving themselves to the team 
 Need to know that they are valued 
 Want to make a difference 
 
Generation X (age 51-37) 
 Work to live 
 Crave independence 
 Scepticism 
 Focused on results 
 Think Globally 
 Adapt to change 
 Eager to learn 
 Thrive on flexibility 
 Education is a necessary means to succeed 
 
Generation Y / Millennials (age 22 – 36), 
 Fully transparent, shares everything 
 Do well with detailed instructions 
 Desire to make an impact 
 Commerce & conscience together 
 Value Diversity 
 Love technology 
 Education is a highly expensive necessity 
 Do not perform at their best in a traditional work environment 
 Find solutions using technology 
 
Gen Z (age 21 -7) 
 Tech-innate (first generation to grow up with modern technology) 
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 Accepting of others 





 Entrepreneurial and inventive spirit 
 Concerned about the cost of education 
 
Whilst the view of modernism and post modernism is essential, another view will 
also be a part of the framework for this study. That view is the generational view. 
“A generation can be considered a segment of the population who have 
shared experiences and have a sense of history that influences their thinking 
and behaviour today. In Western countries like the United States (US) and 
Canada in North America, most countries in Western Europe, Australia and 
New Zealand can be considered to have three distinct generations that 
influence society today, the baby boomers, generation X and generation Y. 
The baby boomer generation came in a mass population bubble after World 
War Two until around 1964.”  (Norway Global 2020) 
The Baby Boomers were the children of the silent generation who in turn were the 
children of the Greatest Generation. Baby boomers’ children born between 1965 and 
1979 are Generation X. Generation X children born between 1980 and 1999 are 
Generation Y.  
Generation Z are the children born after the millennium. Whereas Generation 
Alpha is the new generation being born today. The focus of this study is from Baby 
boomers to Generation Z, as they are the generations of the participants who answered 
the questionnaire. 
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It is known that what we ourselves think and how we view life is often different 
from the generations created before and after us. Furthermore, it is often reflected 
upon that the ideals that we grow up with influence later decisions in life.  
This includes, but is not limited to, the flux of individuals losing their jobs, the 
ever-expanding influence of the Internet, the constant creation of new technology, of 
the updated variations of versions past, the changes in the normal values of society – 
e.g., the LGBT community for one, and lastly the various forms communication – the 
Internet, TV, email, social media, letters, texts etc.  
The reason that understanding how the ideals of different generations change 
and adapt depending upon what they need to or have endured is important due to 
how they perceive different scenarios such as online pharmacies, counterfeits and the 
harm to the public’s health. On that basis the demography is split into four main 
categories; age, gender, ethnicity and level of education. 
As shown in table 11 the demography is laid out to demonstrate the groupings 
the participants answer where clustered in and the percentage of the participants that 
link to the corresponding groups.  
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Table 11: Demographic characteristics reported from the participants in the survey 
 
A total of 12 groups were reported in this study which included 20 – 25 years 
(n=38, 50%), 26 – 30 years (n=4, 5%), 31 – 35 years (n=2, 3%), 36 – 40 years (n=6, 8%), 
41 – 45 years (n=2, 3%), 45 – 50 years ( n=4, 5%), 51 – 55 years (n=9, 12%), 56 – 60 
years (n=5, 7%), 61 – 65 years (n=4, 5%), 66 – 70 years (n=0, 0%), 71 – 75 years (n=1, 
1%) and 76 – 80 years (n=1, 1%). 
It’s should be noted that there is a clear underrepresentation in some of the age 
groups e.g., 66-70 years has no participants claiming to be in that age range, whereas 
others may only have one or two participants. This causes the study overall to have 
limitations in the date analysis.  
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The data collected would not show an accurate depiction of clinical knowledge 
gained as the data correlations would be skewed.  
As one of the main focuses on the study is the ages of the participant and cross 
factors, the results themselves from this analysis need to reflected on and adapted for 
the main study to be conducted in the future.  
However, as there is a wide range of ages from the limited number of participants 
the ages will still be used to gain a general idea of trends and motives for self-
prescribing throughout this study.  
For gender three groups were reported male, female and non-binary with most 
participants identifying as female (n= 51, 67%), males following behind with (n=24, 
32%) and non-binary (n=1, 1%).  
10 ethnic groups were identified with the participants which included Arab (n=1, 
1%), Asian (n=1, 1%), British (n = 11,14%), English (n=3, 4%), European (n=1, 1%), 
Indian Other (n=1, 1 %), Mixed (n=4, 5%), White (n=18, 24%), White British (n=33, 43%) 
and finally White Other (n=3, 4%).  
The reason that some of the groups are typical ethnic groups that are found in 
other surveys, such as White British or Mixed, and some are more uncommon, such as 
English, is because the participants had the ability to write their answers.  
It is believed that some got confused on what ethnicity means and confused it 
with nationality, for example one participant stated ‘sorry, I don’t really understand 
ethnicity – non-native speaker’.  
Following ethnicity, the participants created 10 groups regarding the country of 
their birth; Australia (n=1, 1%), Canada (n=1, 1%), France (n=1, 1%), Germany (n=1, 
1%), Ireland (n=1, 1%), Malaysia (n=1, 1%), Peru (n=1, 1%), Portugal (n=1, 1%), Saudi 
(n=1, 1%) and the UK (n=67, 88%). 
Lastly the highest level of education of the participants was reordered, A Level 
(n=8, 11%), Bachelor’s Degree (n=30, 39%), Doctorate (n=8, 11%), GCSE + BTEC (n=3, 
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4%), Masters (n=11, 14%), O Level (n=2, 3%) and other qualifications such as NVQ’s or 
Aircraft Licence (n=14, 18%). 
The ethnicity and place of birth was originally placed in the study due to a 
hypothesis that people who are from different cultures would purchase different types 
of medicine and comparisons could be made about the birthplace purchases against 
ethnicity.  
However, this was not the case as there was insufficient variety in the results and 
not enough participants for this to be included in the study. 
5.5.2 Use of Pharmacies 
Pharmacies are often used by many people. This part of the study identifies the 
frequency of use and purchase of medicines, and it also introduces the types of 
medicines that are used/purchased.  
One of the penultimate questions of the study was asked in this part of the 
questionnaire, ‘Have you ever used an online pharmacy?’ Due to the way the 
questionnaire is structured some of the questions have multiple answers available for 
selection, therefore some of the percentages will be more than 100% when tallied 
together. 
As shown in table 12 when pharmacies are used and why is shown to 
demonstrate the groupings the participants answer. 
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Table 12: Parameters for questions asked within the questionnaire ‘the use of pharmacies’ section of the study. 
When identifying the frequency in which medicines are purchased the most 
common answer for participants (n=34, 45%) is quarterly – every three months. Close 
behind for the frequency of purchase with 28% is biannually – every six months. The 
least likely for medicine purchase is weekly with 1%. The same goes for a participant 
who stated they have never purchased medicine.  
As expected, the primary reason for self -prescribing is due to the cost (n=46, 
61%), with lack in health care professionals coming in second (n=25, 33%). Other 
reasons that were stated by participants included ‘don’t want to waste NHS time or 
money’ and ‘delivery options. 
At the beginning of the study, it was hypothesised that the top three types of 
medicines that would be purchased would be analgesics as pain relief such as 
ibuprofen and paracetamol are the most common medicines on the market.  
Antihistamine was considered due to it being the hay fever season when the 
questionnaire was distributed, and allergies emerging more commonly. And lastly 
antiseptics as they are often found in first aid kits and so forth to help clean wounds.  
As predicted the analgesics where the most popular medicines purchased by 
participants (n=62, 82%), followed by antihistamine (n=43, 57%) and antiseptics (n=30, 
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39%). When the participants were asked, have they ever used an online pharmacy, 77% 
of participants said no, 21% said yes and 1% said maybe.  
The reason for the maybe when asked the participant stated, ‘I use boots and 
Lloyd’s pharmacies – not sure if they count?’ which leads to the belief that not everyone 
knows what classes as an online pharmacy. 
For this study an online pharmacy is both an original pharmacy and the extension 
of a physical version such as Boots, Lloyds, Tesco and such. 
 
5.5.3 Motivation for Using Them? 
When people take medicines there are often multiple different reasons for 
different people. This section follows what the typical reason is and why they purchase 
the medicines. Also, what brings about the public view that a certain type of medicine is 
better than another.  
This is closely followed by how the public really view online pharmacies and the 
trust freely given to them. Whenever a person falls ill to an ailment, they often show 
symptoms. When these symptoms are then categorised, certain medicines are used to 
counteract the effects and aid in curing the persons affliction.  
As shown in table 13 the reason for using medicines and pharmacies is shown to 
demonstrate the groupings the participants answer. 
Table 13: Parameters for questions asked within the questionnaire for’ motivations for using medicines’ section of the 
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study. 
As was hypothesised before the study was conducted the most common 
symptoms that present themselves are aches and pains, such as a headache and sore 
muscles, with 79% of participants having these as a complaint.  
Nasal congestion and runny nose coming in close second with between 42% and 
53% of participants suffering with an affliction in the nose. And lastly a sore throat that 
has been known to plague many people, which produced lozenges such as Lockets 
and Strepsils to name but a few. 
When a person selects a medicine there are various methods for choice. Most of 
the participants go with their gut instinct and have their own experience (n=57, 75%), 
mostly trial and error as some say, ‘if a medicine did not work, try a new one next time’.  
After a person’s own experience with the medicine they have taken, the opinions 
of the families (n=28, 37%) and GPs (n=27, 36%) are similar in how the participants 
viewed those options.  Meaning they valued opinions of those they trust, be it a family 
member or a healthcare professional.  
 The least common view on the deciding factor of purchasing medicine is the 
advertisement (n=3, 4%) and recommendations from the Internet (n=5, 7%).  
After self-experience or other opinions taking effect on the purchase of medicines 
the appearance and other factors come into play, the most common aspect of a 
medicine being purchased was the type of medicine and its purpose (n=46, 61%).  
The second most common reason was the price of the medicine (n=36, 47%), as 
would be expected. Finally, the third view of the public was the desired reaction (n=26, 
34%) the medicine is known from having, this would coincide with the trial-and-error 
experience.  
When purchasing any item there has to be a certain amount of trust between the 
buyer and the distributer. When the participants were asked to rate the trust, they have 
for online pharmacies the most common answer was 5 (n=18, 24%), with 1 being not 
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trusted and 10 being trustful, this suggests that if people are not used to online 
pharmacies, they would choose neither for or against them in regard to trust.  
This is backed up by the suggestions either side of 5 showing similar results to 
each other ranging from 11% - 13%. Despite this the second most common view was a 
trust score of 1 (n=11, 14%), the view that online pharmacies are not to be trusted. 
 
5.5.4. Opinions 
After investigating the use of pharmacies and the motivations for using them, the 
next section in the questionnaire identified the opinions of counterfeit medicines.  
Could someone from the public identify a counterfeit, how would they identify 
one, and the knowledge the public has on counterfeits with regard to the harm they 
cause.  
As shown in table 14 the participants opinions on counterfeit medicines are 
illustrated to demonstrate the groupings the participants answer. 
Table 14: Parameters for questions asked within the questionnaire for the ‘opinions of counterfeit medicines’ section of the 
study. 
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After being asked to rate their belief on ‘what is the extent of harm caused from 
counterfeit medicines’ most participants selected 10 (n=22, 29%) lethal. There was close 
clustering around 7 and 8 for the harm scale with 17% and 19% respectively, this 
suggests that the public have some degree of knowledge with regard to health issues 
caused by counterfeit medicines. 
When asked about counterfeit medicines and the concern that the participants 
may have taken some, the consensus was that no they were not concerned (n=65, 
85%).  
However, 12% of the participants were on the fence with concern as they were 
not sure if they had taken some. The thinking behind the majority of these participants’ 
thoughts was through the lack of medicines working. 
 On the other hand, when asked if they have ever encountered a counterfeit 
medicine the majority of 96% said no once again. This proved to be an interesting 
statistic when compared to how one would identify a counterfeit and checking the 
authenticity of the medicine. 
For one to identify a counterfeit, various parameters were available to be selected 
including but not limited to; appearance, label, cost and even production stamp. The 
participants were able to select that they have never encountered one. The reason that 
this was an option was for a double blind in the study. 
 By having this available it tested what the public really thought of counterfeit 
medicines and if they could identify them on sight. 89% of participants selected this 
option, suggesting that those who selected other answers may have thought they had 
encountered counterfeits before even if not educated about them at the very least.  
However, when asked how to check authenticity of a medicine, the majority 
selected;’ ask a pharmacist’ (n=42, 55%), with the other options such as barcode, 
medicine tag and ask a doctor being similar in amount of response 11% - 18%.  
Even though asking a health care professional would be a logical step and 
understandable in reason, the only real way – as explained in Chapter One – is for an 
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investigation of the medicine itself. Other studies have shown that packaging can give 
reason to doubt the authenticity of a medicine. However, the real test is if the medicine 
itself holds up to scrutiny.  
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5.6 Discussion 
Due to nature of the questions asked within this study and the results given, it can 
be understood that the results are inconclusive due to the flux in the data. As a side 
note, some of the percentages will overlap and thus not equal 100% when grouped 
together, this is due to the structure of the questionnaire where multiple answers were 
available. 
Modernism and postmodernism are a subtle yet a crucial part of today’s society, 
as they are the cause of the creation of different lifestyles and thought processes 
(Kahraman 2015). Some would say they are the basis of many people’s ideals, and the 
way a person’s perception may be influenced.  
Be it the control of one’s self and the development of tomorrow, or the relevancy 
of the environment in which one is placed (Adak, 2010). These views are critical in 
understanding why a person would purchase a medicine from an online source or stay 
close to home and purchase from a local pharmacy. 
Alongside the perception gained from a modern and post modernism view, 
examining the generational ideals also gives a perspective that individuals of different 
ages will hold. As explained previously, most ideals come from experience. With these 
ideals gained from either the generational outlook or from a modern and post 
modernism view, a person’s age would be a key factor in determining reasons behind 
purchasing medicines.  
Also, another key factor in the determination of a person’s reason to purchase 
medicines is the prerequisite need that an individual will have for the use of them. With 
the modern and post modernism view of society, alongside the generational ideals the 
perception of the public is crucial for understanding how various scenarios affect the 
populace, such as the purchasing of medicines. 
One obvious known reason for purchasing medicines is to alleviate any aliments 
present. The symptoms that generate a need to purchase medicines and the reason for 
purchasing particular medicines were compared to one another.  
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As can be expected, aches and pains were the top symptom to cause the 
purchase of medicines (50%), next came runny nose and nasal congestion (29% and 
28% respectively) then a sore throat (25%). The reason for choosing a particular 
method of purchasing medicines illustrated that the main factor was convenience, with 
cost efficiency come in close second.  
Table 15: Symptons Vs Reason for purchase. A comparison between the symptoms felt by the participants and reason an 
individual would purchase medcines.. The most common grouping is highlighted in red, the next most common groups are 











Other reasons were given such as the medicine ‘was not covered by the NHS’ or 
that a participant wanted to ‘save the NHS money’ as they purchased items such as 
ibuprofen and paracetamol. Other participants have also stated that they have a lack of 
trust in health care professionals. Which gives cause to be examined further in a 
different study where more questions can be asked regarding an individual’s view on  
the NHS and other services. 
Trust, as expected comes from age and some would say wisdom from experience. 
When growing up and having different circumstances or even the fact that the older a 
person becomes the less trusting they are due to being hardened by conditions of life 
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experienced (Breiner et al. 2016). This is the case when a person’s age was compared to 
the trust shown in an online pharmacy. 
The younger the participant was the more trust they were willing to show for 
online pharmacies. As illustrated in ‘Age Vs Trustworthiness’ 12% of participants are 
between the age ranges of 20 – 25 years old and have valued an online pharmacy to 
rate a 5 on the trustworthy scale, with 1 being un-trustworthy and 10 being very 
trustworthy.  
Table 16: Age Vs Trustworthiness. A comparison between the age of the participant and what they rated the 
trustworthyness of online pharmacies. The most common grouping is highlighted in red, the next most common groups are 
highlighted in yellow and the green coloum and rows are the cross points that focus on the most prominent answer.  
 
Throughout this age bracket (20-25) a wide range of ratings occurred, the 
individuals in that age range, trend towards trusting an online pharmacy with the 
highest rating of 8 being formed by 7% of participants and 1% saying they are very 
trustworthy and granting a rate of 10.  
As you progress through the age brackets it can be seen to have a negative 
proportional review, meaning that as the ages of the participants increased the less 
likely they are to trust an online pharmacy.  
Even though there is negative proportional relationship between age and trust, 
the majority of participants (24%) valued the trust of an online pharmacy to be a 5, this 
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value can neither be for or against an online pharmacy, which shows there is hesitation, 
no matter what age an individual may be. 
Despite the differences in ages most participants (61%) give the reason for 
purchasing medicines online to be of convenience. The other reason for purchasing a 
medicine from an online source is of cost efficiency (33%). So, it can be assumed it does 
not matter the circumstances it is in our human nature to be comfortable and look for 
convenience (Dick, 1835).  
Table 17: Age Vs Reason for Purchasing Medcines. A comparison between the age of the participant the reason why they 
purchase medcines. The most common grouping is highlighted in red, the next most common groups are highlighted in yellow and 












When a reaction occurs that is unexpected and unwanted the first thing to do is 
to stop whatever is making us uncomfortable in the first place, be it placing a hand on a 
hot surface or to stop looking at the sun when it shines in your eyes.  
This thought process can be assumed to come from instinct as well as coming 
from knowledge passed on from past generations (Dick 1835).  
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As shown the most common answer no matter the age, was to stop taking the 
medicines (55% of 76 participants) or consult a doctor (47% of 76 participants) when 





Table 18: Age Vs Adverse Reaction.. A comparison between the age of the and what the participants do following on from 
an adverse effect occuring after taing medcines.. The most common grouping is highlighted in red, the next most common groups 










As hypothesised, the top three medicines to be purchased are analgesics (82% of 
76 participants), antihistamines (57% of 76 participants) and antiseptics (40% of 76 
participants).  
This was hypothesised as explained earlier due to the circumstances that happens 
in everyday life. Cuts and grazes, a simple headache and pesky hay fever all play a part.  
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Despite the clusters in each type of medicine, age did not play a part in the 
decision making for these purchases, which may mean in theory that modernism and 
post modernism cannot overcome true human nature in need to alleviate any illness or 
wounds that need to be healed.  
When the types of medicines are once again compared, this time to the 
frequency of purchase of a medicine, the top three medicines from the previous 
statement, remain the leaders with analgesics (80% of 76 participants), antihistamines 
(54% of 76 participants) and antiseptics (39% of 76 participants).  
Table 19: Age Vs Type of Medcines Purchased.. A comparison between the age of the and what type of medcines the 
participants purchase. 
After the main medicines that are purchased are identified the most come 
purchase is monthly – as it was available as a multichoice question with multiple 
answers available for selection, a statistical analysis could not be conducted for this 
comparison for overall frequency purchases. 
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Table 20: Frequency of Purchase Vs Type of Medcines Purchased.. A comparison between the frequency an individual 






However, it is shown that purchasing medicines monthly, is the most common 
amongst participants, this is closely followed by a medicine’s purchase occurring 
quarterly during the year. The last close comparison is the purchase of medicines 
biannually.  
When the questionnaire was first distributed it was hypothesised that the more 
frequent a medicine is purchased, the more likely an individual is to trust a pharmacy 
due to experience and good faith. However, on closer inspection that appears to have 
been a null hypothesis.  
Table 21: Frequency of Purchase Vs Trustworthy.. A comparison between the frequency an individual purcahses medcines 
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The reason being that on closer inspection the opposite held true. The least 
amount of trust came from those who purchased medicines the most frequently, daily 
and sometimes weekly – if any – throughout the year from an online pharmacy. 9% 
(n=7) of participants stated that when they purchased medicines monthly, they valued 
the trust of an online pharmacy as a five.  
Whereas those who purchased medicines once a year, twice a year or even every 
two years rated the value of trust to be six and above.  The most varied range of trust 
however came from those who purchased medicines quarterly. This could be due to 
reason that the option of quarterly – when never purchasing a medicine is excluded 
from the options available – is the middle option. 
 It is neither frequent nor non- frequent when compared to the other available 
options, thus it could be hypothesised that the reason for this option having the most 
range available in trust is due to having multiple different age groups within it.  
This could mean that various generational ideals and viewpoints are clustered 
together in one area/ option. For a further conclusive answer to this question, the 
comparison between age, trustworthiness and the frequency of purchase would need 
to be conducted. 
Even though the frequency of purchase was compared to the level of education 
an individual experienced, the frequency at which an individual will purchase medicines 
stayed constant with monthly and quarterly being the most common.  
Table 22: Frequency of Purchase Vs Education. A comparison between the frequency an individual purcahses medcines 
and the educational level an indiviual has acquired. 
 
Page | 245 
 The commonest level of education of a participant is a bachelor’s degree (38%) 
with a master’s degree (12%) and a doctorate degree (11%) coming in as the second 
and third most common degree held by the participants.   
On the comparison between the education and the reason for purchasing 
medicines on the Internet, the results support those explained earlier with convenience 
and cost efficiency being the determined reasoning for the purchases.  
Table 23: Reasons for Purchasing Medicines Vs Education Level. A comparison between the reason an individual purcahses 









The hypothesis however was that the more educated an individual was, the less 
likely they would use convenience as a staple for purchasing medicines online as they 
may know the dangers that presents. However, that was found to be incorrect and a 
failed hypothesis. 
On a further examination of an individual’s education, when questioned if the 
participants would be able to identify a counterfeit, most participants (89%) stated that 
they did not know how to. 
Table 24: Identifying a Counterfeit Vs Identification of a Counterfeit. A comparison between if an individual believe they 
have come into contact with an counterfeit  and how they would identify the presence of a counterfeit medicine. 
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 The category itself of N/A was a combination of written answers that gave the 
participants the freedom to write what they believed was how to identify a counterfeit.  
It is shown that they did not deviate from their thoughts and answer a question 
with an already suggested answer. In an opinion this can be classed as a modernism 
view of an enlightened individual, as they have a freedom of thought, but in a 
controlled environment. 
Table 25: Identifying a Counterfeit Vs Education Level. A comparison between the educational level an indiviual has 
acquired and how they would identify the presence of a counterfeit medicine. 
 
When the individuals were then presented with the question of asking if they 
could tell if a counterfeit had come into their possession, the results were in parallel to 
whether they could identify a counterfeit.  
The majority of those who believed they did not come into contact with a 
counterfeit stated that they could not tell if medicine was in fact a counterfeit.  
Whereas those who stated they could detect a counterfeit selected the options of 
scientific analysis, the packaging and the cost.  
Some of the individuals however believed they had not had contact with a 
counterfeit in their possession, even though they gave answers for how to detect a 
counterfeit, these included the appearance of the medicine, the label on the packaging 
and brand, and the production stamp on the packet. 
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As mentioned previously the trust in online pharmacies can be seen to 
accommodate the full spectrum of answers. Some participants stated they do not trust 
them and believe they are untrustworthy; others believe they are very trustworthy.  
Even though the value of trust varies amongst the participants, when questioned 
how they can identify a counterfeit most participants state once again they are not sure, 
or that it is not applicable as they have never encountered one. 
Table 26: Trustworthiness of an online pharmacy Vs Indentifying a Counterfeit. The comparison betwee n how the 
participants believe can identify counterfeit medcines and how trustworthy a participant rates online pharmacies overall. 
 
This becomes interesting when the trust of an online pharmacy is used in 
comparison to the question as to whether they have ever used an online pharmacy. 
The results showed a similarity between those who have used an online pharmacy 
against those who have not.  
The trust did not deviate as there was still a wide range of answers given. The 
difference being that most participants have claimed to have never used an online 
pharmacy.  
 Table 27: Trustworthiness of an online pharmacy Vs the Use of Online Pharmacies. The comparison between how many 
participants use online pharmacies and how trustworthy a participant rates online pharmacies overall. 
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.  
When looking at the trustworthiness of the online pharmacies from the viewpoint 
of the participants, compared to the view of how harmful counterfeits are, the trend is 
indirectly proportionally to the estimate.  
It was hypothesised at the beginning of the distribution that no matter the 
trustworthiness of an online pharmacy the harm caused by a counterfeit would be 
reflected just so.  
The reason for this hypothesis is that no matter the source of purchase and the 
trust built up in that environment, the harm caused by a counterfeit entering an 






Table 28: Trustworthiness of an online pharmacy Vs the Harm a Counterfeit. The comparison between how trustworthy a 
participant rates online pharmacies overall against how harmful they believe a countefeit medicine can be. The scale for 
trustworthiness is 1- untrustowrthy – 10 – trustworthy, the scale of how harmful a counterfeit is viewed to be 1- less likely to cause 
harm and 10- lethal. 
 










The participants mostly believed that counterfeits could cause severe health risk 
or even fatalities, so they ranked them high on the harmful scale. The trustworthiness of 
the online pharmacies as perceived by the participants as concluded before has a full 
range of answers. 
In conclusion, despite differences in age and the education an individual has 
achieved, they are still likely to purchase medicines. It can also be determined that 
regardless of the education a person may have received the participants were not able 
to determine if they had received a counterfeit medicine or how to identify one. 
 The consensus of trust towards an online pharmacy has a variety of outcomes, 
depending on the subject it has been compared to.  
Overall, this shows that no matter a person’s age and education, an individual is 
still likely to purchase medicines, so it can be concluded that despite the education a 
person may have received the participants were not able to determine if they have 
received a counterfeit medicine or how to identify one.  
This proves that the public need to be cautioned on identifying a counterfeit 
medicine and what to do in case they encounter one.  
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5.7 Critical Analysis 
5.7.1 Research Question and Study Design 
The purpose of this study was to explore the knowledge and experience of 
individuals regarding self-prescription and online pharmacies.  
The study investigated the consumer perspective by examining different parts of 
the participants responses relating to their demography, the use of pharmacies, the 
reason behind using them and the public’s opinions of counterfeit medicines and online 
pharmacies. 
The objectives were for the majority successful as trends and reasoning became 
apparent. As a recap these were the objectives set out in this study: 
1. Identifying the demographic factors of self-prescribing 
medicine users. 
2. Identifying a correlation between gender or age and the 
reasons for purchasing medicines. 
3. Exploring the motivation of the purchasing of medicines. 
4. Assessing the public’s opinion on counterfeit medicines. 
5. Investigating the public’s concern over the trustworthiness of 
online pharmacies.  
For this type of research, the questionnaire as a basis was the correct 
method for data collection as it was constructed as semi structured. 
Thus, the participants could freely answer what their thoughts and feelings 
were without influence, and ultimately it gave the truest representation of the 
publics opinion from the sample data collected.  
This is paired with the structured multiple-choice questions which gave the 
study some structure but also sectioned that could be statistically analysed without 
much data handling. 
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For this type of research there have been previous questionnaires in supply 
for the public to answer regarding counterfeits and medications in general.  
The reason a new questionnaire was created and adopted for this study is to 
create an amalgamation of previous successful study questions into one 
combined resource.   
The reason for this new questionnaire is so that questions that enable the 
aims to be answers were used, were some of the questions used in the previous 
studies were not relevant.  
One fallback of the questionnaire was that the publics/participants opinion 
of design, distribution, and administration of the questionnaire were not sought 
after in great detail.  
If the feedback had been apparent then the modifications of the 
questionnaire for the future would be more suited to the public and perhaps the 
data set would be more significant.  
5.7.2 Validity and Reliability 
The accuracy of the study can be rated as medium to high due to the questions 
asked measuring what needed to be measured from the goals of the objectives.  
The reliability of this study is considered to be high as with most questionnaires 
the more closed questions used the more reliable the research in general. However, 
this study could potentially be put into question what is reliability? 
 As this is the pilot study for future work meaning that it has yet to have all the 
problems have not been resolved if any were to crop up. One way this can be solved in 
the future is to ask a set number of questions and ask them again a set amount of time 
apart to the same participants. Following that identify if the participants have changed 
their answers of kept consistency. 
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5.7.3 Format 
It is believed that the title of the questionnaire ‘Knowledge and Experience of 
Pharmaceuticals Regarding Online Pharmacies and Self-prescription’ was sufficient for 
the main goals of study.  
However, it may have caused limitations to what could be asked of the public. 
Furthermore, the questions themselves may have not been as in depth as they could 
have been asked and thus not all the answers were a good representation of 
subconscious decisions.    
As said previously the questionnaire was forced of open and closed questions, 
illustrating that the questions themselves were not restrictive. The use of both types of 
questions for this study was the correct method of approach.  
During this study the questions that were asked may have seem to be threatening 
– not in a violent or rude way but they may have come across as aggressive.  
The aggression comes from the way the question was asked, for example: 
 How frequently do you buy medicine(s)? 
 What type of medicine(s) did you use when self-prescribing? 
 Have you ever used an online pharmacy? 
 Do you change the dosage of your medicine during a course of 
treatment?  
By forming the question in such a way, the participants may have subconsciously 
defended themselves, rather than neutral open-ended questions that would have more 
open results.  
For example, a question for the future would be ‘tell me more about your 
experience when purchasing medicines’. This type of question leaves the participants in 
control of how much they answer.  
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Overall, the questionnaire was kept as brief as it could be considering how many 
questions were asked and what types of questions were involved. Also, the language 
for the questionnaire was kept simple and not overly complicated.  
The majority of the public would understand it as shown by the participants who 
answered the questionnaire. However, the definitions even though direct from source 




The participants did not need much instruction on how to complete the and 
return the questionnaire as it was done automatically when the participants selected the 
finish button at the end of the questionnaire.  
If certain questions needed a response and none was given it would highlight the 
question that needed the answer for the participant to add something in the criteria 
box even if it was as simple as a N/A.  
When a ticked or written response was needed it was indicated at the beginning 
of the question, for example – please tick all that apply. 
At the beginning of the questionnaire there was an introduction stating the 
research that was being conducted and why the information was important. A thank 
you message was presented both at the beginning and the end of the questionnaire to 
show appreciation for the participants answering the questions.  
 
5.7.5 Sampling 
The data set collected from the participants was not a significant and sufficient 
amount. The reason being is that not all groups were represented well enough for 
them to have an accurate data response.  
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For example, with age being one of the main focuses it is an important part of the 
basis of this study, but some of the groups of specific ages did not have a high 
response rate. Meaning that they could not be accurately represented for data trends.   
The same limitation occurred with ethnicity and what country of origins and 
individual came from. These questions help to understand what culture an individual 
grew up with and if that upbringing could influence how an individual perceives 




5.7.6 Distribution, Administration and Response 
The questionnaire was created for an online form database – this online 
questionnaire was then distributed on various social media platforms to gain a 
worldwide presence.  
The questionnaire was left open for a certain amount of time as explained 
previously and the results were then collected once the questionnaire had closed for 
new entries.  
Those results were then administrated to determine if the answers were 
something that was workable or if a different approach to the distribution of the 
questions ask needed to be adapted.  
Not all the information pertaining to the individuals who opened the 
questionnaire were acknowledged due to some of the participants closing the survey 
before they had answered all questions, thus eliminating them from the study as the 
data was not saved.  
Out of all the results gathered only one set of data was removed due to not being 
a serious answer to any of the questions, however those answers were still recorded 
and mentioned earlier such as the individual whose gender was a shark.  
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Most if not all biased was removed when this study was conducted to show that 
the results were more accurately defined and could be used for determining trend such 
as cause and effects.  
 
5.7.7 Coding and Analysis 
The data that was collected from the questionnaire, was subjected to multiple 
types of statistical analysis; descriptive, inferential, casual and exploratory. The reason 
being that the data itself fell into different categories. The data itself is both quantitative 
and qualitative in nature.  
The data could be illustrated via graphs and models, whilst it could be combined 
to create relationship and trends to help in making predictions of what could occur for 
the whole population.  
Even though some of the data was based on hypothesis in how it was correlated 
and compared for analysis, there was however some data dredging due to not all of 
the data being analysed was due to a hypothesis being created.  
 
5.7.8 Results 
The majority of the data reported was relevant for the study except from a few 
answers that had a shark stated as a gender and Tatooine as an answer to where an 
individual lived. These answers were not added into the main data analysis however it 
was still recorded.  
The qualitative results were unbiasedly categorised and analysed, where 
appropriate quotes were used to determine the thoughts of the participants and lastly 
the data collected was justified as the answers led to trends and characteristics of how 
the public perceives online pharmacies and counterfeit medicines.   
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5.7.9 Conclusions and Discussion 
The data collected even though it was a small sample size, it has illustrated that 
there could be a potential link between the age of an individual and how they purchase 
their medicines.  
Along with the relationship between the age/education and the level at which the 
individual identifies the harm that a counterfeit can cause and if they are able to 
distinguish if they have seen a counterfeit medicine before.  
This can aid in understanding the principles that lead to counterfeit medicines 
from being prevented from entering the supply chain to end with the consumer.  
This study can help to breach the gap left in today’s societal knowledge of the 
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5.8 Questionnaire 
Part I: 
1. With what gender do you identify with, if any? 
2. In what year were you born? 
3. With which ethnic group do you identify yourself? 
4. What country were you born in? 
5. What is your occupation? 
6. What is the highest level of education you have completed? 
 
Part II: 
Self-prescribing can be defined as prescribing medicines yourself. E.g., buying cough 
medicine when you have a sore throat. In this survey the medicines that are being described 
are medicines such as antibiotics, antimalarials and such.  






f. Biannually (twice a year) 
g. Annually 
h. Biennially (once every 2 years) 
 
2. Can you identify the country of origin with regards to the medicines you buy? 
a. Yes (please specify) 
b. No  
 
3. To the best of your knowledge can you tell you are buying from an authentic 
source. 
a. Yes (please specify) 
b. No  
 
4. What was the reason behind self-prescribing? 
a. Convenience  
b. Cost efficient 
c. Lack of trust in health care professionals 
d. Any other reasons, please specify 
 
5. What type of medicine(s) did you use when self-prescribing? (Please select all 
that are applicable)  
a. Analgesics (pain relief) 
b. Antibiotics 
c. Anticancer  
d. Antiemetics (anti sickness) 
e. Antihistamine (allergy) 
f. Antimalarial (treat malaria) 
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g. Antipyretics (fever relief) 
h. Antiseptics (cuts and wound treatment) 
i. Hormone replacements  
j. Mood stabilisers (lithium and valpromide etc.) 
k. Oral contraceptives (the pill) 
l. Statins (simvastatin etc.) 
m. Stimulants (amphetamine etc.) 
n. Tranquilisers (diazepam and anti-psychotics) 
o. Any other please specify 
 





1. For which of the following symptoms (adverse effects) did you use the 
medicine(s) purchased for? (Please select all that are applicable) 




e. Nasal congestion 
f. Runny nose 
g. Skin wounds 
h. Sore throat 
i. Vomiting 
j. Any others please specify 
 
2. When you selected the medicine(s) what was your solution based on? (Please 
select all that are applicable) 
a. My own experience 
b. Opinion of family members 
c. Previous doctor’s prescription 
d. Recommendation on online forums 
e. Recommendation by community pharmacists 
f. The advertisement 
g. Opinion of friends 
h. If any other reasons, please specify 
 
3. When you purchased medicine(s) what were the deciding factor(s)? (Please 
select all that are applicable) 
a. The brand  
b. The price  
c. The type (e.g., penicillin, ciprofloxacin or erythromycin etc.) 
d. Possible adverse reactions 
e. Desired reaction 
f. Indications for use 
g. Any others please specify 
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4. How did you know what correct dosage of medicine(s) to use were? (Please 
select all that are applicable) 
a. From the Internet 
b. From my previous experience 
c. By consulting a doctor/GP 
d. By consulting a pharmacist 
e. By checking the package insert 
f. By guessing the dosage  
g. By consulting friends or/and family members 
h. Any other reason please specify 
 
5. On a scale of 1 - 10 how much do you trust online pharmacies? (1- 
untrustworthy, 10 – trustworthy) s  
 
6. Do you change the dosage of your medicine during a course of treatment?  
a. Yes 
b. Sometimes 
c. No  
 
If yes, how often did you change and what were the reasons? 
7. Would you switch your medicine during a course of treatment? 
a. Yes 
b. Sometimes 
c. No  
 
If you do, please state how often and whether it is like for like (e.g., antibiotic for 
antibiotic) or different (antibiotic for anti-inflammatory)? 
8. Have you ever found out that you have taken the same antibiotics/antimalarial 
just under a different name at the same time? (For example, Paracetamol maybe called 
Panadol). 
a. Yes (please specify) 
b. No 
 
9. What do you do when you encounter an adverse reaction? (Please select all 
that are applicable) 
a. Switch to another medicine 
b. Consult a GP 
c. Consult a pharmacist 
d. Nothing 
e. Stop taking the medicine 
f. Consult family members/ friends 
g. If any other, please specify 
 
Part IV: 
As Stated by the World health Organisation a counterfeit is: “A product that is 
deliberately and fraudulently mislabelled with respect to identity or source. Counterfeiting 
occurs with both branded and generic products and counterfeit medicines may include 
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products with the correct ingredients but fake packaging, with the wrong ingredients, without 
active ingredient or with insufficient active ingredients”.  
Whereas “Substandard drugs are manufactured with the intent of making a genuine 
pharmaceutical product, but the manufacturer saves costs by not following GMP (Good 
Manufacturing Practice) or using poor quality raw materials. Another potential problem relates 
to inadequate storage or transport conditions, leading to deterioration of the product. The 
performance of such medicines is questionable”. 
7. Are you concerned that you may have taken counterfeit and/or substandard 
medicine(s)? 
a. Yes (please explain your concerns) 
b. Somewhat 
c. No  
 
8. How did you decide to use a certain online pharmacy? (Please select all that are 
applicable) 
a. Friends’ recommendation 
b. Family recommendation 
c. Own experience 
d. The advertisement 
e. If any other, please specify 
f. For any other reason please specify 
 
9. How would you check the authenticity of your medicine? (Please select all that 
are applicable) 
a. Barcode 
b. Medicine tag 
c. Ask a doctor 
d. Ask a pharmacist 
e. If other, please specify  
 
10. Have you ever encountered a counterfeit medicine? 
a. Yes 
b. No  
 
If yes, how did you identify it? 
a.Appearance 
b. Label 
c. Never encountered one 
d. Packaging 
e.Side Effects 
f. Any other reason, please specify  
11. On scale of 1 to 10, what do you believe is the extent of harm resulting from counterfeit 
medicines? (1 - Very mild, 10 - Lethal):  
Any Further Comments - (please state any online pharmacies that you may use of that you  
know about below): 
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Chapter Six. Conclusion & Summary 
This project has investigated the issues surrounding counterfeit/falsified 
medicines. The main topic areas of discussion and review were as follows; the 
increasing issue caused by counterfeit/falsified medicines, the public perception of such 
drugs, the overall use of medicines and the distribution of medicines, the analysis of the 
online pharmacies and the distribution of medicines, the quantification of counterfeits 
and the law that regulates the supply chain. 
As discussed in the introduction, the issue of counterfeit medicines is a very 
serious threat to the public’s health that has shown traction in recent years and is 
continuously growing, especially in the case of counterfeit medicines.  
Other studies have surmised that the threat of counterfeits is non-discriminatory 
in respect of which countries are affected. Everyone is at risk. On record 50% of 
products sold are counterfeits and 30% are counterfeit medicines.  
For a future safe from counterfeits certain measures need to be taken to protect 
the public from harm. One such measure would be to first fully understand the reasons 
influencing the purchase of medicines even if it seems like a common notion. 
The finding of Chapter Five suggests that medicines are purchased primarily for 
relief and healing, with the exception of a few cases where individuals buy medicines for 
bodily control (e.g contraceptive or hormone control).  
These results are found to be independent of the age groups, education levels 
and genders. Thus, illustrating that despite the ideals of generations growing up and 
the modern and postmodernism view as a framework there is not a conclusive rule or 
trend to follow. The same can be assumed about the frequency of purchase and the 
reasons for purchasing medicines, experience is the key to everything. 
However, if an individual purchased medicine more frequently, they would be 
more inclined to trust the source of purchase, even if the purchasing occurred from an 
online source.  
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Some individuals did not realise that a pharmacy who had an online delivery 
service was classed as an online pharmacy, which suggests that the public need to be 
made aware of the distribution and risk of buying form online sources. 
Despite the purchases from physical pharmacies being known to be a trustworthy 
source of pain relief, the route of distribution using the Internet has not been inspected 
regularly or uniformly in one place.  
Chapter 4 analysed the route of distribution for medicines including online 
pharmacies. Not only do online pharmacies offer deals and sales promotions of some 
description, they can offer prescription medicines without a consultation from a medical 
practitioner.  
This alone can entice a clientele or consumer base. The study also confirmed the 
known fact that offering deals encourages individuals to purchase more than they 
need; especially if it is a prescription medicine such as antibiotics, which could cause 
serious harm in the future. 
 The individual may consume more than the recommended dose for the ailment 
it is trying to control, or at the other end of the spectrum they may not have enough to 
combat the issue. 
As shown in Chapter Four the online pharmacies are outnumbered by the 
physical brick and mortar pharmacies. However, the distribution range when compared 
illustrates those online pharmacies outreach the range of the brick and mortar.  
This alone demonstrates that if the online pharmacies gain traction, then the 
brick-and-mortar pharmacies would eventually become redundant as is the way with 
small vendors competing with large chains. 
The next logical step as illustrated in this research is the isolation and detection of 
counterfeits within the supply chain. This follows on from the previously discussed 
perception of counterfeits and the distribution of medicines.  
 
Page | 264 
To do this they must first be identified, and as it has been tested in previous 
studies, the only true way of discovering a counterfeit is to analyse the medicines 
chemical compositions and phases. One such way of this identification process is to use 
spectroscopic techniques such as FT-NIR that was used in Chapter Two.  
The identification of counterfeit ciprofloxacin tablets was successful in Chapter 
Two, where five counterfeit batches were detected, 14 authentic and nine generic 
batches were identified as well. The regions of origin of the medicines were also 
ascertained and grouped with the aid of PCA.  
Even if the manufacturer was not the same, the medicines from the same region 
clustered together, which could potentially show that the regulations within the regions 
have an impact on the manufacturing process. More research would need to be 
conducted to confirm this hypothesis as discussed in recommendations further on.  
PCA was useful in determining counterfeit medicines, it was also helpful with 
determining the composition of the binary mixtures. It catalogued the change of ratio 
within the mixture from 100% difference between the components, 100:0 ratio, to a 
50:50 ratio mix.  
The differences enabled clusters to be formed, which in itself suggested the 
strength of the FT-NIR and the PCA combination. By using a various ratio mix, it could 
be ascertained that even the smallest number of components could be detected, and a 
counterfeit match could be found. 
The use of CWS on the other hand proved an efficient protocol to correlate 
various classes of antibiotics and the chemical components themselves. It justly 
illustrated that the same component /medicine when compared to itself shows a very 
high match. 
 On the other hand, various classes of antibiotics had some similar components 
and some that were completely unique/rare to the antibiotic class. Also, as illustrated 
with the binary mixtures of PCA, the components that have a similar chemical structure 
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tend to cluster together, when CWS is applied the correlation becomes more 
significant.  
Due to similar mixtures in both PCA and CWS showing almost parallel results, it 
demonstrates that stronger instruments or techniques would be needed to completely 
isolate the chemical present in a mixture, one such method would be to use GCMS. 
All of the findings illustrated in Chapter Four & Five showed the significance of the 
threat of counterfeit medicines and the possibility for inflicting a health risk on the 
public as they can come from any source and throughout the supply chain. 
Counterfeit/falsified medicines are becoming a health risk with the dangers of the 
medicines themselves being harmful to a patient’s progress, and the public maybe not 
being aware fully of the hazards of counterfeits or the process of purchasing medicines 
online.  
A path for discouraging falsified medicines from entering the supply chain is to 
make it as difficult as possible for those who wish to make profit from these falsified 
products. 
Therefore, with the understanding of how to identify a counterfeit being the 
primary function of this study along with the inclusion of public perception, the law is 
the secondary. Countless changes have been made to the laws over the years to 
reduce the risk of counterfeit/ falsified medicines from entering the supply chain.  
To combat the risk of counterfeit/ falsified medicines entering the supply chain 
and ultimately reaching the patients, the Falsified Medicines Directive (Directive 
2011/62/EC) was created in 2011 and published on the 2nd January 2013. This EU 
directive was created with the aim of preventing the entrances of counterfeit/falsified 
medicines into the legal supply chain.  
Eventually it was amended with the Commission Delegated Regulation (EU) 
2016/161 that was published on the 9th February 2016 and implemented February 
2019. This amendment as discussed in Chapter Three, was created to set out detailed 
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rules for the new safety features that would be used on the medicinal packages that are 
for human use. 
As demonstrated in Chapter Three the FMD contains new safety features on the 
medicine’s packaging, which incorporate barcodes and anti-tampering strips. With 
these safety features, the number of counterfeits should be reduced.  
However, the implementation of such features may cause some disruptions within 
the supply chain system for the consumers and pharmacies, such as hospital 
pharmacies. The reason being that there are some flaws within the system as discussed 
in Chapter Three. Some of these flaws are: 
1. The UI barcodes may not be scanned in the system 
2. There could be duplicates of the UI Code 
3. The counterfeit could pass through the supply chain and the 
authentic medicine stopped.  
4. The ATD can be tampered with, without much hassle. 
5. Added pressure would be on the staff to check the packages 
thoroughly, which would mean a few more jobs just for this 
purpose. 
Overall, the identification of the public perceptions leads to the identification of 
the distribution methods such as online pharmacies. Those distributional areas lead to 
the identification of the counterfeits entering the supply chain and the supply chain 
must adhere to the laws and regulations set. Separately the chapters tell a picture, 
together they explain how the future will proceed. For counterfeits to be truly 
eradicated the public need to be much more informed.  
Thus, by understanding the public perception and motivation for purchasing 
online, and who is more likely to, more advertisement in awareness can be aimed at a 
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target audience. Therefore, the public become knowledgeable and the threat to the 
collective health diminishes.  
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6.1 Outlook - Strengths and Limitations  
6.1.1 Quantification of Counterfeit Medicines  
The identification of counterfeit ciprofloxacin tablets was successful in Chapter 
Two, where five counterfeit batches were detected, 14 authentic and nine generic 
batches were identified as well.  
The regions of origin of the medicines were also ascertained and grouped with 
the aid of PCA. Even if the manufacturer was not the same, the medicines from the 
same region clustered together, which could potentially show that the regulations 
within the regions have an impact on the manufacturing process.  
Even though the identification methods used (CWS & PCA) were able to identify 
counterfeit medicines, the methods themselves could not easily distinguish between 
batches of the various groups.  
When placed together the counterfeits stood out against the generic and the 
authentic, but when clustered together the counterfeit batches posed a difficulty for 
analysis. 
PCA was useful in determining counterfeit medicines, it was also helpful with 
determining the composition of the binary mixtures. It catalogued the change of ratio 
within the mixture from 100% difference between the components, 100:0 ratio, to a 
50:50 ratio mix.  
The differences enabled clusters to be formed, which in itself suggested the 
strength of the FT-NIR and the PCA combination. By using a various ratio mix, it could 
be ascertained that even the smallest number of components could be detected, and a 
counterfeit match could be found. 
The use of CWS on the other hand proved an efficient protocol to correlate 
various classes of antibiotics and the chemical components themselves. It justly 
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illustrated that the same component /medicine when compared to itself shows a very 
high match. 
 On the other hand, various classes of antibiotics had some similar components 
and some that were completely unique/rare to the antibiotic class. Also, as illustrated 
with the binary mixtures of PCA, the components that have a similar chemical structure 
tend to cluster together, when CWS is applied the correlation becomes more 
significant.  
The binary mixtures themselves were beneficial to be used as they could help 
show the accuracy in which the FTNIR functioned. However, for the future more mixture 
at a greater level would need to be analysed such as tertiary mixtures as explained 
previously.  
If it was found that there was not sufficient tablet data in the future, but there was 
an authentic batch available, tablet/powder models may be used. These powder 
models may be created by; mixing a dilution of crushed tablets or API excipients, 
standard addition of crush tablets to the API or sequential addition of various excipients 
to the crush tablets.  
These models can be used in conjunction with the other powder mixtures such as 
the binary and tertiary ones. The one drawback with these methods is that only 
powdered tablets can be analysed using the data gathered where as new models 
would be needed if capsules and liquid solvents were used.  
Due to similar mixtures in both PCA and CWS showing almost parallel results, it 
demonstrates that stronger instruments or techniques would be needed to completely 
isolate the chemical present in a mixture, one such method would be to use GCMS. 
One limitation that was identified during the experimental process was that there 
were not enough batches of medicines available to set a sufficient sample size. By not 
having a large data set with samples collected from multiple regions but also from 
multiple manufacturers, a true trend in the data could not be successfully determined.  
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For example, one question to be answered in the future would be ‘which 
manufacturer or region of supply is more heavily affected by counterfeit medications?’  
All of the findings illustrated in Chapter Five showed the significance of the threat 
of counterfeit medicines and the possibility for inflicting a health risk on the public as 
they can come from any source and throughout the supply chain.  
6.1.2 Effectiveness of the FMD 
Even though the FMD takes into consideration each stage of the supply chain, 
and that will subsequently limit the risks of a counterfeit being procured, it fails to 
realise that there are still holes in the directive that can be abused.  
One such example being that the blister packs themselves could be taken out of 
the packets and the counterfeit version could be reinserted in their place, the blister 
packs would need a stamp of production (manufacturer), the expiry date and batch 
number.  
The authentic versions of the counterfeit could then be used at a later date, some 
could be crushed and mixed in with the other batch materials. The anti-tampering strips 
are the same, there is insufficient deterrent to prevent someone from removing the 
strip and placing a new one in its place when the pack is due for shipping further along 
the supply chain. It has been proven that it can be tampered with without damaging it 
or leaving any evidence that it has been tampered with. 
The blister packs themselves or the packaging in which they are contained do not 
have a guarantee that the medicines within them are what they say they are. For this to 
be overcome the blister packs themselves could be scanned at random stages in the 
supply chain by instruments that can examine the tablets contents through the blister 
pack, thus limiting further the risk of counterfeits being supplied to the public.  
As illustrated in Chapter Five, the only way to thoroughly examine medicines and 
properly identify a counterfeit is with various scientific instruments, this has had proven 
success for many years. 
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 A disadvantage with this process is that it would be time consuming and cause 
waste of the ATDs when they need to be replaced at the stage that they are opened to 
scan. There is no guarantee that the seal would break successfully recording opening of 
the package which would skew results later on in the supply chain if that package was 
tampered with. 
One thought would be for the ATD to have a design that only those that 
produced them and scanned them would know, a hidden identification that would not 
be possible to replicate without a certain type of machine. It would also be beneficial 
for the seals to be heat resistant so that they cannot be removed as stated in Chapter 
Six.  
As an extra precaution the QI codes could be printed on both the blister packs 
and a feature of the anti-tampering strip. This unfortunately does not limit the risk of 
the codes being reproduced with a falsified version being passed into the supply chain; 
it does however limit the risk with regards to replacement of the blister packs.  
Overall, I accept as true that with any regulation there will be growing pains for 
individuals and organisations to comply with, agree to and implement such regulations.   
My belief is that by analysing the FMD and various aspects of the problem 
resulting from counterfeit/falsified medicines, the public, health care professionals and 
policy regulators have a better understanding in creating new systems to target the 
problem.  
The FMD is one step of many that have been introduced. However, more of an 
effort needs to be made towards the public and patients to make them aware of the 
risks inherent in purchasing medicines online. By killing the demand, the supply will 
reduce, thus limiting the risk of health issues and falsified medicines entering the supply 
chain. 
In my opinion the FMD needs to be re-evaluated to become second nature for 
everyone and not a tedious task that is faulty. Meaning that if there are purchases 
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directly from the manufacturer, just as hospitals do, then only various scans of batches 
need to be conducted for quality control. Only time will tell its effectiveness, until then 
more analysis needs to be conducted. 
  
 
Page | 273 
6.1.3 Online Pharmacy Data  
The data collected for research regarding the online pharmacies’ aids in the 
future knowledge of how to further prevent counterfeits; from entering the supply 
chain, from giving the producers profit and gain, and to reduce the risk posed to the 
public’s health. 
The online pharmacies have an influence on an individual enabling them to 
confidently self-prescribe medication, be it from simple cold and flu treatment to 
antibiotics for infection. 
These influences also demonstrate how the public is targeted with regards to 
certain sales and profit margins for the pharmacies. 
Some of the strengths of the online pharmacy data collection is that multiple 
sources were found and categorised. The whole country was able to be configured in a 
way that the online pharmacies could be mapped.  
The data that was able to be analysed whether the pharmacy is geographically 
situated or what types of medicines can be sold. Even the privacy disclaimers and 
contact details that are obtained could be categorised through extensive research.  
One of the limitations is only the information that can be seen at face value is 
gathered such as prices or reviews, rather than the information that is used solely by 
the website creators, such as online traffic. 
By viewing how much the website is seen and the rough the IP address (location) 
of the consumer. By tracking how many people visit a website the true value of an 
online pharmacies influence can be ascertained to a greater degree of accuracy.  
Another limitation of the research is that it took a considerable amount of time to 
gain the data but to also categorise it in a way that would be analytically beneficial. For 
the information to be sufficient in both gathering and analysing the data itself needs to 
be collated in a way that would thorough and not time consuming. 
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6.1.4 Questionnaire Study 
Every part of research has both strength and weaknesses. By understanding those 
it makes it easier to succeed in the future and overcome the obstacles that are faced. 
On that note one limitation that was discovered in this study was that when the 
participants can answer questions in their own way rather than a closed question and 
tick box answers.  
This enabled inappropriate answers in the study, one example being ‘which 
gender do you identify with’ and the answer coming back as ‘shark’. This makes the 
study subject to vulnerability.  
A response to counter this is to have three boxes, one for male, female and other, 
the other box will then have a further response of ‘please specify’. That way it will make 
the data closed and outliers such as imputes like shark can be discarded from the 
results. 
On the other hand, one strength of this study is how it was distributed on social 
media such as LinkedIn and Facebook, as well as via email distribution. The reason this 
factor is a strength is because the study had a wide reach and participants from all over 
the world had an opportunity to answer.  
As can been seen in the demography there were participants from Australia, 
France, Malaysia and Portugal to name but a few. 
Another limitation of this study is that the ethnicity and birthplace/nationality 
could not be used further. The reason being that the number of participants could not 
represent the various ethnic backgrounds and the nationalities around the world well 
enough for the data to be used in a conclusive study.  
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Future researchers could use different means of distribution - such as emails to 
universities around the world or collection booths in different countries/ overpopulated 
cities e.g., London – to overcome this problem. 
However, another strength of this study is that the participants are of a wide 
range of ages, from 22 years to 79 years of age. The reason that this is so important is 
that it shows that society adapts and changes, and with that the use of the Internet 
becomes ingrained into society. The use of the Internet is important in this study as a 
primary topic relates to online pharmacies and how the public perceives them. 
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APPENDIX: 
8.1 Tablet Spectra 
Information Given: 
 Chemical Name 
 Chemical Formula 
 Chemical Structure 


















Only some of the antibiotics and Raw Materials are used in this appendix to give 
examples of what was used in this research. 
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